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Breast cancer
In 2012 breast cancer was diagnosed worldwide in approximately 1.7 million women and 
521.900 women died as a result of the disease (1). The worldwide incidence of breast cancer is 
increasing. Fortunately, the breast cancer related mortality is getting lower in Western Europe 
and the United States of America, likely because of the introduction of population based 
mammographic screening programs and improvement of modern therapy regimes. In contrast, 
breast cancer mortality is inclining in Latin America and the Asian continent in areas with limited 
access to screening or state-of-art breast cancer therapies. In the Netherlands the breast cancer 
related mortality decrease is estimated to be around thirty percent after the implementation 
of population based mammographic screening in the population at average risk of developing 
breast cancer (2,3), still about 25% of women who develop breast cancer eventually die from 
the disease.
Breast imaging
In order to detect and evaluate abnormalities in the breast, imaging has played a continuously 
increasing role. The major imaging techniques are mammography and/or digital breast 
tomosynthesis, breast MRI and ultrasound, which is the major topic of this thesis. These common 
imaging modalities are described below: 
Mammography
Mammography is the most commonly used breast imaging modality worldwide and it is used 
in both clinical diagnostic settings and in breast cancer screening programs (4). Mammography 
is a two-dimensional conventional x-ray technique based on the attenuation differences of fat 
lobes, fibroglandular tissue and benign and malignant breast lesions. During the acquisition 
of a mammogram, the breast of a woman is placed on the x-ray detector and compressed 
using a pressure paddle. Compression is needed to limit the dose of ionizing x-rays and to 
spread out the breast tissue structures to prevent superimposition of the tissue on the two-
dimensional mammogram. A standard mammography examination includes two mammograms 
per breast, one cranial to caudal (CC) and one medial to lateral oblique (MLO) radiograph. If 
needed, additional mammograms at other angles or spot-compression images can be acquired. 
A limitation of 2D mammography is superimposition of structures in the breast that may have 
similar x-ray attenuation properties as breast cancer. This is specifically an issue for women with 
large amounts of fibroglandular tissue, or ‘dense breasts’, where breast cancer may be masked 
by surrounding fibroglandular tissue patches on the 2D mammogram (5,6). The BI-RADS lexicon 
(American College of Radiology, 5th edition, 2013) recommends to report mammographic 
breast density according to a visual scale where category A represents fatty breasts and category 
D represents extremely dense breasts (7). Breast density may also be quantified automatically 
using volumetric density quantification software such as Volpara (Matakina ltd., Wellington, 
New-Zeeland) that uses a similar four-point scale (Volpara Density Grade A-D) that correlates 
with the visual analogue BI-RADS estimation of breast density. In most states in the United States 
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of America, a law has even been ratified that mandates physicians to inform women about their 
breast density and the risk of a false-negative mammogram (8). 
Digital breast tomosynthesis
A relatively novel extension of mammography is digital breast tomosynthesis (DBT). Unlike 2D 
mammography, DBT is not impaired by superimposing breast structures. DBT acquisition is 
similar to 2D mammography where the breast is compressed by a compression paddle, however 
in DBT the x-ray tube rotates over the breast in a certain set of angles. By doing so multiple 
low-dose x-ray slices are made which together form a (pseudo) 3D volume of the breast, hence 
the term 3D mammography. DBT has been shown to detect breast cancers that would have 
been masked by fibroglandular tissue patches on 2D mammography (9–12). Post-processing 
algorithms can summarize the 3D information of DBT into a 2D image not unlike a conventional 
2D mammogram, hence the term synthetic mammogram.
Breast Magnetic Resonance Imaging
Breast magnetic resonance imaging (MR) is considered the most accurate technique for the 
detection of breast cancer (13–16) and assessing the tumor extent in pre-operative breast cancer 
patients (17–19). A state-of-art breast MR protocol consist of multiple sequences that when 
combined form a multi-parametric tool to evaluate women’s breasts. A breast MR protocol 
includes multiple spoiled gradient echo T1-weighted sequences before and after intravenous 
injection of a gadolinium-based contrast agent, and commonly a diffusion weighted and T2-
weighted imaging sequence. Breast MR takes around 15-25 minutes of so-called magnet time 
which is relatively costly compared with mammography and ultrasound. Furthermore, the need 
for an intravenously placed cannula and the administration of contrast agents makes breast MR 
a more invasive examination than mammography, DBT or breast ultrasound (US).
Breast ultrasound (and a brief history)
In 1951 Wild et al. published a landmark paper on ultrasonic differentiation with sonograms of 
in-vivo human breast tumours, using an “ultrasonoscope” with high-frequency ultrasonic waves 
(20). Wild et al. recognized the potential of breast ultrasound (US) in differentiating malignant 
from benign breast disease without bringing short-term or long-term harm to women and 
pursued further development of this technique (21). Hereafter the technique of US for clinical use 
in human tissue was further improved and by the late 1960’s and 1970’s US systems were able to 
produce relatively clinically useful two-dimensional gray scale sonograms of the breast (22–25). 
In this era dedicated systems were designed to acquire breast US images using so-called water 
path techniques with women in either supine or prone positions (26–29). In the following years, 
US devices evolved from large contraptions into smaller handier handheld devices. Technological 
advances in the 1980’s, in particular the rise of digital technology, boosted breast US image 
quality further. Clinical usefulness improved with the introduction of real-time US imaging. Real 
time imaging also offered radiologists needle guidance for histologic biopsies and fine needle 
aspiration (30). During the 1990’s the clinical use of breast US increased dramatically. Stavros et 
al. (31) published a highly cited paper on the sonographic B-mode appearance of breast masses, 
which formed the basis of today’s standardization of reporting breast US examinations.  Breast 
US has played a key-role in breast imaging since then. In current clinical practice, breast US is 
used by breast radiologists as a supplement to digital mammography and magnetic resonance 
imaging (MRI) to further analyse breast abnormalities. In many cases it is the first imaging 
modality of choice in women with a palpable abnormality for its discriminatory capacity of 
healthy and diseased breast tissue without the need for intravenous contrast agents and is also 
preferred because of its ability to precisely guide biopsy core needles or fine aspiration needles. 
Moreover, breast US does not use ionizing radiation such as conventional mammography, digital 
breast tomosynthesis and dedicated breast computed tomography.
Automated 3D breast ultrasound
Automated 3D breast ultrasound (ABUS) systems are relatively novel extensions to breast 
US devices and are developed for mass screening as a supplement to mammography. ABUS 
has standardized protocols for the acquisition of bilateral whole breast US volumes and can 
be performed by non-radiologists after a short training course, as opposed to whole breast 
US using hand held US devices that is highly dependent on the experience of its operator 
(32). Further advantages of ABUS systems over hand held US devices are the acquisition of 
large 3D whole breast volumes that can be stored in digital medical imaging archives and 
thus retrieved for temporal comparison during subsequent screening rounds which is limited 
with hand held US, but very important in screening. ABUS systems are equipped with a wide 
linear array high frequency transducer that is mechanically driven and acquires high resolution 
subsequent transverse slices. The original transverse ABUS slices are stacked to form a 3D volume 
and processed into multiplanar reconstructions (MPR) that can be simultaneously reviewed 
on a dedicated workstation. Multiple 3D ABUS volumes are scanned per breast during image 
acquisition to ensure coverage of the whole breast. The acquisition protocol is described in 
more detail in chapter 2.
Breast cancer and screening
Screening for breast cancer with annual or biennial mammography has been shown to reduce 
breast cancer related mortality by at least 20% (33). Detection of breast cancer at an early 
stage has also been shown to improve breast cancer patient survival significantly despite 
the introduction of more effective therapy strategies in the 2000’s in the Netherlands (34). 
Nonetheless, mammographic screening programmes are not uniformly beneficial for all 
women who are invited to screening. In particular women with a relatively large amount of 
fibroglandular tissue , so called dense breasts (mostly younger women), are at risk of having 
breast cancer that is not recognized during mammographic screening (5). Fibroglandular breast 
tissue may have similar x-ray attenuation properties as breast lesions such as invasive cancers. 
Consequently, large compact patches of fibroglandular breast tissue, may mask underlying 
breast cancers on a two-dimensional mammogram and decrease the sensitivity of breast cancer 
screening programs (6).
The sensitivity of population based mammographic screening in women with extremely dense 
breasts is a reported as low as 61% with an interval cancer rate of 4.4% compared to 85.7% and 
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0.7%, respectively, for women with fatty breasts in the population of women at average risk for 
the development of breast cancer and between 50-74 years of age (6).
There is mounting evidence showing that supplemental breast US detects two to five 
mammography occult early stage breast cancers per 1000 screens in asymptomatic women 
with dense breasts at various risk levels in a wide range of ages (35–47). In addition, early reports 
indicate that detecting mammographically occult cancers with breast US reduces the number 
of interval cancers in subsequent screening rounds in women with dense breasts (42,48). 
Similar to handheld breast US, supplemental ABUS screening has also been shown to detect 
mammographically occult early stage breast cancers (two to seven per 1000 screening rounds). 
Unfortunately for both handheld US and ABUS an increase in unnecessary recalls has also been 
observed (49–53). Whether (AB)US reduces interval cancers in population based mammographic 
screening programs for women at average risk and older than 50 years has not been thoroughly 
investigated.
An alternative to supplemental breast US in women at average and elevated risk is annual breast 
magnetic resonance imaging (14,54). Breast MR imaging has been shown to be superior in the 
detection of breast cancer compared to mammography and ultrasound (15,55–57). However, 
due to the high costs of the magnet time of breast MR imaging, screening is only considered 
cost-effective in women with a lifetime risk of more than 50 percent of developing breast cancer 
such as BRCA1 and BRCA2 germline mutation carriers and women who underwent radiation 
therapy to the chest at a young age (usually for morbus Hodgkin) (58–61). Despite the superiority 
of breast MR imaging in cancer detection, interval cancers are also observed in women with an 
indication for breast MR screening (62), mostly in BRCA1 mutation carriers where the interval 
cancer rate has been reported as high as 29% of all cancers detected (63). Moreover, these 
women are more susceptible to radiation induced cancers, therefore there might be a role for 
supplemental (AB)US in BRCA mutation carriers.
Computer Aided Detection
Artificial intelligence is rapidly finding its way into healthcare in general and radiology in 
particular. Automated analysis of digital imaging by artificial intelligence is known as Computer 
Aided Detection (CAD). CAD-software has been relatively successful in breast imaging (64). In 
mammography CAD software is mostly used as a tool to aid in decision support and to prevent 
oversight errors (65,66). CAD has also been investigated as a second independent reader in 
mammographic screening (67,68).
Three-dimensional imaging modalities such as ABUS are composed of many images, hence 
reading is relatively lengthy and distinct abnormalities may easily be overlooked. Therefore, 
CAD-software has high potential in ABUS as a tool to help radiologists detect breast cancer (69–
76). Besides helping radiologists detect breast cancer in ABUS as a conventional aid, CAD might 
also be beneficial in terms of efficiency by preselecting relevant cases to read or summarizing 3D 
volumes into a 2D image (including synthetical enhancement of abnormalities). Independent 
combinations of CAD and human readers might improve the accuracy of reading ABUS and 
(partially) replace second human readers (64,77).
In several studies that are included in this thesis we have used commercially developed CAD-
software for ABUS (QVCAD by QVIEW medical Inc. Los Altos, Ca., USA). This software package 
is designed to detect and classify suspicious regions in an ABUS volume. Highly suspicious 
regions are marked with a so-called CAD-mark. The CAD-software also includes an intelligent 
minimum intensity projection (MinIP) of the breast tissue after automated removal of the chest 
wall using machine learning algorithms. The fibroglandular tissue is relatively white, fatty tissue 
is somewhat darker and possible lesions are projected as “dark spots” in the MinIP.  The suspicious 
region candidates that are detected by the CAD-algorithm are synthetically enhanced in the 
intelligent MinIP. The multiplanar hanging in the workstation automatically snaps to the 3D 
location of the region candidate after a radiologist clicks on a dark spot in the MinIP. The MinIP 
thus summarizes the content of a three-dimensional ABUS volume in a two-dimensional image 
and can be used to navigate through the ABUS exams.
Thesis outline
Chapter 2 describes the current functionality of ABUS, focussing on the most common artefacts 
in ABUS, the appearance of benign and malignant findings, and reasons for non-detection of 
malignant lesions in ABUS. Automated breast ultrasound allows an evaluation of the images in 
multiplanar reconstructions, which is not feasible with standard hand-held breast ultrasound. In 
chapter 3 we have investigated the added value of multiplanar reconstructions in ABUS on lesion 
differentiation by radiologists. Breast cancer detection in ABUS may depend on the sonographic 
appearance of breast cancer because some cancers mimic benign lesions, which might be 
associated with the molecular building blocks of the tumors. In chapter 4 the association of 
molecular subtypes of invasive ductal carcinoma with the BI-RADS US lexicon descriptors and 
specific ABUS descriptors are investigated. The frequency of interval cancers is relatively high 
in BRCA germline mutation carriers despite intense surveillance with annual breast MR and 
mammography. In chapter 5, we investigated a triple-modality surveillance regime for BRCA 
germline mutation carriers including biannual ABUS. In chapter 6 we investigated the effect of 
implementing commercially developed CAD-software for ABUS in a pilot observer study with 
multiple breast radiologists and senior radiology residents. In chapter 7 we describe the results 
of the effect of a CAD-based reading workflow for ABUS that is specifically designed for this 
study and implemented in a dedicated high throughput screening workstation. An alternative 
concept for implementing CAD-software is presented in chapter 8 where CAD-software is used 
as a tool that validates findings reported by Radiologists. In this chapter we investigate the effect 
of CAD-validation on the performance of radiologists.
Chapter 2 
Automated 3D breast ultrasound for screening: Technique, artifacts, 
and lesion characterisation 
Published in Radiographics 2018 May-Jun;38(3):663-683
Jan C.M. van Zelst MD, MSc and Ritse M. Mann MD, PhD
Department of Radiology and Nuclear Medicine, Radboud University Medical Centre, Nijmegen, The 
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Abstract
Automated breast (AB) ultrasonography (US) scanners have recently been brought to market 
for breast imaging. AB US devices use mechanically driven wide linear-array transducers that 
can image whole-breast US volumes in three dimensions. AB US is proposed for screening 
as a supplemental modality to mammography in women with dense breasts and overcomes 
important limitations of whole-breast US using handheld devices, such as operator dependence 
and limited reproducibility. A literature review of supplemental whole-breast US for screening 
was performed, which showed that both AB US and handheld US allow detection of 
mammographically negative early-stage invasive breast cancers but also increase the false-
positive recall rate. Technicians with limited training can perform AB US; nevertheless, there is a 
learning curve for acquiring optimal images. Proper acquisition technique may allow avoidance 
of common artifacts that could impair interpretation of AB US results. Regardless, interpretation 
of AB US results can be challenging. This article reviews the US appearance of common benign 
and malignant lesions and presents examples of false-positive and false-negative AB US 
results. In situ breast cancers are rarely detected with supplemental whole-breast US. The most 
discriminating feature that separates AB US from handheld US is the retraction phenomenon on 
coronal reformatted images. The retraction phenomenon is rarely seen with benign findings but 
accompanies almost all breast cancers. In conclusion, women with dense breasts may benefit 
from supplemental AB US examinations. Understanding the pitfalls in acquisition technique and 
lesion interpretation, both of which can lead to false-positive recalls, might reduce the potential 
harm of performing supplemental AB US.
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Introduction
Recently, automated breast (AB) ultrasonography (US) machines have been introduced on the 
market. These machines are mainly designed to overcome some of the limitations of handheld 
US in supplemental screening of women for breast cancer.
During the past 30 years, mammographic screening programs have reduced breast cancer–related 
mortality by up to 38%, although exact estimates vary (2,78,79). The success of mammographic 
screening programs is attributed to the detection of breast cancer at an early stage (34). However, 
in women with mammographically dense breasts, the sensitivity of mammographic screening 
is as low as 61%, yielding a relatively large number of interval cancers in women with dense 
breasts (6). In particular, small cancers are masked by the normal fibroglandular tissue of the 
breast and therefore cannot be detected. Additional US demonstrates a proportion of these 
masked cancers owing to better discrimination between normal and abnormal areas in dense 
tissue; therefore, it is already implemented as a supplemental screening modality in screening 
programs. US has been a key imaging modality in breast cancer diagnostics for many years 
and is therefore widely available. It is a relatively inexpensive technique that does not require 
intravenous injection of contrast agent and is radiation free. 
However, the quality of supplemental screening with handheld US in women with dense breasts 
is dependent on the expertise of the operator. Therefore, highly trained US specialists are needed 
to perform handheld US, which requires substantial resources. Furthermore, the reproducibility 
of handheld US for whole-breast US screening is limited, and temporal comparison with 
subsequent screening rounds is not possible (32). Finally, while recent prospective trials have 
shown that handheld US can help detect additional mammography-negative early-stage 
invasive breast cancers in asymptomatic women with dense breasts (summarized in table 2.1) 
(41–44,80), additional handheld US also increases the recall rate and decreases specificity. 
AB US can overcome some of the limitations of handheld US, as it allows structured image 
acquisition by non-specialists, whole-breast evaluation, multiplanar reformation, and temporal 
comparison. Therefore, AB US appears more suitable and more affordable as a supplemental 
screening technique. Nevertheless, while supplemental AB US screening also increases the 
sensitivity of mammographic screening, an increase in recall rate and decrease in specificity are 
observed, similar to handheld US (50,51,53). This is probably because of otherwise unoberved 
suspicious-looking regions that warrant further evaluation and may partly be attributed to 
a first-round effect, as most studies report the results of one additional round of screening 
only (81). In addition, supplemental AB US screening is subject to a learning curve for both 
technicians and radiologists. 
In this article, we describe the technique and common pitfalls of AB US examination, discuss 
common reasons for false-positive and false-negative findings, and present the AB US 
appearance of different benign lesions and histologic breast cancer types.
Supplemental whole breast ultrasound screening
Table 2.1 summarizes recent reports on supplemental whole-breast US screening in as-
ymptomatic women with dense breasts by using either (automated) handheld US devices or 
AB US (41–44,51,53). Supplemental whole-breast US screening results in increased detection 
of small early-stage invasive cancers (range, 0.9–7.7 per 1000 screening whole-breast US 
examinations) compared with screening with mammography alone. 
Whole-breast US barely increases detection of ductal carcinoma in situ (DCIS), as DCIS detection 
with US is rare and virtually all DCIS lesions are detected with mammography. This implies that 
the risk of overdiagnosis with AB US is relatively limited; however, evidence of a reduction in the 
rate of interval cancers is available only for supplemental screening with handheld US (42). DCIS 
is therefore a common reason for false-negative AB US examinations. The false-negative rate of 
AB US has been reported to be in the range of 9%–22% (50–52). The downside of supplemental 
whole-breast US screening is an increase in false-positive recalls and consequently a decrease in 
the specificity of personalized breast cancer screening programs. However, whole-breast US has 
a learning curve, and sonologists tend to report fewer false-positive findings over time (81,82). 
This seems to also hold true for AB US as a supplemental screening modality. 
False-positives AB US examinations
When AB US is used for supplemental screening in women with heterogeneously or extremely 
dense breasts, it is obvious that the large amount of possible artifacts and the abundance of 
benign lesions in the breasts of healthy women—as described later—will lead to false-positive 
findings. Brem et al (51) reported an additional recall rate of 134.6 per 1000 women screened 
and an additional biopsy rate of 36.0 per 1000. Wilczek et al (50)  and Choi et al (52)  also reported 
an increased recall rate when AB US was used as a supplemental screening tool, but at lower 
rates of 9.0 and 2.6 per 1000. Wilczek et al. reported an increase in biopsy rate of 7.2 per 1000 
women screened. These variations may be the result of local or study factors. As with screening 
mammography, the accepted recall rate for supplemental AB US in the population will likely 
vary highly between different countries (2,83).  However, supplemental AB US is not impaired by 
fibroglandular tissue. It is a three-dimensional volumetric imaging technique that may resolve 
specific false-positive findings from mammographic screening, such as superimposition of 
glandular tissue, asymmetry caused by normal fibroglandular tissue, and typical benign lesions 
(e.g., cysts or fibroadenomas). Therefore, the number of false-positive recalls from combined 
mammography and AB US screening will be lower than the sum of false-positive recalls from 
each of the examinations.
Other supplemental breast imaging techniques
The breast density paradigm is not exclusively resolved by supplemental breast US. Other 
imaging techniques such as digital breast tomosynthesis (DBT) and magnetic resonance (MR) 
imaging have also been shown to have great potential. The most accurate imaging modality 
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for detection of breast cancer is undisputedly breast MR imaging (15,55,56). MR imaging allows 
detection of substantially more breast cancers, both invasive and in situ, than the other available 
techniques. In women at average risk of developing breast cancer, the additional cancer yield 
of current state-of-the-art breast MR imaging has been reported to be 15.5 cancers per 1000 
screening rounds (14) compared with 1.9–2.7 cancers per 1000 for DBT (84,85). Current state-of-
the-art breast MR imaging has a slightly higher recall rate (90 per 1000) compared with those of 
DBT (35–91 recalls per 1000 (9,85–87)) and breast US (table 2.1). However, breast MR imaging has 
been shown to be cost-effective only in women with a lifetime risk of developing breast cancer of 
greater than 50%. In these high-risk women, the role of breast US has been shown to be limited. 
Whether supplemental breast US or DBT is the optimal screening strategy in women at average 
or intermediate risk of developing breast cancer is unclear. However, early comparative studies 
have shown that breast US may have a benefit over DBT in women with extremely dense breasts 
(88,89). Since results of current studies on supplemental AB US are comparable to those of 
studies on supplemental handheld US, we expect that women with extremely dense breasts 
may benefit more from AB US compared with DBT.
Technique of AB US and common pitfalls
To ensure coverage of the whole breast, AB US systems acquire at least two, and usually on 
average three, overlapping B-mode US volumes per breast with a wide high-frequency linear-
array transducer. The transducer is automatically driven by a mechanical arm and acquires 
more than 300 sections with a minimal section thickness of 0.5 mm per volume. By acquiring 
overlapping volumes, the technician can image the anatomic breast area between the midsternal 
line and the midaxillary line. 
The angle at which the transducer is placed on the breast is adjustable to correct for anatomic 
variations and optimize contact with the skin of the breast. In standard acquisition protocols, the 
volumes obtained are predefined (Fig 2.1). In large breasts, additional volumes can be acquired 
of the superior and inferior sections of the breast (Fig 2.1). 
To obtain good-quality images, abundant use of water-based gels or lotion on the skin of the 
breast is mandatory. This prevents poor contact between the transducer and the skin and allows 
the ultrasonic wave to pass into the breast. The acquisition depth of the transducer is adjustable 
to up to 6 cm, depending on breast size. The operating technicians can adjust the time-gain 
function and focus region of the transducer to improve the image quality. 
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Post-processing, multiplanar reconstructions and image interpretation
A dedicated workstation for AB US acquisitions reformats the original transverse images into 
coronal and sagittal images, which are displayed and read with a multiplanar hanging protocol 
in dedicated reading environments. The time needed to evaluate AB US examinations is reported 
to be 3–5 minutes for a full normal case (51). The interpretation and diagnostic accuracy of AB 
US are comparable to those of handheld US (90–93). In general, interpretation of AB US images 
using the Breast Imaging Reporting and Data System (BI-RADS) US lexicon (7,94) is sufficient 
for screening and diagnostic purposes. Using the BI-RADS lexicon for AB US appears to provide 
higher agreement between radiologists than using it for handheld US (95). The coronal and 
sagittal reformatted images contain additional information that can aid in differentiation of 
breast lesions (93,96).
Incorrect placement of the transducer
The anteroposterior acquisition should be performed with the nipple in the center of the AB US 
image. The lateral acquisition should have some overlap with the anteroposterior acquisition; 
however, the lateral boundary of the transducer should be aligned with the midaxillary line to 
image even the most lateral breast sections. Figure 2.2 shows an invasive breast cancer that was 
only partially imaged with AB US, as it was very laterally located and for that reason was not 
seen by the reporting radiologist. The medial boundary of the transducer should be aligned 
with the midsternal line for a medial acquisition. 
A challenge is correctly positioning linear-array AB US transducers in women with very firm 
breasts or large breast implants. The linear transducer may have difficulty in achieving an optimal 
contact area because the breast is difficult to compress. AB US systems with a curved transducer 
might have fewer difficulties with firm breasts and large breast implants. Additional AB US 
volumes may be needed to ensure coverage of the entire breast.
Air contact artifacts
Application of water-based media to the whole breast is vital to avoid air contact artifact. This 
artifact is caused by entrapment of sound waves in an enclosed space between the transducer 
and the skin. This creates a typical reverberation pattern from the skin and total loss of signal 
underneath the air bubble (Fig 2.3). 
The typical size of US-only detected breast cancers ranges between 10 and 15 mm (Table 2.1). Air 
contact artifact prevents reliable evaluation of the underlying breast tissue. Therefore, artifacts 
larger than 10–15 mm can potentially obscure breast cancers, and technicians should check 
the contact area for air bubbles before each acquisition. 
Figure 2. 1 For average-size and smaller breasts, three acquisitions—anteroposterior (AP), lateral (LAT), 
and medial (MED are sufficient to cover the entire breast with AB US. For larger breasts, the AB US operator 
might need to perform additional scans to cover the superior (SUP) or inferior (INF) parts of the breast. 
Illustration by Patrick van den Akker.
Figure 2. 2 Malignant mass in a 66-year-old woman with a spiculated mass on her heterogeneously dense 
screening mammograms (Fig E1 [online]). The mass was not seen at supplemental AB US. In retrospect, AB 
US images show that the transducer did not fully image the lateral section of the right breast. The mass 
is visible along the outer left boundary of the images (arrowheads). More laterally oriented AB US images 
were not acquired. In all figures, C = coronal, S = sagittal, T = transverse.
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Nipple shadowing
In a proportion of women who undergo AB US screening, heavy shadowing artifacts in the 
area behind the nipple and areola make reliable evaluation challenging. Figure 2.4a shows a 
periareolar invasive ductal carcinoma (IDC) seen on anteroposterior views from AB US that was 
occult at screening mammography. Figure 2.4b shows the lateral views; the tumor is present, 
but heavy nipple shadowing obscures the lesion. 
Nipple shadows are usually more prominent on lateral and medial views than on anteropos-
terior views (Fig 2.5), likely because of peripheral signal loss in combination with the low acoustic 
impedance of the area behind the nipple and the tangential angle at which sound waves 
encounter the curved structures in the nipple region. Therefore, the area behind the nipple is 
usually best evaluated on anteroposterior views. Nipple shadowing can be reduced by applying 
an abundance of water-based medium on the nipple area. 
Figure E 1 Malignant mass in a 
66-year-old woman with a spiculated 
mass on her heterogeneously
dense screening mammograms. 
Craniocaudal (CC) and mediolateral 
oblique (MLO) mammograms show 
a spiculated mass (arrowheads) in 
the upper outer quadrant (posterior 
depth) of the right (R) breast. Figure 
3 Air contact artifact in a 54-year-
old woman with negative results 
at screening mammography and 
AB US. Images from a left medial 
AB US acquisition show a large 
air contact artifact on the medial 
side of the nipple (arrowheads). A 
typical reverberation pattern is seen 
(multiple white lines parallel to the 
skin). No reliable diagnosis can be 
made in the area behind the artifact.
Figure 2. 3 Air contact artifact in a 54-year-old woman with negative results at screening mammography 
and AB US. Images from a left medial AB US acquisition show a large air contact artifact on the medial side 
of the nipple (arrowheads). A typical reverberation pattern is seen (multiple white lines parallel to the skin). 
No reliable diagnosis can be made in the area behind the artifact.
Figure 2. 4 continues on next page
A
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Figure 2. 4 Invasive ductal carcinoma (IDC) in a 64-year-old woman with negative results at mammographic 
screening of the left breast (Fig E2). (a) Left anteroposterior images from supplemental AB US show an IDC 
(arrowheads) in the retroareolar area of the left breast. (b) On left lateral AB US images, nipple shadowing 
(arrowheads) obscures the cancer completely. (Case courtesy of Matthieu J. C. M. Rutten, MD, PhD, Jeroen 
Bosch Hospital, ‘s-Hertogenbosch, the Netherlands.)
Figure E 2 IDC in a 64-year-old 
woman with negative results at 
screening mammography. Left 
(L) CC and MLO mammograms 
show scattered areas of  
 fibroglandular density.
Supplemental AB US revealed 
a small low-grade IDC in the 
retroareolar area.
Continuation of figure 2. 4
Figure 2. 5 Normal AB US results in a 54-year-old woman. (a) Left anteroposterior AB US images show 
relatively mild nipple shadowing (arrowheads). (b) Left lateral AB US images show heavy nipple shadowing 
(arrowheads).
B A
B
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Wandering shadows
Wandering shadows are observed in virtually all AB US acquisitions. The shadows “wander” 
with the radiologist in the scrolling direction of the transverse planes (Fig 2.6) and are caused 
by Cooper ligaments in the breast. Ultrasonic waves encounter the curved surface of ligaments 
at a tangential angle and are scattered and refracted, leading to loss of signal and thus acoustic 
shadowing. The effect is similar to when ultrasonic waves encounter other curved structures in 
the breast, such as cysts (Fig 2.7). 
This artifact is relatively specific to AB US, since in handheld US acquisitions, every sonographer 
will adjust the angle of the transducer to reduce this artifact. The design of AB US systems 
does not allow correction of the transducer angle. Hence, these artifacts are common in AB US 
examinations. 
Sinusoidal wave pattern
AB US acquisitions should be performed while the patient breathes superficially, and patients 
should be instructed not to talk during the acquisition. Heavy breathing or talking causes a 
sinusoidal wave pattern on AB US images. The frequency of the sinusoidal waves usually ranges 
between 12 and 20 per acquisition; acquisition of a volume takes approximately 1 minute, hence 
this frequency is the breathing frequency (Fig 2.8). This wave pattern is more evident closer 
to the chest wall and can distort the deeper regions of the coronal and sagittal reformations.
Figure 2. 6 Wandering shadows in a 50-year-old woman with heterogeneously dense breasts. Images from 
a normal AB US examination show multiple dark areas (arrowheads). These are caused by sound waves that 
refract and scatter from the curved surface of Cooper ligaments, causing wandering shadows in the breast.
Figure 2. 7 AB US images show multiple dark areas (arrowheads), an effect similar to that in Figure 6. 
Sound waves refract and scatter from the edges of a curved structure, in this case an uncomplicated cyst.
Figure 2. 8 Sinusoidal distortion due to heavy breathing in a 70-year-old woman with IDC. AB US images 
show patterns of heavy breathing during the acquisition (between arrowheads). The original transverse 
image is not affected by breathing. However, both the coronal and sagittal reformatted images show 
sinusoidal distortion of the deeper breast regions. A small IDC is seen (*) but is hardly visible on the coronal 
image, likely because of heavy breathing artifacts. (Courtesy of André R. Grivegnée, MD, PhD, Institute Jules 
Bordet, Brussels, Belgium.)
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ABUS appearance of benign lesions
At mammographic screening, benign breast disease is underdiagnosed because the lesions are 
not seen or reported. However, at supplemental whole-breast US, these unreported lesions are 
visualized, and sometimes histologic verification is needed. Common benign findings at AB US 
are cysts, fibroadenomas, complex sclerosing lesions (CSLs), and intraductal papillary lesions 
(IPLs). While fibroadenomas are generally regarded as completely benign, the relative risk for 
developing breast cancer with other proliferative lesions is 1.5–2.0 without signs of atypia and 
increases to over 4.0 with signs of atypia (97,98). Other completely benign lesions, such as 
stromal fibrosis and intramammary lymph nodes, may also raise suspicion at AB US.
Cysts 
Simple cysts, as opposed to complicated cysts, are anechoic round or oval benign masses with 
posterior acoustic enhancement at US. However, with AB US systems, unspecific focus settings, 
lack of local compression, postprocessing, and movement of the patient can artificially create 
signal inside a cyst. Therefore, cysts may resemble proliferative masses and may not always be 
unambiguously ruled out as benign (Fig 2.9). 
Figure 2. 9 Simple cyst in a 40-year-old woman with heterogeneously dense breasts and a hereditary risk 
of developing breast cancer. AB US images show an oval, circumscribed, parallel lesion (arrowheads) in 
the retroareolar area. The lesion has a heterogeneous internal echo pattern, posterior acoustic shadowing 
along the edges, and enhancement centrally. This lesion was regarded as a solid mass; however, handheld 
US showed a clear anechoic cyst (Fig E3).
Figure E 3 Simple cyst in a 40-year-old woman with heterogeneously dense breasts and a hereditary risk 
of developing breast cancer. Supplemental screening AB US showed a lesion in the retroareolar area that 
was not anechoic and thus not unambiguously benign. Image from handheld US shows a completely 
benign cyst.
Especially in the initial phase of using supplemental AB US in asymptomatic women, the recall 
rate for cysts may be high. In the 1st month of using AB US, Arleo et al (99) found that the recall 
rate for cysts was 23 of 66 false-positive recalls. The false-positive recall rate declined in the 
following months, and the recall rate for cysts was five of 24 recalls in the 3rd month after first 
use. Arleo et al. (99) reported that all recalls due to cysts were resolved with targeted handheld 
US.
Fibroadenomas
Fibroadenomas are seen in 15%–25% of women undergoing breast cancer screening and 
are more common in younger women (100).  They usually manifest as well-circumscribed, 
oval or lobulated, hypoechoic masses (Fig 2.10). Fibroadenomas can show posterior acoustic 
shadowing, acoustic enhancement, or no acoustic effect. They have a capsule that may be seen 
as a thin hyperechoic line surrounding the lesion. Calcifications and septa may be present. In 
general, fibroadenomas do not cause architectural distortion.
Complex sclerosing lesions 
CSLs or radial scars are considered high-risk lesions (relative risk > 3.0) and may harbor breast 
cancer in 10%–15% of excised lesions (101,102). At histologic analysis, CSL shows radiating ducts 
and lobules surrounding a fibrous core. At US, CSL manifests as architectural distortion, which 
appears as a retraction pattern on coronal AB US images and cannot be easily differentiated 
from a malignant lesion (Fig 2.11). 
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Figure 2. 10 Fibroadenoma in a 52-year-old woman with heterogeneously dense breasts and negative 
results at screening mammography (Fig E4). AB US images show an oval, parallel, circumscribed, hypoechoic 
lesion without posterior acoustic features (arrowheads). There are no signs of retraction on the coronal AB 
US image. Histologic core needle biopsy showed a simple fibroadenoma without signs of atypia.
Figure E 4 Fibroadenoma in 
a 52-year-old woman with 
heterogeneously dense breasts. 
Left CC and MLO screening 
mammograms show a normal 
appearance. Supplemental 
AB US revealed a small 
circumscribed mass, which was 
histologically confirmed to be a 
fibroadenoma.
Figure 2. 11 CSL in a 30-year-old woman at high risk of developing breast cancer. Images from supplemental 
AB US show a small, irregular, indistinct, hypoechoic lesion with minimal posterior acoustic shadowing 
(arrowheads). The coronal image shows a severe retraction pattern. Histologic core needle biopsy 
showed a CSL without signs of invasive or in situ carcinoma or atypia. The lesion was not initially seen at 
mammography (Fig E5).
Figure E 5 CSL in a 30-year-old woman 
at high risk of developing breast cancer. 
Left CC and MLO screening mammograms 
show a normal appearance with 
heterogeneous density. Supplemental AB 
US revealed an architectural distortion, 
which was histologically confirmed to be 
a CSL without atypia.
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Biopsy markers
Women who have undergone biopsy procedures may have had a radiographically visible marker 
inserted. Some biopsy markers may cause a small desmoplastic reaction and can thus be seen 
as a (usually linear) hypoechoic area surrounded by retracted breast tissue, thus resembling 
invasive cancer (Fig 2.12). Correlation between AB US images and corresponding mammograms 
is essential to avoid unnecessary recalls.
Intraductal papillary lesions
IPLs or papillomas consist of papillary cells that grow from the cystic wall into the lumen of an 
ectatic duct or cyst. IPLs are associated with atypia and malignancies, but non-atypical IPLs are 
also considered high-risk lesions (relative risk = 2) (103). Moreover, 14%–15% of IPLs without 
atypia at histologic core needle biopsy show in situ or invasive cancer after surgical excision 
(104,105). Therefore, surgical management or radiologic follow-up is often recommended. 
At US, IPLs manifest as iso- or hypoechoic lesions that are round or oval. Calcifications may 
be present. Most IPLs show a more heterogeneous echo pattern and posterior acoustic 
enhancement. IPLs may be surrounded by ductal fluid that appears anechoic, but they can 
also fill the duct or cyst completely (Fig 2.13).   
Figure 2. 12 Biopsy marker in a woman with dense breasts at high risk of developing breast cancer. AB 
US images of the right breast show a linear hypoechoic area (arrowheads) with a strong retraction pattern 
on the coronal image, mimicking invasive breast cancer. However, a cancerous mass is not seen on the 
sagittal and transverse images. This finding correlated with a biopsy marker seen at mammography (Fig E6). 
Biopsy markers are likely to cause a fibrous response, thus retracting surrounding tissue toward the marker.
Figure E 6 Biopsy marker in a woman with 
dense breasts at high risk of developing 
breast cancer. Right CC and MLO screening 
mammograms show a normal appearance 
with extreme density and a biopsy marker 
(arrowheads). Supplemental AB US 
showed a strong linear retraction pattern 
surrounding the biopsy marker.
Figure 2. 13 Papilloma in a 30-year-old asymptomatic woman at high risk of developing breast cancer. AB 
US images show an irregular, nonparallel, angular lesion with a heterogeneous internal echo pattern and 
some posterior acoustic enhancement (arrowheads). Histologic core needle biopsy showed an intraductal 
papilloma without signs of invasive or in situ carcinoma or atypia. The lesion was not initially seen at 
mammography (Fig E7).
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Fibrosis
Stromal fibrosis is seen in 6%–9% of biopsied lesions in the breasts (106–109). Stromal fibrosis 
can mimic proliferative lesions and therefore warrant histologic verification. There is a slight 
possibility of underdiagnosis of breast cancer, since, in approximately 2% of lesions diagnosed 
as stromal fibrosis, the final pathologic analysis shows breast cancer (108).  This is likely because 
invasive breast cancer is accompanied by a desmoplastic reaction with fibrotic changes as a 
result. Stromal fibrosis usually manifests as a non-circumscribed irregular lesion but may also 
appear as a circumscribed, oval or round, hypoechoic lesion with a hyperechoic ring, mimicking 
a fibroadenoepithelial lesion. Stromal fibrosis may manifest with posterior acoustic shadowing 
and calcifications (Fig 2.14). In principle, stromal fibrosis does not show a retraction pattern at 
AB US.
ABUS appearance of breast cancers
At mammographic breast cancer screening, approximately 80%–90% of screening-detected 
cancers are invasive cancers, of which 78% are the ductal type (IDC) or ductal mixed type. 
Invasive lobular carcinoma (ILC) accounts for approximately 11%, and the remaining 11% consist 
of specific histologic cancer types such as invasive tubular carcinoma (ITC), invasive apocrine 
carcinoma (IAC), and invasive mucinous carcinoma (IMC) (6,34).  Supplemental AB US has been 
shown to allow detection of 1.9–7.8 additional cancers per 1000 women screened, and the 
average size of US-only detected cancers is 12–15 mm (41–44,47,51,53). Detected cancers are 
predominantly invasive and of no special type.
Retraction phenomenon
A specific descriptor for malignancies in the breast at AB US is the retraction phenomenon, which 
is seen in almost all breast cancers. Retraction is seen as a stellate pattern around the cancer, 
hyperechoic or isoechoic to fibroglandular tissue, and is likely caused by desmoplastic reaction 
in the normal tissue surrounding the cancer. A desmoplastic reaction to breast cancer is likely 
triggered by chemotactic agents and results in stiffening (scarring) of the surrounding tissue, 
affecting other breast structures that are normally more compliant in healthy breasts, such as 
the Cooper ligaments. Retraction patterns are best visualized on coronal reformatted images 
(93,96,110,111). The retraction phenomenon is highly discriminative for breast cancer and is 
rarely seen in benign breast lesions. Examples of the coronal retraction phenomenon are seen in 
the figures cited in the following sections. As a note of caution, retraction is more prominent in 
relatively indolent cancers with a low proliferative profile and may be almost completely absent 
in fast-growing cancers such as high-grade triple-negative cancers (112,113).
Invasive ductal carcinoma
IDC (not otherwise specified) is by far the largest group of carcinomas. The US appearance 
depends on prognostic factors such as proliferation rate and hormone receptor status (113). 
Early stage, fast growing, and more aggressive subtypes of IDC, such as triple-negative IDC and 
other high-grade IDCs, tend to be more round, have circumscribed or microlobulated margins, 
and show posterior acoustic enhancement (114–118) (Fig 2.15). Some of the more aggressive 
Figure E 7 Papilloma in a 30-year-old 
asymptomatic woman at high risk of 
developing breast cancer. Left CC and MLO 
screening mammograms show a normal 
appearance. Supplemental AB US revealed 
an isoechoic mass in the retroareolar area, 
which was histologically confirmed to be 
an intraductal papilloma without atypia.
Figure 2. 14 Stromal fibrosis in a 36-year-old woman with extremely dense breasts, a strong family history 
of breast cancer, and normal results at screening mammography. Images from supplemental AB US show a 
round, nonparallel, circumscribed, hypoechoic lesion with posterior acoustic enhancement and shadowing 
(arrowheads). Histologic core needle biopsy demonstrated focal stromal fibrosis.
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subtypes of IDC may therefore mimic benign lesions (113,114,116). More indolent subtypes of 
IDC are often hypoechoic, are irregular or indistinct, have spiculated margins, and show posterior 
acoustic shadowing (114,115,117–119) (Fig 2.16). IDCs are therefore a heterogeneous group 
with a variety of US appearances. In the coronal plane, the retraction phenomenon is present 
in the majority of IDCs.
Figure 2. 15 High-grade IDC in a 70-year-old woman with a focal asymmetry at mammography (Fig E8). AB 
US images show an irregular, parallel, hypoechoic mass that is not completely circumscribed with angular 
margins and posterior acoustic shadowing (arrowheads).
Figure E 8 High-grade IDC in a 
70-year-old woman with a focal 
asymmetry at mammography. Right 
CC and MLO screening mammograms 
show heterogeneous density with a 
focal asymmetry (arrowheads), which 
was confirmed with supplemental AB 
US. Histologic analysis showed high-
grade IDC.
Figure 2. 16 Intermediate-grade IDC in a 50-year-old woman with heterogeneously dense breasts. AB US 
images show an irregular, not parallel, hypoechoic mass with lobulated and angular margins, posterior 
acoustic shadowing, and a subtle retraction pattern on the coronal image (arrowheads). The mass proved 
to be a 17-mm intermediate-grade IDC. The mass was not seen at screening mammography (Fig E9).
Figure E 9 Intermediate-
grade IDC in a 50-year-old 
woman. Left CC and MLO 
screening mammograms 
show a normal appearance 
with heterogeneous density. 
Supplemental AB US revealed 
an irregular hypoechoic mass, 
which proved to be a 17-mm 
intermediate-grade IDC.
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Invasive lobular carcinoma
Approximately 11% of invasive cancers are of the lobular type (120). In the majority of ILCs, the 
US features are a hypoechoic irregular mass with indistinct angulated margins, an echogenic 
halo, and posterior acoustic shadowing (Fig 2.17) (121,122). At diagnostic US, more than 10% 
of ILCs manifest without a clear mass (121,123). Hyper- and isoechoic patterns with or without 
focal acoustic shadowing are more frequently observed in ILCs than in IDCs (Figs 2.18, 2.19). 
Consequently, the extent of ILCs is prone to underestimation with US (124,125). Therefore, 
MR imaging staging is recommended in cases of mammographically or US-detected ILC (126) 
(Fig 2.19). Nevertheless, US has higher sensitivity for depicting ILC than does mammography 
(123,127). At supplemental AB US screening, a retraction pattern on coronal images may help 
detect ILCs even without the presence of a clear mass.
Invasive Tubular cancer
Approximately 2% of all breast cancers are ITCs (120). ITC manifests as a low-grade cancer. The 
most common US appearance is a relatively small, hypoechoic, irregular mass with an echogenic 
halo. The margins are not circumscribed and are mostly spiculated. In the majority of ITCs, there 
is posterior acoustic shadowing (128–131). At AB US, ITCs show a severe retraction pattern on 
coronal images (Figs 2.20, 2.21).
Figure 2. 17 ILC in a 50-year-old woman with heterogeneously dense breasts and a clear architectural 
distortion seen at mammography (Fig E10). AB US images show an irregular nonparallel mass with indistinct 
and angular margins (arrowheads). A strong retraction pattern is seen on the coronal image. Histologic 
analysis confirmed a 28mm ILC, which manifested as a hypoechoic lesion with posterior acoustic shadowing. 
The longest imaging diameter was 18 mm at AB US.
Figure E 10 ILC in a 50-year-old woman 
with heterogeneously dense breasts. Right 
CC and MLO mammograms show a clear 
architectural distortion (arrowheads). The 
architectural distortion was confirmed with 
supplemental AB US and histologically 
confirmed to be an ILC.  
Figure 2. 18 ILC in a 64-year-old woman with heterogeneously dense breasts and a small focal asymmetry 
seen at screening mammography (Fig E11). Images from supplemental AB US show a small, irregular, 
indistinct, hyper-/hypoechoic architectural distortion with posterior acoustic shadowing (arrowheads) and 
a subtle retraction pattern on the coronal image. Histologic core needle biopsy showed an ILC. (Courtesy 
of Francisca Gras, MD, Centre de Diagnosi per la Imatge, Tarragona, Spain.)
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Figure E 11 ILC in a 64-year-old 
woman with heterogeneously dense 
breasts. Left CC and MLO screening 
mammograms show a focal asymmetry 
(arrowheads) in the upper outer 
quadrant. Supplemental AB US showed 
a subtle lesion, which was histologically 
confirmed to be an ILC.
Figure 2. 19 ILC in a 70-year-old woman with a focal asymmetry at screening mammography (Fig E12). 
Images from supplemental AB US show a hypo-/isoechoic indistinct lesion without a clear mass but with 
focal shadowing and architectural distortion (arrowheads). A clear retraction pattern is seen on the coronal 
image. The maximum diameter measured at AB US was 44 mm. Histologic analysis of the mastectomy 
specimen showed an ILC, the largest diameter of which was 71 mm.
Figure E 12 ILC in a 70-year-
old woman. Right CC and MLO 
screening mammograms show 
scattered areas of fibroglandular 
density and a focal asymmetry 
(arrowheads) in the upper outer 
quadrant of the right breast. 
Supplemental AB US showed 
an indistinct lesion without a 
mass, which was histologically 
confirmed to be an ILC.
Figure 2. 20 ITC in a 52-year-old woman with extremely dense breasts and negative results at screening 
mammography (Fig E13). Supplemental AB US images show a small, irregular, indistinct, hypoechoic lesion 
with posterior acoustic shadowing (arrowheads). There is a strong retraction pattern on the coronal image. 
Surgical excision revealed a 9-mm ITC.
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Invasive Apocrine cancer
One percent to 4% of cancers are IACs. IAC usually stains negative for estrogen and progesterone 
receptors. At US, the appearance of IAC is diverse. IACs may resemble triple-negative IDCs well-
defined, hypoechoic, round or oval masses that may show posterior acoustic enhancement and 
are almost cyst-like but some case reports have shown IACs as nonparallel, irregular, hypoechoic 
masses (114,116,132,133). At AB US, IACs may manifest as irregular or oval hypoechoic masses 
with posterior acoustic enhancement. IACs tend to be circumscribed and show a hyperechoic 
rim, but not an echogenic halo. Minimal retraction patterns are observed on coronal images 
(Figs 2.22, 2.23).    
Invasive Mucinous Carcinoma
IMC or colloid carcinoma is seen in approximately 2% of breast cancer patients (120). IMC 
develops from the milk ducts, and the cancer cells typically “float” in mucin. IMCs often manifest 
with a distinctive US appearance. IMCs may appear as isoechoic or heterogeneous and complex 
solid/cystic masses or as well-defined circumscribed or microlobulated masses. They tend to be 
oval or lobulated and mostly show posterior acoustic enhancement (134–136). At AB US, IMCs 
may demonstrate a retraction pattern on coronal images (Fig 2.24).
Figure E 13 ITC in a 52-year-old woman 
with extremely dense breasts. Left CC 
and MLO screening mammograms show 
a normal appearance. Supplemental AB 
US showed a small architectural distortion 
with acoustic shadowing in the upper 
outer quadrant, which was histologically 
confirmed to be an ITC.
Figure 2. 21 Grade 1 ITC in a 50-year-old woman with a small retroareolar mass and architectural distortion 
at mammography (Fig E14). AB US images show a corresponding small, irregular, heteroechoic mass with 
minimal posterior acoustic shadowing, an echogenic halo, and a relatively strong coronal retraction 
phenomenon (arrowheads). Pathologic evaluation showed an 11-mm grade 1 ITC. (Courtesy of Matthieu 
J. C. M. Rutten, MD, PhD, Jeroen Bosch Hospital, ‘s-Hertogenbosch, the Netherlands.)
Figure E 14 Grade 1 ITC 
in a 50-year-old woman 
with fatty breasts. Left CC 
and MLO mammograms 
s h o w  a  s m a l l 
architectural distortion 
in the retroareolar area 
(arrowheads).
Supplemental AB US 
showed a corresponding 
small  architec tural 
distortion. Histologic 
evaluation showed a low-
grade ITC.
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Figure 2. 22 IAC in a 74-year-old woman with a mass at screening mammography (Fig E15). AB US images 
show an irregular nonparallel mass with angular margins, a heterogeneous echo pattern, and combined 
posterior acoustic shadowing and enhancement (arrowheads). The coronal image shows a moderately 
severe retraction pattern. Pathologic evaluation showed a 9-mm IAC.
Figure E 15 IAC in a 74-year-old 
woman with heterogeneously 
dense breasts. Right CC and 
MLO screening mammograms 
show a mildly spiculated mass 
in the upper outer quadrant 
(arrowheads). It was histologically 
confirmed to be an IAC.
Figure 2. 23 IAC in an asymptomatic 45-year-old woman with heterogeneously dense breasts and 
a suspicious lesion at screening mammography (Fig E16). Images from supplemental AB US show an 
irregular, nonparallel, indistinct, angular, hypoechoic mass (arrowheads). The mass has posterior acoustic 
enhancement and a subtle retraction pattern on the coronal image. It was histologically proved to be an IAC.
Figure E 16 IAC in an asymptomatic 
45-year- old  woman with 
heterogeneously dense breasts. Left 
CC and MLO screening mammograms 
show a small irregular asymmetry 
in the posterior part of the breast at 
the 12-o’clock position (arrowhead). 
Histologic evaluation confirmed it to 
be an IAC.
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Common reasons for false-negative examinations
Like all other screening modalities, AB US as a supplemental screening modality will yield false-
negative results. These are partly due to interpretation and overlook errors by the reporting 
radiologist, which have been documented for every modality in breast imaging. 
In large imaging volumes, such as in AB US, small invasive cancers may be easily missed (Fig 
2.25). In fact, small aggressive cancers may look like tiny cysts and are hence easily disregarded 
when evaluating AB US images (Fig 2.26). These cancers are more easily detected with breast 
MR imaging or, in the case of microcalcifications, with mammography. Nevertheless, most 
cancers are accompanied by (subtle) architectural distortion, which is seen on the multiplanar 
reformatted images of AB US. Consequently, detection of this distortion may lead to timely 
detection of the cancer. 
In addition, false-negative examinations may result from lesions that are not at all visible or 
only discreetly visible at AB US. 
Figure 2. 24 IMC in a 39-year-old woman with a hyperdense asymmetry centrally located in the breast at 
mammography (Fig E17). Images from supplemental AB US show an irregular, lobulated, iso-/ hypoechoic 
mass that is both solid and cystic (arrowheads). A combined pattern of posterior acoustic enhancement 
and shadowing is seen. The retraction phenomenon is seen on the coronal image. Histologic evaluation 
showed an IMC. (Courtesy of Francisca Gras, MD, Centre de Diagnosi per la Imatge, Tarragona, Spain.)
Figure E 17 IMC in a 39-year-old woman 
with dense breasts and a palpable mass 
behind the nipple. Left CC and MLO 
screening mammograms show a dense 
spiculated focal asymmetry at the 12-o’clock 
axis middle-depth position (arrowheads). It 
was histologically confirmed to be an IMC.
Figure 2. 25 IDC in a 44-year-old woman with extremely dense breasts at high risk of developing breast 
cancer. Images from screening AB US show a 7-mm irregular hypoechoic mass with combined acoustic 
shadowing and enhancement (arrowheads); however, this mass was not reported. In the subsequent 
screening round, mammography showed a new group of fine pleomorphic calcifications (not shown). 
Handheld US showed an 11-mm irregular mass (Fig E18), which corresponded to the lesion missed in the 
previous screening round. Pathologic evaluation showed an 11-mm IDC with surrounding DCIS.
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Figure E 18 IDC in a 44-year-old woman with extremely dense breasts at high risk of developing breast 
cancer. Handheld US image shows an irregular angular mass (cursors) with combined posterior acoustic 
shadowing and enhancement. This screening-detected IDC corresponded to a smaller mass seen at prior 
supplemental AB US screening (Fig 25).
Figure 2. 26 High-grade IDC in a 48-year-old woman with a BRCA2 germline mutation who underwent a 
6-month surveillance program with AB US in addition to MR imaging and full-field digital mammography. 
Images from the 6-month interval AB US examination show a round hypoechoic lesion with minor posterior 
acoustic enhancement (arrowheads). The lesion was interpreted as a cyst. Six months later, handheld US 
showed that the lesion had tripled in size (Fig E19). It was diagnosed as a high-grade IDC after histologic 
evaluation of the surgically excised specimen.
Figure E 19 High-grade IDC in a 48-year-old woman with a BRCA2 germline mutation. Handheld US image 
obtained 6 months after AB US (Fig 26) shows a hypoechoic, taller than wide, circumscribed mass in the 
same position as the lesion classified as BI-RADS 2 at prior AB US. The lesion has grown and was histologically 
confirmed to be a high-grade IDC.
Ductal Carcinoma in Situ
Pure DCIS (stage pTis in the TNM system) is rarely detected by means of breast US (Table 2.1). 
Pure DCIS is detected mostly because of microcalcifications at mammography or enhancement 
at breast MR imaging. Only incidentally does DCIS manifest as a circumscribed mass at US. 
The majority of cases of pure DCIS are inconspicuous at US. They do not manifest as a mass 
or architectural distortion, but appear with more subtle imaging characteristics such as filled/ 
dilated ducts, in which microcalcifications might sometimes be discreetly visible (Figs 2.27, 2.28) 
(137). These findings are likely more difficult to see at AB US than at handheld US, thus even 
further reducing the sensitivity for DCIS.
Sonographically inconspicuous invasive cancers
Some cancer types, such as ILC, may also have a more subtle appearance at AB US and remain 
a challenge for detection. Lobular cancers have a more diffuse growth pattern in the breast 
and may be less conspicuous at AB US than clear tumor foci of invasive ductal cancer. This 
typical growth pattern is also the reason why ILCs are an important cause of false negatives 
at mammographic screening (127). However, fast-growing high-grade IDCs may also have an 
inconspicuous appearance at AB US (Fig 2.29), as they resemble benign lesions.
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Figure 2. 27 IDC and DCIS in a 35-year-old woman with extremely dense breasts at increased risk of 
developing breast cancer. Screening mammography showed suspicious microcalcifications (Fig E20). Images 
from supplemental AB US show a large area with milk ducts filled with hypoechoic tissue and calcifications 
(arrowheads). At least two masses were also seen (*), which were not identified at mammography. Simple 
mastectomy after neoadjuvant chemotherapy showed an area of 60 mm that included two foci of IDC of 
6 and 4 mm with grade 2 DCIS in between.
Figure E 20 IDC and DCIS in a 35-year-old 
woman with extremely dense breasts at 
increased risk of developing breast cancer. 
Left CC and MLO screening mammograms 
show suspicious microcalcifications 
(arrowheads). Supplemental AB US confirmed 
the calcifications in the milk ducts and also 
showed two suspicious irregular masses. 
Histologic analysis showed the area with 
microcalcifications to be DCIS and the masses 
to be IDC.
Figure 2. 28 Intraductal papillary carcinoma and DCIS in a 45-year-old woman with heterogeneously 
dense breasts. Mammography showed a central-lateral area with extensive micro-calcifications (Fig 
E21). AB US images also show a solid oval hypoechoic mass with posterior acoustic enhancement and 
no retraction phenomenon (*). Histologic evaluation of a surgically excised area showed an intraductal 
papillary carcinoma (*) and low-grade DCIS with microcalcifications in the surrounding area (arrowheads). 
(Courtesy of Matthieu J. C. M. Rutten, MD, PhD, Jeroen Bosch Hospital, ‘s-Hertogenbosch, the Netherlands.)
Figure E 21 Intraductal papillary carcinoma 
and DCIS in a 45-year-old woman with 
heterogeneously dense breasts. Right CC 
and MLO mammograms show a central-
lateral area with extensive microcalcifications 
(arrowheads). Supplemental AB US confirmed 
the calcifications in dilated milk ducts and 
also showed a suspicious mass. Histologic 
evaluation of a surgically excised area showed 
an intraductal papillary carcinoma, along with 
low-grade DCIS with microcalcifications in the 
surrounding area.
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Figure 2. 29 Grade 3 IDC in a 50-year-old woman with heterogeneously dense breasts and suspicious 
microcalcifications at screening mammography (Fig E22). Results of supplemental AB US screening were 
reported as negative. Results of staging MR imaging correlated with the mammographic findings (Fig E23). 
In retrospect, AB US images show a subtle architectural distortion (arrowheads), which correlated with the 
MR imaging findings. Histologic evaluation showed a 15-mm grade 3 IDC.
Figure E 22 Grade 3 IDC in a 50-year-old woman with heterogeneously dense breasts. Left CC and MLO 
screening mammograms show suspicious microcalcifications (arrowheads). Results of supplemental AB US 
were reported as negative, but in retrospect a subtle irregular mass was seen (Fig 29). Histologic evaluation 
showed a 15-mm grade 3 IDC.
Figure E 23 Grade 3 IDC in a 50-year-old woman with heterogeneously dense breasts and suspicious 
microcalcifications at screening mammography (Fig E22) but negative results at supplemental AB US 
(Fig 29). Staging MR image shows an enhancing spiculated mass with malignant washout characteristics 
(arrowhead). Histologic evaluation showed a 15-mm grade 3 IDC.
Conclusion
AB US is a promising technique that allows whole-breast evaluation to be performed by 
technicians in a standardized way. Radiologists may choose to perform supplemental screening 
in women with dense breasts by using AB US. In fact, the reproducibility and standardized 
acquisition protocols provide an advantage for AB US over handheld US in supplemental 
screening. 
In women with dense breasts, supplemental US performed with AB US systems leads to ad-
ditional detection of small early-stage invasive breast cancers. However, supplemental AB US 
will also lead to an increase in recall rate and decrease in specificity. There is a learning curve 
for both acquisition and interpretation of AB US images. The appropriate amount of training 
to optimize the learning curve depends highly on the experience of the radiologists. With pre-
existent knowledge of the US appearance of structures in the female breast, the learning curve 
for AB US is expected to be comparable to that for DBT. 
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Understanding the pitfalls in acquisition and interpretation of AB US images may improve the 
quality of AB US evaluations and hence increase the value of supplemental US as offered to 
asymptomatic women with dense breasts in daily screening practice.
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Abstract
Rationale and Objectives
To investigate the value of multiplanar reconstructions (MPRs) of automated three-dimensional 
(3D) breast ultrasound (ABUS) compared to transverse evaluation only, in differentiation of 
benign and malignant breast lesions.
Materials and Methods
Five breast radiologists evaluated ABUS scans of 96 female patients with biopsy-proven 
abnormalities (36 malignant and 60 benign). They classified the most suspicious lesion based on 
the breast imaging reporting and data system (BI-RADS) lexicon using the transverse scans only. 
A likelihood-of-malignancy (LOM) score (0–100) and a BI-RADS final assessment were assigned.
Thereafter, the MPR was provided and readers scored the cases again. In addition, they rated the 
presence of spiculation and retraction in the coronal plane on a five-point scale called Spiculation 
and Retraction Severity Index (SRSI). Reader performance was analysed with receiver-operating 
characteristics analysis.
Results 
The area under the curve increased from 0.82 to 0.87 (P = .01) after readers were shown the 
reconstructed planes. The SRSI scores are highly correlated (Spearman’s r) with the final LOM 
scores (range, r = 0.808–0.872) and ∆LOM scores (range, r = 0.525–0.836). Readers downgraded 
3%–18% of the biopsied benign lesions to BI-RADS 2 after MPR evaluation. Inter-reader 
agreement for SRSI was substantial (intraclass correlation coefficient, 0.617). Inter-reader 
agreement of the BI-RADS final assessment improved from 0.367 to 0.536 after MPRs were read.
Conclusions
Full 3D evaluation of ABUS using MPR improves differentiation of breast lesions in comparison 
to evaluating only transverse planes. Results suggest that the added value of MPR might be 
related to visualization of spiculation and retraction patterns in the coronal reconstructions.
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Introduction
Handheld ultrasound (HHUS) is a standard diagnostic modality in breast cancer diagnosis.  HHUS 
is also increasingly used for screening, due to the increasing awareness of underperformance of 
mammography in women with dense breasts. Additional screening with bilateral whole breast 
HHUS in these women improves the cancer detection rate (36,41,138,139). However, HHUS 
whole breast screening is time consuming and should be performed by a trained physician. 
HHUS is therefore relatively expensive. Automated three-dimensional (3D) breast ultrasound 
(ABUS) can overcome these limitations of HHUS. The acquisition is performed by a technician 
who positions the automatically driven wide linear array transducer for each volume on a 
predefined location of the breast. Depending on the size of the breast, three–five separate ABUS 
volumes are required for full breast coverage (140,141). The acquisition of standardized volumes 
enables comparison of new examinations to relevant priors, which is not feasible with HHUS.
ABUS volume scans consist of a series of sequential transverse images. These are reconstructed 
into coronal and sagittal images on a dedicated workstation (Fig. 3.1). Coronal reconstructions 
provide a comprehensive view of the breast anatomy (140) and visualize the effect of breast 
lesions on neighboring breast tissue (142,143). Spiculation of malignant lesions and the retraction 
phenomenon caused by an accompanying desmoplastic reaction give rise to architectural 
distortion, which is best viewed in this coronal plane (93,144,145). The architectural distortion 
discriminates strongly between benign and malignant breast lesions (31,146).
Recent studies investigated reader variability in ABUS using the breast imaging reporting and 
data system (BI-RADS) lexicon and scoring system for breast US showing good reproducibility 
of ABUS interpretation (90,143). Moreover, agreement between observers seems to be similar 
or even higher when compared to HHUS inter-reader agreement (32,147–149). Standard HHUS 
systems do not enable the user to evaluate lesions in the coronal plane and the BI-RADS lexicon 
provides no particular descriptors for lesions in coronally reconstructed ABUS images. Additional 
descriptors would help to standardize and eventually improve breast lesion characterization 
in ABUS images. Standardization is desired because screening with ultrasound detects many 
otherwise unobserved benign lesions, some of which may require histologic verification 
(41,150,151).  Consequently, improvement of ABUS-based lesion characterization may help to 
reduce referrals and avoid unnecessary biopsies.
The purpose of this study was to investigate the incremental value of multiplanar reconstructions 
(MPRs) of ABUS in differentiation between benign and malignant breast lesions. In addition, 
we evaluated the importance of the better visibility of spiculation and retraction in the coronal 
plane.
Methods
We performed a retrospective multi-reader multi-case study (MRMC) in a sequential design 
(152,153) using ABUS scans of women who underwent histologic biopsy for a breast lesion. The 
institutional review board approved the study, allowed the use of medical images, and waived 
the need for informed consent.
Inclusion and exclusion of patients
We searched our consecutive database of female patients who underwent ABUS scans between 
October 2010 and October 2012. Scans were included when they contained a lesion that was 
confirmed by an HHUS examination and biopsied under ultrasound guidance. This yielded a 
total of 136 patients. Exclusion criteria were inconclusive US biopsy results followed by magnetic 
resonance (MR) biopsy (n = 16) or stereotactic biopsy (n = 1). These patients had lesions that were 
detected on MRI or mammography and were not unambiguously reproducible by HHUS and 
consequently MR biopsy or stereotactic biopsy followed. Furthermore, we excluded non-breast 
lesions (n = 1), ultrasound-guided drainage of uncomplicated cysts (n = 5), poor quality scanning 
where artefacts obscured the visibility of the lesion (n = 3), and non-ABUS examinations coded 
as ABUS in the hospital’s register (n = 4). This left a total of 60 noncancer cases and 46 cancer 
cases eligible for our study. We increased the ratio of benign versus malignant lesions, to obtain 
a positive predictive value of ABUS findings more in line with earlier reported results (between 
Figure 3. 1 Multiplanar reconstructions of automated breast ultrasound (ABUS) and reading protocol. The 
original transverse ABUS images are reconstructed into coronal and sagittal planes. The reader can therefore 
view the breast lesion in three orthogonal planes (e.g. transverse, coronal, and sagittal). The coronal 
reconstructions provide a comprehensive view on the breast anatomy. During the reader experiment, 
the readers initially were shown the transverse images only on full screen (top plane of this figure only) 
to classify the most suspicious lesion. Thereafter, the MPRs were shown and readers were asked to classify 
the lesion again and rate spiculation and retraction in the coronal plane.
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30.7% and 38.4%) (44) by randomly excluding 10 malignant lesions. Consequently, 96 cases 
were presented to the readers.
Gold standard
Histopathologic evaluation of the biopsy specimen, or, in case of malignant lesions, of the 
surgical excision was regarded as gold standard. Biopsies were performed under ultrasound 
guidance (8–12 MHz AplioXG ultrasound system; Toshiba, Japan) or Acuson S2000 (Siemens 
Medical Solutions; Mountain View, CA) using a 14–18G large core needle (BARD Magnum; Bard 
Biopsy Systems, Tempe, AZ). All biopsied lesions were annotated in the ABUS scans by a clinical 
researcher with 1-year experience with ABUS based on the primary radiology images and reports 
and biopsy results from the pathology reports. The annotations served as gold standard for 
evaluation of lesion location.
ABUS examination
ABUS images were obtained with an Acuson S2000 ABVS (Siemens Medical Solutions). Using 
this machine volumes of 154 x 168 x 60 mm3 are imaged with a 14L5BV 5–14 MHz automatically 
driven linear array transducer. The original ABUS images are acquired in the 154-mm wide 
transverse plane and consist of 318 contiguous images of 0.5-mm thickness. The MPRs, in sagittal 
and coronal planes, are automatically created using a dedicated diagnostic workstation. Because 
the width of the transducer is generally not sufficient to image the entire breast, three–five 
slightly overlapping volumes are acquired for each breast. These overlapping volumes are 
acquired at predefined sections of the breast. In smaller breasts, sections called the anterior–
posterior (AP), lateral (LAT), and medial (MED) view are sufficient. In larger breasts, additional 
inferior (INF) and superior (SUP) sections can be imaged. One view or volume takes approximately 
70 seconds scanning time.
Readers
ABUS images were evaluated by five dedicated breast imaging radiologists with extensive 
experience with mammography (6, 35, 23,15, and 29 years, respectively) and breast ultrasound 
(6, 35, 23, 15, and 23 years, respectively). The first four radiologists had 3, 6, 3, and 2 years of 
experience with ABUS, respectively. The fifth radiologist was the least experienced in reading 
ABUS with <6 months of experience. Readers were blinded to patient-specific information such 
as name and date-of-birth, clinical examination, anamnesis, reports from the ABUS examination, 
other diagnostic imaging tests, pathology results, and annotations in the ABUS images.
Patient characteristics
Clinical indications for radiologic work-up, including ABUS, were symptoms such as a palpable 
lump, skin or nipple retraction, nipple discharge or breast pain (n = 51), or referral from the 
national breast cancer screening program in the Netherlands (n = 26). Furthermore, 19 patients 
underwent ABUS as part of a high-risk screening program for women with >50% lifetime risk of 
developing breast cancer. Mean patient age was 49 years. Mean age in cancer cases was 57.7 
years. In the noncancer cases, the mean age was 44 years. Median size of malignant lesions was 
20.5 mm (range, 7.5–130) and median size of benign lesions was 10 mm (range, 3–44). Table 
3.1 summarizes lesion and patient characteristics of the malignant lesions and Table 3.2 of the 
benign lesions.
Table 3. 1 Characteristics of malignant lesions. A total of 36 cases showed a malignant lesion with a variety 
of cancer types and sizes. All malignant lesions were biopsied under ultrasound guidance.
Pathology results Median Lesion size in mm (range)
Invasive Ductal Carcinoma (n=6) 19 (13-40)
IDC, DCIS combined (n= 22) 19.5 (7.5-70)
Invasive Lobular Carcinoma (n=6) 30 (17-130)
Papillary carcinoma (n=2) 18.5 (15-22)
Table 3. 2 Characteristics of benign lesions. 60 cases showed lesions that were proven benign with a variety 
lesion types and sizes. All benign lesions were biopsied under ultrasound guidance.
Pathology results Median Lesion size in mm (range)
Infectious lesion (n=6) 15 (5-25)
Fibroadenoma (n=21) 10 (6-18)
Complex cysts (n=5) 10 (6-25)
Adenosis (tumor) (n=3) 8 (5-20)
Fibrosis (n=6) 20 (8-40)
Intraductal papilloma (n=5) 12 (4-18)
Hamartoma (n=1) 16
Clustered microcysts (n=3) 10 (10-16)
Complex sclerosing lesions (n=3) 20 (15-44)
Fasciitis nodularis (n=1) 8
Atypical inflammation (n=6) 8 (5-17)
Methodology of ABUS reading
Before reading the cases, all readers were instructed in the use of the research workstation 
with two example cases (beta-release of Syngo Ultrasound Breast Analysis [sUSBA] version 
VA25A; Mevis Breast Care, Bremen, Germany). No further training was provided because all 
readers were familiar with ABUS and the BI-RADS-US lexicon. In the reading sessions, we only 
presented one volume per case after visibility of the biopsied lesion was confirmed by the clinical 
researcher. We chose a sequential design for this MRMC study. A sequential design was preferred 
over an independent MRMC study design for our study purposes. In a sequential reader study 
design, in contrast to an independent reader study design, the reader reads the second reading 
mode immediately after the first reading mode without an interval period. Several reports have 
shown that sequential reader studies have higher power as a result of less observed reader 
variance and do not affect the effect size compared to independent reader studies (152,153). 
The cases were presented in a randomized reading order. At first, only the original transverse 
images were presented (Fig 1, top plane only). Readers were instructed to scroll through the 
transverse slices to find the most suspicious lesion, and to subsequently classify this lesion 
using the BIRADS (154–156) ultrasound lexicon and scoring system. A BI-RADS score between 
2 and 5 was requested, BI-RADS 0, 1 and 6 were excluded. BI-RADS category 4 subdivisions (a, 
b, and c) were not used. To further specify the suspiciousness of each lesion, a ‘‘likelihood-of-
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malignancy’’ (LOM) score was requested on a quasi-continuous linear scale from 0 to100. In this 
LOM scale, a score of 0 indicates no suspicion of cancer and 100 indicates the highest suspicion 
of a cancer. A quasi-continuous scale is commonly used in reader studies and is preferred over a 
ordinal scoring system, such as BI-RADS, in ROC analysis (157,158). Readers were instructed to be 
consistent in their use of the LOM scoring method. Thereafter, a multiplanar hanging was shown 
to the readers including the original transverse images, and reconstructions in coronal and 
sagittal planes (Fig 1). The readers were instructed to grade spiculation and retraction patterns 
independently in the coronal planes on a five-point scale (‘‘none,’’ ‘‘mild,’’ ‘‘moderate,’’ ‘‘strong,’’ 
and ‘‘severe’’). ‘‘Spiculation’’ was defined as hypoechoic lines radiating from the margins of the 
lesion. ‘‘Retraction’’ was defined as hyperechoic tissue forming a stellate pattern surrounding 
the lesion, likely caused by a desmoplastic reaction. We allocated points for each of the five 
grades (‘‘none’’ is 1 point, ‘‘mild’’ is 2 points, ‘‘moderate’’ is 3 points, and so on). To obtain a single 
measure, we averaged the scores for spiculation and retraction in the ‘‘Spiculation and Retraction 
Severity Index’’ (SRSI), which was used for further calculations. The SRSI ranges between one (no 
spiculation or retraction) and five (severe spiculation and retraction). Next, readers were asked 
to reconsider their interpretation of the lesion, and if necessary adjust, the BI-RADS and LOM 
scores given after transverse evaluation based on the multiplanar evaluation.
Statistical analysis
The performance of the readers based on the LOM scores before and after evaluation of the MPR 
was analysed using the area under the curve (AUC) of receiver-operating characteristics analysis 
(ROC). ROC analysis was performed with the Dorfman–Berbaum–Metz method (DBM-MRMC 
package v2.33, http://perception.radiology.uiowa.edu) as is commonly used for MRMC studies 
in medical imaging (159–161).  This software package employs ANOVA and jackknifing (162). 
To analyse whether the spiculation and retraction patterns in the coronal plane are in itself 
predictive of a benign or malignant nature of a breast lesion, ROC analysis of the SRSI values 
was also performed. To assess whether the observed spiculation and retraction patterns in 
the coronal plane contribute to eventual changes of radiologists’ perception of the nature of 
the lesion after MPR reading of ABUS volumes, we determined the correlation between final 
LOM scores and SRSI values. Correlation was also determined between SRSI values and the 
change in LOM scores defined as the reassessed LOM scores minus the initial LOM scores (∆LOM). 
Correlations were calculated using spearman’s rank correlation coefficient (33). Furthermore, 
the intraclass correlation coefficient (ICC, two-way random, single measure) was calculated 
for SRSI values to assess interreader agreement of the assessment of architectural distortion 
in the coronal plane. Finally, inter-reader agreement was also calculated for the BI-RADS 
final assessment before and after the MPRs were shown to the readers. P values < 0.05 were 
considered significant. Statistic tests, other than DBM–MRMC analysis, were performed with 
SPSS 20.0 (IBM business Analytics, NY).
Results
Reader performance
AUC’s for transverse reading only ranged from 0.74 to 0.88. Evaluating the MPR’s after the 
transverse ABUS images increased the AUC for each individual reader (Table 3.3). The overall 
AUC values significantly improved from 0.82 (95% confidence interval [CI], 0.747–0.906) to 0.87 
(95% CI, 0.802– 0.942; P = .01; Fig 3.2) after case-based MRMC ROC analysis.
After evaluation of the MPR, readers downgraded several benign cases from a BI-RADS 3 or 4 
score to a BI-RADS 2 score. Although this study was conducted retrospectively and did not affect 
the clinical routine, a BI-RADS 2 assessment would have avoided an unnecessary biopsy of a 
benign lesion. This occurred in 7%, 5%, 13%, 18%, and 3% of all benign cases, respectively. One 
reader downgraded one cancer case after evaluation of coronal reconstructions to BI-RADS 2.
Figure 3. 2 Overall ROC curves before and after MPR evaluation. ROC curves for all readers combined in 
the differentiation between benign and malignant lesions. The AUC improves when comparing curves 
for transverse evaluation of the cases and after reading MPR. AUC values improve from 0.82 to 0.87 at P 
= .01. The ROC curve of the SRSI scores shows that SRSI is useful in differentiating between benign and 
malignant lesions. Results are considered significant when P < .05. ABUS, automated breast ultrasound; 
AUC, area under the ROC curve; MPR, multiplanar reconstruction; ROC, receiver-operating characteristics; 
SRSI, Spiculation and Retraction Severity Index.
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Spiculation and Retraction Severity Index
Evaluation solely based on SRSI differentiates very well between malignant and benign lesions. 
The mean AUC obtained with SRSI (0.825) is similar to the AUC of the transverse lesion evaluation 
(0.826) (Table 3.3).
SRSI values correlate strongly positive with reassessed LOM scores (r= 0.872, 0.852, 0.847, 0.808 
and 0.825, p<0.001) and change in LOM scores (r=0.836, 0.671, 0.525, 0.629 and 0.646, p<0.001). 
This indicates that SRSI values are strongly associated with the overall classification of cases by 
the readers. Readers classifying cases as less likely to be malignant tend to score low on the 
SRSI index and vice versa. 
Reader agreement
Only cases where at least three readers chose the same lesion to evaluate were included in the 
agreement analysis. Consequently, 12 out of 60 benign cases were excluded from the agreement 
analysis. Interreader agreement of SRSI classification is substantial (ICC = 0.617 (95% CI 0.521-
0.709)). Interreader agreement of the BI-RADS final assessment scores was 0.367 (95% CI 0.246-
0.492) and improved to 0.536 (95% CI 0.429-0.640) after the radiologists were shown the MPR. 
Table 3. 3 Areas under the curve after transverse reading, multiplanar reconstructions reading and based 
on SRSI values. The AUC for each radiologist prior to and after evaluation of multiplanar reconstructions. 
All radiologists improve in differentiation between benign and malignant lesions. Overall performance 
increased significantly. Averaged AUC of SRSI is almost equal to the averaged AUC after transverse reading.
Reader Transverse AUC SE MPR AUC SE SRSI AUC SE
1 0.881   0.038 0.907 0.034 0.883 0.036
2 0.852 0.039 0.884 0.036 0.828 0.047
3 0.826 0.044 0.897 0.036 0.796 0.052
4 0.743  0.054 0.818 0.049 0.797 0.051
5 0.829 0.044 0.854 0.045 0.824 0.045
Average 0.826 0.039 0.872 0.035 0.825 0.034
AUC = Area under (ROC) curve; SE = Standard Error; SRSI = Spiculation and Retraction Severity Index
Discussion
To our knowledge, this is the first report that clearly shows the positive effect of the MPR 
of ABUS scans on radiologists’ performance. Although the benefit of the coronal planes has 
been hypothesized in several earlier studies (93,144,145,163,164) the effect on radiologists’ 
interpretations has not been quantified before.
This study shows that evaluating the MPR, after reading transverse ABUS data only, improves the 
overall and individual accuracy of the radiologists. Overall reader agreement in the use of the 
BI-RADS scoring system improved by adding additional (reconstructed) planes to the original 
transverse ABUS images. Furthermore, the study results suggest that the clear presentation of 
spiculation and retractions patterns on the coronal reconstructions contributes strongly to the 
additional value of MPR.
The American College of Radiologists (ACR) recommends to evaluate breast lesions in orthogonal 
planes (e.g., transverse and sagittal) using HHUS because breast cancer features can be very 
subtle and may only be detectable in either one of the orthogonal planes (94). The ABUS system 
generates 3D volumes, and therefore, adds a third plane to the evaluation of breast lesions 
in ultrasound. The additional information in this third (coronal) plane significantly aids in the 
differentiation between benign and malignant breast lesions, given our AUC improvement from 
0.82 to 0.87 (P = .01), and the MPR should therefore also be evaluated. In earlier descriptive 
evaluations of ABUS, image reconstruction in the coronal plane is also considered to be of 
added value. These studies mainly describe the  comprehensive view on breast anatomy and the 
retraction phenomenon as likely beneficial (93,144,145,164). In our subset, there are malignant 
lesions where spiculation is almost absent while retraction is evident and vice versa (Figs 3.3 and 
3.4). Spiculation of malignant lesions and the retraction phenomenon of malignant lesions are 
results of invasive growth and accompanying desmoplastic reaction, patterns that are mostly 
seen parallel to each other in malignant lesions (165). Therefore, we chose to combine both 
features into one index, SRSI. In this study, we asked radiologists to score SRSI on the coronal 
planes only. 
Figure 3. 3 Example of an automated breast ultrasound scan. A 78-year-old woman with a palpable lump 
in the right outer upper quadrant. Pathology reports showed this is a grade III invasive ductal carcinoma. 
This lesion shows spicules in coronal and transverse planes; however, retractions patterns are rated as none.
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Rotten et al. (146) already showed that these patterns extend from the mass to the peripheral 
tissue and that they are best seen on reconstructed coronal planes. Presumably these patterns 
that are seen on the coronal planes correspond with what BI-RADS describes as architectural 
distortion and spiculated or ill-defined margins in orthogonal HHUS planes. Studies where the 
inter-reader variability of BI-RADS lexicon for HHUS was investigated consistently report low 
agreements for the margin descriptors and in particular for the spiculated margin (147–149). The 
agreement in those studies is considerably lower than the coronal SRSI agreement of 0.617 in our 
study. Moreover, architectural distortion was only reported on rare occasions (147). Therefore, 
rating spiculation and retraction patterns in transverse and sagittal planes seems a difficult task 
and is prone to inter-reader variability, whereas rating these features on coronal planes is easier 
and reasonably reproducible by multiple readers. This is in line with a study by Zhang et al., who 
investigated inter-reader agreement in ABUS of the BI-RADS-US lexicon descriptors (143). They 
additionally proposed a three-class descriptor for the retraction phenomenon in the coronal 
plane (absent or present or indeterminate), which reached moderate agreement. However, 
they did not report on the classification properties of their descriptor. Chen et al. (93) recently 
did report on the classification properties of retraction in the coronal plane. They concluded 
that the retraction phenomenon is highly specific for cancer (100%), providing a 100% positive 
predictive value. However, the histopathology of the lesions included in their analysis was not 
described in detail. In our study, the AUC of SRSI itself was also high for each individual reader 
ranging from 0.796 to 0.883. We thus confirm the discriminating value of the evaluation of 
architectural distortion in the coronal plane. The mean AUC solely based on SRSI scores was 
similar to the mean AUC after transverse reading (0.826 and 0.825, respectively). This implies 
that rating spiculation and retraction patterns on the coronal reconstructions performs as well 
as differentiating breast lesions based on features in the transverse images. However, our readers 
Figure 3. 4 Automated breast ultrasound image of a screening-detected cancer in a 58-year-old woman. 
Pathology reports described a 9-mm wide grade I invasive ductal carcinoma. The lesion showed mild 
spicules but a severe retraction pattern.
read the transverse images before using SRSI on the coronal reconstructions. This may have 
biased the rating of the SRSI. Nevertheless, the high positive (significant) correlation between 
∆LOM and SRSI for each reader shows that the SRSI score improves the overall interpretation of 
breast lesions by radiologists: the higher the SRSI score, the higher the LOM. This implies that 
coronal spiculation and retraction patterns are a pivotal characteristic in ABUS evaluation, and 
the use of MPR is thus essential for optimal lesion evaluation. It can be argued that better lesion 
differentiation is not useful if it does not change the clinical recommendations. However, in our 
study, all readers downgraded several benign cases to BI-RADS 2 (range, 3%–18%) based on 
evaluation of the MPR. In a clinical setting, these cases would therefore not have been biopsied. 
One radiologist downgraded a cancer case from BI-RADS 3 to BI-RADS 2. This particular cancer 
was isoechoic to fatty tissue and oval, it proved to be a 15-mm wide papillary carcinoma, but 
was not clearly located in a duct or cyst. It showed no spiculation or retraction. Some caution is 
thus essential. However, 16 cancers got an average SRSI score of <3; therefore, most malignant 
masses remain suspicious even in the absence of spiculation and retraction.
Spiculation and retraction patterns also occur in non-malignant lesions, for example in complex 
sclerosing lesions or radial scars. However, better detection of these lesions does not seem to be 
a limitation. In approximately 10% of complex sclerosing lesions, malignant lesions are found 
at pathologic examinations. Consequently, current advice is to excise all these lesions as the 
presence of cancer cannot be excluded based on imaging alone (101). Therefore, we believe that 
referring all women with retraction patterns is favourable, unless there is a history of surgery to 
the breast as this can also be a cause of architectural distortion and will present with retraction 
patterns in the coronal reconstructions.
Our study has limitations. The ABUS scans in our data set were obtained for multiple indications. 
However, the purpose of this study was to determine the value of MPR in differentiating between 
benign and malignant lesions regardless of the clinical indication. Therefore, our data set and 
results remain valid. We instructed readers to select the most suspicious lesion in each of the 
transverse ABUS views we presented. Because of this, in some cases, particularly those with 
multiple benign lesions, readers did not all score the same lesion to characterize the view. 
This study design was chosen to prevent a lesion selection bias by the investigators (e.g., by 
only selecting the benign lesions with the least spiculation). As a direct consequence of this 
choice, the overall analysis actually differentiates between a volume with cancer and a volume 
without cancer, rather than being truly lesion specific. However, cases in which readers scored 
different lesions were infrequent, and mainly limited to cases with benign findings (e.g., multiple 
fibroadenomas or cysts). Consequently, the differentiation between malignant and benign 
lesions remains valid. The evaluation of multiple views (e.g., AP, LAT, MED, INF, or SUP) may aid 
in distinguishing lesions from artifacts in clinical practice. In this study, we only showed one 
of these views where the lesion was visible to save reading time, which may have reduced the 
reading accuracy slightly. Although readers were not asked to rate the sagittal reconstructions 
specifically, they were not blinded from these reconstructed images. Therefore, the sagittal 
images may have contributed to the effect of MPR.
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In daily use radiologists do not interpret ABUS cases without clinical examination, patient and 
medical history, nor should ABUS scans be evaluated without knowledge of findings from 
corresponding imaging examinations such as mammography or MRI, when present. 
In conclusion, our study shows that evaluating the MPR of ABUS improves the performance of 
radiologists in the differentiation between malignant and benign lesions. Rating spiculation 
and retraction patterns on coronal reconstructions is important and helps the radiologists using 
the full diagnostic potential of ABUS. The simple index scale (SRSI) presented in this paper, is 
well suited for this task, it is reproducible and easy to use by radiologists. It may help to avoid 
unnecessary biopsies of benign lesions by downgrading BI-RADS scores to BI-RADS 2 after MPR 
evaluation. Adding a descriptor for spiculation and retraction patterns as an ABUS feature to the 
BI-RADS-US lexicon may help standardize and improve lesion characterization in ABUS scans.
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Abstract
Our aim was to investigate whether Breast Imaging Reporting and Data System-Ultrasound 
(BIRADS-US) lexicon descriptors can be used as imaging biomarkers to differentiate molecular 
subtypes (MS) of invasive ductal carcinoma (IDC) in automated breast ultrasound (ABUS). We 
included 125 IDCs diagnosed between 2010 and 2014 and imaged with ABUS at two institutes 
retrospectively. IDCs were classified as luminal A or B, HER2 enriched or triple negative based on 
reports of histopathologic analysis of surgical specimens. Two breast radiologists characterized 
all IDCs using the BI-RADS-US lexicon and specific ABUS features. Univariate and multivariate 
analyses were performed. A multinomial logistic regression model was built to predict the MSs 
from the imaging characteristics. BI-RADS-US descriptor margins and the retraction phenomenon 
are significantly associated with MSs (both p<0.001) in both univariate and multivariate analysis. 
Posterior acoustic features and spiculation pattern severity were only significantly associated in 
univariate analysis (p<0.001). Luminal A IDCs tend to have more prominent retraction patterns 
than luminal B IDCs. HER2-enriched and triple-negative IDCs present significantly less retraction 
than the luminal subtypes. The mean accuracy of MS prediction was 0.406. Overall, several 
BI-RADS-US descriptors and the coronal retraction phenomenon and spiculation pattern are 
associated with MSs, but prediction of MSs on ABUS is limited.
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Introduction
From gene expression profiling, it is clear that breast cancer is a heterogeneous disease (166–
168). Four clinically relevant molecular subtypes (MSs) (luminal A, luminal B, HER2- enriched and 
triple-negative cancers) have been identified with very different prognoses (169). These MSs vary 
in estrogen and progesterone receptor expression, human epidermal growth factor receptor 2 
(HER2) status and proliferation indexes such as Ki-67 and the mitotic activity index (MAI) (170). 
Apart from the prognostic significance, medical treatment of breast cancers is increasingly being 
tailored to this molecular subclassification (171,172).
Currently, the MS of a breast cancer can only be determined by surgical resection specimen 
analysis. Tissue samples obtained by core needle biopsy (CNB) or vacuum-assisted biopsy (VAB) 
during the diagnostic workup produce the earliest available material for this classification 
(171,173–175). However, biopsies are vulnerable to sampling error, and this may negatively 
affect the treatment decision, especially in the era of increasing use of primary systemic therapy 
over primary surgery (176–179). In addition, these sampling errors can significantly increase 
health care costs of breast cancer diagnosis when repeated testing on hormonal receptors and 
HER2 status is needed (180–184).
Breast cancer imaging is readily available in many breast cancer patients from routine workup 
or screening. Thus, determination of imaging phenotypes for prediction or confirmation of 
the MS might be a non-invasive, low-cost tool in better breast cancer diagnosis and treatment 
planning. The use of breast ultrasound (US) has been established in the clinical workup of breast 
lesions. Automated 3-D breast ultrasound (ABUS) systems are a relatively novel extension of this 
technique. In contrast to handheld US devices, ABUS obtains 3-D volumes of the entire breast 
and, hence, allows evaluation of breast lesions in multiple planes. In addition, ABUS enables 
temporal comparison and batch reading of ultrasound examinations. Hence, the availability of 
ABUS in clinical practice is increasing.
Several reports indicate that sonographic imaging features from the Breast Imaging Reporting 
and Data System for US (BI-RADS-US) lexicon are associated with histologic subtype, grade 
and hormone and HER2 receptor status of breast cancer in handheld ultrasound examinations 
(114,116,185). However, the imaging biomarkers for differentiation of MS (186) in ABUS 
examinations have not been explored.
Therefore, the purpose of our study was to investigate whether BI-RADS-US lexicon descriptors 
and specific ABUS features can be used as imaging biomarkers for non-invasive determination 
of the MS of breast cancers in ABUS.
Material and methods
The use of ABUS examinations in this retrospective study was approved by the institutions’ local 
ethics committees, and the need for informed consent was waived.
ABUS examination
All ABUS scans were acquired with an ACUSON S2000 Automated Breast Volume Scanner (ABVS) 
(Siemens, Erlangen, Germany). All ABUS examinations were performed by trained technicians. 
The ABVS acquires 318 transverse 0.5-mm-thick B-mode ultrasound slices with a mechanically 
driven linear array (14L5BV) 5- to 14-MHz transducer. These scans form a 3-D volume of 15.4 
x 16.8 cm with a depth adjustable up to 6 cm. ABVS systems use pre-defined settings that 
technicians can select based on a woman’s breast cup size (A–D+). Each cup size setting has 
a specific frequency and focus depth. Technicians were instructed to select the pre-sets that 
ensure that the pectoral muscle and underlying ribs are seen and the fibroglandular breast 
tissue is in the focal zone. Radiologists subsequently evaluate the ABUS images on a dedicated 
multiplanar hanging workstation (Fig 4.1). Depending on the size of the breast, two to five scans 
per breast are made on predefined locations to ensure the entire breast is covered. Each scan 
takes approximately 60-70 seconds. The 3D volumes are stored in the hospital image archiving 
system from which they can be retrieved when revisiting prior examinations is needed. 
Figure 4. 1 Example of a luminal A invasive ductal cancer on automated breast ultrasound on a standard 
multiplanar hanging workstation (left plane: coronal reconstruction, top right plane: transverse acquisitions, 
bottom right plane: sagittal reconstructions). This invasive ductal cancer is an irregularly shaped, non-parallel 
oriented, non-circumscribed and hypoechoic lesion that presents with posterior acoustic shadowing and 
a strong retraction pattern on the coronal plane.
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Patient data and gold standard
We retrospectively searched the electronic patient charts of an academic hospital and a non-
academic hospital for consecutive patients who were imaged with ABUS and diagnosed with 
invasive ductal cancer (IDC) between August 2010 and December 2014. We recorded tumor 
grade, immunohistochemistry (IHC) results for estrogen receptor (ER) and progesterone receptor 
(PR) and the results from IHC or in situ hybridization for HER2 status performed on surgical 
resection specimens. Tumor grade was assessed according to the Nottingham Histologic Grade 
(modified Bloom–Richardson–Elston), which consists of three variables; gland formation or 
tubular differentiation, nuclear pleomorphism and MAI. We stratified each tumor into one of 
four molecular subgroups based on a combination ER and PR status, HER2 status and MAI. The 
groups are defined in Table 4.1. Cases were not assigned to a subgroup and were excluded from 
analysis if any of the three components was missing.
Tumor location was marked in the ABUS images so that the panel of dedicated breast radiologists 
were pointed directly to the lesions in each ABUS examination during image evaluation.
Table 4. 1 Stratification scheme of invasive ductal cancers into molecular subtype groups.
Molecular subgroup Estrogen/
Progestrone receptor expression
HER2 amplification Mitotic activity index (MAI)
Luminal A + - 6 or less (MAI 1)
Luminal B + -/+ 7 or more (MAI ≥2)
HER2 enriched - + n/a
Triple negative - - n/a
MAI is defined as the number of mitoses per 2 mm2. n/a = not applicable
Image evaluation
Two dedicated breast radiologists with more than 4 years of experience with ABUS evaluated 
all cancers on the ABUS examinations independently. To ascertain that the correct lesion was 
evaluated, all cancers were marked by an experienced researcher based on the original radiology 
report. For each case, the radiologists were blinded to the pathology and radiology results, 
clinical information, medical history, age and institution where the images were acquired. 
Discrepancies between the ratings of the readers after the independent reading sessions were 
solved in a consensus panel meeting.
The radiologists were asked to describe each marked malignancy using the BI-RADS-US lexicon 
(American College of Radiology 2013). The BI-RADS descriptors for masses (shape, orientation, 
margin, echo pattern, posterior acoustic features) were reported for each cancer. Presence of the 
associated finding ‘‘calcifications’’ was also reported. The fifth edition of the ACR BI-RADS-US atlas 
is the first edition with ABUS images revealing the associated finding ‘‘architectural distortion.’’ 
This pattern is recognized in recent literature as the retraction phenomenon and is best seen 
on coronal reconstructions of ABUS (93,110,142,143).
We hypothesize that architectural distortion in the coronal plane is caused by two distinct, but 
related processes: spiculation (radial outgrowth of the tumor in the surrounding tissue) and 
retraction (fibrous response of the body to the tumor). We evaluated spiculation as hypoechoic 
lines radiating from the margin of malignancies. Retraction was evaluated as a hyper-echoic 
stellate pattern surrounding cancers that seem to retract the surrounding breast tissue toward 
the malignancy’s center (e.g., Fig. 4.1). These processes may vary in severity, which may be 
related to the underlying MS. The radiologists were asked to quantify the severity of the coronal 
spiculation and retraction patterns on a 5-point scale (none, mild, moderate, strong and severe). 
In a previous report, we described the effect of quantifying the severity of coronal spiculation 
and retraction patterns on differentiation of benign from malignant breast lesions (96). 
Statistical analysis
We performed chi-square-tests for each descriptor to determine the association between the 
BI-RADS-US descriptors and the four molecular subgroups (univariate analysis). Thereafter, 
we determined whether the significant associations remained valid in a stepwise backward 
elimination multinomial logistic regression analysis (MLR). We analysed what the accuracy of 
the BI-RADS-US descriptors is in predicting the MS of each IDC using an MLR model after fivefold 
cross-validation and balancing both independent training and testing data sets using only the 
descriptors with a significant association with the MS from the MLR analysis. All statistical tests 
were performed with SPSS Version 20 (IBM, Armonk, NY, USA). Differences were considered 
statistically significant at p<0.002 after Bonferroni correction of α.
Results
IDC characteristics
Mean age at the time of diagnosis was 54 (range: 21–84) y. Based on the definition used (Table 
4.1), we included 48 luminal A, 45 luminal B, 13 HER2-enriched and 19 triple-negative cancers. 
Table 4.2 summarizes the cancer characteristics.
As expected, luminal A IDCs are usually low/intermediate-grade cancers, whereas luminal B, 
HER2-enriched and triple-negative IDCs tend to be higher-grade tumors. This pattern of tumor 
grade is also observed for accompanying ductal carcinoma in situ (DCIS) components.
Table 4. 2 Patient characteristics of 111 women diagnosed with 125 invasive ductal cancers.
Patient and cancer characteristics Luminal A 
(n=48*)
Luminal B 
(n=45*)
HER2-enriched 
(n=13*)
TNBC
(n=19*)
Mean Age [SD] 56.9 [10.2] 53.4 [12.9] 51.4 [7.9] 50.5 [14.8]
Multifocality 6 4 2 0
Grade* (%)
I 31 (64.6) 3 (6.7) 0 (0) 1 (5.3)
II 17 (35.4) 22 (48.9) 2 (15.4) 1 (5.3)
III 0 (0) 20 (44.4) 4 (30.8) 15 (78.9)
X 0 (0) 0 (0) 7 (53.8) 2 (10.5)
Table 4. 2 continues on next page
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Imaging biomarkers
Table 4.3 summarizes the imaging phenotypes based on the BI-RADS-US lexicon of our IDC data 
set per MS. In univariate analysis, the descriptors margin (circumscribed vs. non-circumscribed) 
and posterior acoustic features were significantly associated with different MSs. Furthermore, 
coronal spiculation and retraction patterns, summarized in the BI-RADS-US atlas as architectural 
distortion, are also significantly associated with MSs of IDC. However, in the MLR analysis, 
only the coronal retraction pattern (on a 5-point scale) and the binomial descriptor ‘‘margins’’ 
remained significant in characterizing MSs of IDC in ABUS (p<0.0001 and p<0.0001, respectively). 
The margins of all the luminal cancers in our dataset were non-circumscribed, but a small 
proportion of HER2-enriched and TNBC IDCs was described as circumscribed. Luminal IDCs are 
more likely to exhibit a stronger coronal retraction pattern than HER2-enriched cancers and 
TNBCs. Interestingly, luminal A IDCs tend to exhibit a stronger retraction pattern than luminal B 
IDCs, and luminal B IDCs tend to have a stronger retraction pattern than the hormone receptor-
negative IDCs (Table 4.4 and Fig. 4.2).
Patient and cancer characteristics Luminal A 
(n=48*)
Luminal B 
(n=45*)
HER2-enriched 
(n=13*)
TNBC
(n=19*)
c/p TN † (%)
T1 29 (70.7) 16 (39.0) 8 (80.0) 10 (52.6)
T2 10 (24.4) 23 (56.1) 1 (10.0) 8 (42.1)
T3 1 (2.4) 1 (2.4) 1 (10.0) 1 (5.3)
T4 1(2.4) 1 (2.4) 0 (0) 0 (0)
N0 29 (70.7) 23 (56.1) 8 (80.0) 14 (73.7)
N+ 12 (29.3) 18 (43.9) 2 (20.0) 5 (26.3)
DCIS
Grade *
I 12 (25.0) 2 (4.4) 0 (0) 0 (0)
II 19 (39.6) 14 (31.1) 0 (0) 2 (10.5)
III 0 (0) 23 (51.1) 7 (53.8) 12 (63.2)
X 17 (35.4) 6 (13.3) 6 (46.2) 5 (26.3) 
* On cancer level 
† On patient level 
SD Standard deviation 
HER2 Human Epidermal Growth Factor Receptor 2 
TNBC Triple Negative breast cancer 
c/p TN clinical/pathological Tumour size and lymph node status (TNM) 
DCIS Ductal Carcinoma in Situ 
X Not present or not reported
Continuation of table 4. 2
Figure 4. 2 Retraction pattern severity per molecular subtype. Note that the data points are ‘‘jittered’’ to 
visualize the distribution. HER2 human epidermal growth factor receptor 2; TNBC triple-negative breast 
cancer.
Table 4. 3 Result from expert panel consensus of sonographic features (BI-RADS lexicon for US) per 
molecular subtype of invasive ductal cancer. 
BI-RADS-US Luminal A Luminal B HER2-enriched TNBC χ2 p-value MLR p-value
No. (%) No. (%) No. (%) No. (%)
Shape 0.012 0.554
Oval 1 (2.1) 5 (11.1) 1 (7.7) 4 (21.1)
Round 0 (0) 0 (0) 2 (15.4) 1 (5.3)
Irregular 47 (97.9) 40 (88.9) 10 (76.9) 14 (73.7)
Orientation 0.043 0.473
Parallel 4 (8.3) 13 (28.9) 4 (30.8) 6 (31.6)
Non-parallel 44 (91.7) 32 (71.1) 9 (69.2) 13 (68.4)
Margin‡ 0.001 <.0001
Circumscribed 0 (0) 0 (0.0) 2 (15.4) 4 (21.1)
Non-circumscribed 48 (100.0) 45 (100.0) 11 (84.6) 15 (78.9)
Table 4. 3 continues on next page
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Continuation of table 4. 3
BI-RADS-US Luminal A Luminal B HER2-enriched TNBC χ2 p-value MLR p-value
No. (%) No. (%) No. (%) No. (%)
Echo pattern 0.199 0.825
Anechoic 0 (0) 0 (0) 0 (0) 0 (0)
Hypoechoic 39 (81.2) 34 (75.6) 11 (84.6) 17 (89.5)
Hyperechoic 0 (0) 0 (0) 0 (0) 0 (0)
Isoechoic 3 (6.2) 0 (0) 0 (0) 0 (0)
Heterogeneous 6 (12.5) 11 (24.4) 2 (15.4) 2 (10.5)
Complex cystic and solid 0 (0) 0 (0) 0 (0) 0 (0)
Posterior acoustic features < 0.0001 0.939
No features 5 (10.4) 10 (22.2) 5 (38.5) 6 (31.6)
Shadowing 37 (77.1) 18 (40.0) 4 (30.8) 3 (15.8)
Enhancement 3 (6.2) 12 (26.7) 4 (30.8) 8 (42.1)
Combined 3 (6.2) 5 (11.1) 0 (0) 2 (10.5)
Associated findings
Calcifications 0.564 0.518
Yes 9 (18.8) 14 (31.1) 3 (23.1) 4 (21.1)
No 39 (81.2) 31 (68.9) 10 (76.9) 15 (78.9)
Architectural Distortion
Spiculation pattern < 0.0001 0.871
None 0 (0) 2 (4.4) 5 (38.5) 3 (15.8)
Mild 6 (12.5) 16 (35.6) 4 (30.8) 14 (73.7)
Moderate 19 (39.6) 21 (46.7) 3 (23.1) 2 (10.5)
Strong 17 (35.411) 5 (11.1) 1 (7.7) 0 (0)
Severe 6 (12.5) 1 (2.2) 0 (0) 0 (0)
Retraction pattern < 0.0001 <0.0001
None 0 (0) 10 (22.2) 7 (53.8) 13 (68.4)
Mild 3 (6.2) 14 (31.1) 5 (38.5) 5 (26.3)
Moderate 17 (35.4) 16 (35.6) 1 (7.7) 1 (5.3)
Strong 15 (32.2) 5 (11.1) 0 (0) 0 (0)
Severe 13 (27.1) 0 (0) 0 (0) 0 (0) 
‡ univariate and multivariate analysis of binomial descriptor of Margins e.g. circumscribed vs. non-circumscribed 
BI-RADS-US Breast Imaging-Reporting And Data System for Ultrasound 
IDC Invasive Ductal Carcinoma 
ABUS Automated 3D Breast Ultrasound 
HER2 Human Epidermal Growth Factor Receptor 2 
TNBC Triple Negative breast cancer 
MLR Multinomial Logistic Regression analysis
Molecular subtype prediction 
Table 4.5 summarizes the performance of predicting the MSs of the IDCs in our data set using 
the significant variables from the MLR analysis only. The mean accuracy was 0.406 using the 
binomial BI-RADS-US descriptor for margins and the coronal retraction pattern.
Discussion
Our study indicates that the BI-RADS-US lexicon descriptors margin and posterior acoustic 
features are significantly associated with the MSs of invasive ductal cancer. In addition, the 
severity of spiculation and retraction patterns (also known as the retraction phenomenon), 
summarized in the 2013 BI-RADS-US atlas as ‘‘architectural distortion,’’ evaluated in the coronal 
reconstruction of ABUS acquisitions is also significantly associated with MS (p<0.0001 and 
p<0.0001, respectively). In fact, the coronal retraction pattern severity and the binomial margins 
descriptor are the two most dominant ABUS imaging biomarkers for MSs of IDCs in a multinomial 
logistic regression model. The results indicate that aggressive subtypes have a less prominent 
or even no retraction pattern compared with more indolent subtypes (Fig. 4.3), and more 
frequently exhibit a smooth circumscribed margin.
Table 4. 4 Odds ratios of the severity of retraction per molecular subtype of IDC. 
Molecular Subtype ± B Std. Error p-value Odds Ratio
95% Confidence Interval for Odds Ratio
Lower Bound Upper Bound
Luminal A 3.204 0.563 0.000 24.642 8.172 74.305
Luminal B 1.566 0.451 0.001 4.789 1.977 11.596
HER2-enriched 0.397 0.549 0.470 1.488 0.507 4.364 
± The reference molecular subtype is TNBC 
IDC Invasive Ductal Carcinoma 
HER2 Human Epidermal Growth Factor Receptor 2 
TNBC Triple Negative breast cancer
Table 4. 5 Cross-table for observed and predicted molecular subtypes of our IDC dataset for a MLR prediction 
model using the only the two most dominant descriptors retraction pattern and margins. Matches between 
molecular subtypes as observed based on histopathological evaluation and predicted using the margins 
and retraction descriptors in an MLR-model are bold entries in the cross-table.
 Margin and Retraction descriptors Predicted 
Luminal A
Predicted 
Luminal B
Predicted 
HER2-enriched
Predicted 
TNBC
Predicted 
Total
Observed Luminal A 26 (54.2) 12 (25.0) 5 (10.4) 5 (10.4) 48 (100%)
Observed Luminal B 13 (28.9) 17 (37.8) 6 (13.3) 9 (20.0) 45 (100%)
Observed HER2-enriched 2 (15.4) 3 (23.1) 3 (23.1) 5 (38.6) 13 (100%)
Observed TNBC 3 (15.8) 6 (31.6) 1 (5.3) 9 (47.7) 19 (100%) 
IDC Invasive Ductal Carcinoma 
HER2 Human Epidermal Growth Factor Receptor 2 
TNBC Triple Negative breast cancer 
MLR Multinomial Logistic Regression 
MS Molecular subtypes.
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An understanding of the molecular basis of breast cancer may lead to better, personalized, 
targeted therapy strategies. The imaging biomarkers associated with these molecular building 
blocks have the potential to aid in identifying the best personalized therapy regimes before 
women undergo surgery, possible reducing the sampling error inherent to core needle biopsy. 
Imaging biomarkers may also confirm histopathologic evaluations, thus saving resources 
needed to perform additional or repeated testing. Breast cancer images, such as ABUS images, 
are often already available because they are part of the standard diagnostic workup or screening. 
Nevertheless, our study indicates that prediction of the IDC MSs in ABUS using BI-RADS- and 
ABUS specific descriptors is only moderately accurate, likely because of a large overlap of 
sonographic features seen in the different subgroups of IDC. However, breast cancer staging 
is usually a multimodal approach. Consequently, combining ABUS imaging biomarkers with 
those derived from other imaging modalities (e.g., tomosynthesis, magnetic resonance imaging) 
may in the future help to further stratify IDC more accurately into clinically relevant subgroups. 
Therefore, more research is needed on breast imaging biomarkers from multimodality imaging 
for (molecular) subtyping of breast cancers.
Molecular subtype signatures in breast cancer have higher power in prognostication than tumor 
grade and ER status in multivariate analysis of independent prognostic factors, likely because 
of a large spread of proliferation rates in the ER-positive group (169,187). 
ER-positive breast cancers with a genetically high proliferation profile (luminal B) have a 
distinctly worse survival than low-proliferative ER-positive breast cancer (luminal A), but a better 
survival than HER2-enriched and triple-negative breast cancers (169). Proliferation is therefore 
considered a key factor in predicting the outcome of breast cancer, especially in ER-positive 
groups. Pathology guidelines recommend the assessment of proliferation with either the mitotic 
activity index (MAI) as part of the tumor grading and/or with Ki-67, a proliferation associated 
antigen. In the Netherlands, the latter is not part of the standard pathology workup as it currently 
has no standardized role in prognostic modelling of breast cancer outcomes. Nevertheless, 
Ki-67 and the MAI are of similar prognostic value in terms of survival and are highly correlated 
Figure 4. 3 Detailed coronal ABUS images of typical presentations for each molecular subtype. From left 
to right are a coronal ABUS reconstruction of a luminal A IDC (a), luminal B IDC (b), human epidermal 
growth factor receptor 2-enriched IDC (c) and triple-negative IDC (d). The retraction pattern was rated by 
the expert panel as severe, moderate, mild and none, respectively. ABUS automated breast ultrasound; 
IDC invasive ductal carcinoma.
(170,188). Therefore, we chose MAI as a measure of proliferation and applied the same high 
versus low proliferation categories as in Aleskandarany et al. (170). According to our study, this 
distinction between luminal A and luminal B IDC’s based on proliferation is also reflected by 
sonographic features in ABUS imaging such as the retraction phenomenon.   
The retraction phenomenon measured in the coronal reconstruction of ABUS is the most 
predictive feature in ABUS. The retraction pattern is in general more severe in luminal A than in 
luminal B, HER2-enriched and triple negative IDCs, and it appears to be more severe in luminal B 
IDCs than in HER2-enriched and triple negative IDCs. Therefore, we believe that there is a relation 
between retraction severity and proliferation rate or growth rate of IDCs, because luminal A 
IDCs grow at a slower rate than the other MSs of breast cancer. Other reports on the retraction 
phenomenon speak of a desmoplastic reaction surrounding malignant lesions causing this 
distinctive retraction pattern (110,111).
In a slow-growing luminal A IDC, the human body has more time to react to cancer cells and to 
form the fibrosis that causes the retraction pattern, whereas in faster-growing IDC subtypes, the 
desmoplastic response may not yet have occurred. Although the explanation is very likely, to our 
knowledge this has not been investigated thoroughly, and the true histopathologic aetiology 
of the retraction pattern in ABUS remains to be determined. 
The association between the terms in the BI-RADS-US lexicon and prognostic factors of IDC 
has been described in a few previous reports, but never for the distinct MS as in our study. 
Furthermore, other reports have used 2-D image stills acquired with handheld ultrasound 
devices to characterize cancers, whereas ABUS systems allow whole-tumor characterization in 
a 3-D reproducible ultrasound volume. Nevertheless, the BI-RADS ultrasound features and the 
coronal retraction and spiculation patterns may also be visualized with 2-D handheld ultrasound, 
although the retraction pattern and its extent are best seen in a coronal plane also with handheld 
devices (146). 
Several studies have indicated that the posterior acoustic features differ between high grade 
and low grade breast cancers (115,185). Posterior acoustic features result from use of image 
processing to compensate for a decrease or increase in sound wave passage in tissue areas 
with respectively high or low acoustic impedance compared with the surrounding tissue. We 
did not test which histologic structures were associated with BI-RADS-US descriptors; however, 
the tumor composition of luminal A IDCs apparently results in a higher acoustic impedance 
than the other three groups. Histologically, TNBCs and HER2-enriched tumours exhibit less 
connective tissue and more solid sheets of tumor cells than low proliferative breast cancers, 
such as luminal A IDCs (189,190). 
Therefore, it is likely that the posterior acoustic shadowing in luminal A IDCs is associated with 
larger amounts of connective tissue than in other MSs (Fig 4.4). Posterior acoustic enhancement 
in luminal B, HER2-enriched and triple-negative IDCs may be associated with higher proliferation 
rates and less connective tissue (191) (Fig 4.5). Proliferation may also explain the association with 
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margins, orientation and shape descriptors, because breast cancers with a higher proliferation 
rate also histologically tend to have pushing margins and may appear as round or oval lesions 
that are well circumscribed on ultrasound (189). 
Nevertheless, in our study, the majority of cancers, regardless of MS group, are irregularly 
shaped, non-circumscribed hypoechoic lesions with no posterior acoustic features or acoustic 
shadowing in ABUS.
Figure 4. 4 Detailed coronal (a) and transverse (b) ABUS images of a luminal A IDC with a severe retraction 
pattern on the coronal plane (left). On the transverse plane is an irregularly shaped, non-parallel oriented, 
non-circumscribed and hypoechoic lesion with acoustic shadowing. On the corresponding pathology slide 
is a central tumor with surrounding spicules, often called a stellate (or star-shaped) pattern (c). The tumor 
grows in fields, strands and tubules. The tumor is surrounded by desmoplastic changes in the stroma. 
The tumor cells are small with eosinophilic cytoplasm and exhibit little nuclear pleomorphism (d). ABUS 
automated breast ultrasound; IDC invasive ductal carcinoma.
Figure 4. 5 Detailed coronal (a) and transverse (b) ABUS images of a triple-negative IDC with no retraction 
pattern on the coronal plane (left). Note that the hyper-echoic tissue is mere fibroglandular tissue and not 
a stellate retraction pattern. On the transverse plane is an irregularly shaped, non-parallel oriented, non-
circumscribed and hypo-echoic lesion with some posterior acoustic enhancement. On the corresponding 
pathology slide is a relatively well-circumscribed mass, consisting of tumor cells that are growing in strands 
and nests (c). The tumor cells have enlarged, moderately pleomorphic nuclei. Mitotic figures are present. 
The tumor is diffusely infiltrated by lymphocytes (d). ABUS automated breast ultrasound; IDC invasive 
ductal carcinoma.
Our study has some limitations. The most sensitive method used to determine MS is gene 
expression profiling; however, this method is costly and not (yet) implemented in standard 
care at our institutes. Therefore, we chose combinations of MAI as a binomial proliferation index 
(low vs. high), ER and PR status and HER2 status from histopathologic evaluations to stratify 
IDCs into the MS groups. With these quantitative pathology assessments, inter-tumor and inter-
subgroup heterogeneity may be underestimated. This might also explain some of the overlap 
seen in sonographic features within molecular subgroups of IDC.
B-Mode parameters such as frequency, focus setting, dynamic range and power and intensity 
may vary slightly in the breast size pre-sets of the ABUS equipment used. These variations may 
have had some effect on the B-mode appearance of invasive ductal cancer.
Furthermore, only qualitative B-mode features were used to characterize these ductal cancers. 
Other ultrasound parameters such as Doppler ultrasound, elastography and other ultrasound 
radiofrequency signals were not included in this study. These parameters may also help 
predict the MS of breast cancer. However, ABUS devices are currently not (yet) able to measure 
ultrasound parameters other than B-mode parameters.
Conclusions
We found that the descriptors in the BI-RADS-US atlas (American College of Radiology 2013) and 
ABUS-specific features are associated with the four MSs of invasive ductal cancer. Nevertheless, 
the accuracy of prediction of MSs using these imaging features is limited, likely because of a large 
overlap of sonographic features between the MS groups. Our study indicates that the severity 
of the retraction phenomenon, typically seen on coronal reconstructions of ABUS imaging and 
described in the BI-RADS-US atlas as ‘‘architectural distortion,’’ is the most dominant imaging 
biomarker for MSs of IDC in ABUS imaging. More aggressive subtypes tend to exhibit a mild 
or even no retraction pattern, and more indolent types exhibit a stronger retraction pattern.
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Abstract
Purpose
To evaluate a multimodal surveillance regimen including yearly full-field digital (FFD) 
mammography, dynamic contrast agent–enhanced (DCE) magnetic resonance (MR) imaging, 
and biannual automated breast (AB) ultrasonography (US) in women with BRCA1 and BRCA2 
mutations.
Materials and Methods
This prospective multicenter trial enrolled 296 carriers of the BRCA mutation (153 BRCA1 and 
128 BRCA2 carriers, and 15 women with first degree untested relatives) between September 
2010 and November 2012, with follow-up until November 2015. Participants underwent 2 years 
of intensified surveillance including biannual AB US, and routine yearly DCE MR imaging and 
FFD mammography. The surveillance performance for each modality and possible combinations 
were determined.
Results
Breast cancer was screening-detected in 16 women (age range, 33–58 years). Three interval 
cancers were detected by self-examination, all in carriers of the BRCA1 mutation under age 43 
years. One cancer was detected in a carrier of the BRCA1 mutation with a palpable abnormality in 
the contralateral breast. One incidental breast cancer was detected in a prophylactic mastectomy 
specimen. Respectively, sensitivity of DCE MR imaging, FFD mammography, and AB US was 
68.1% (14 of 21; 95% confidence interval [CI]: 42.9%, 85.8%), 37.2% (eight of 21; 95% CI: 19.8%, 
58.7%), and 32.1% (seven of 21; 95% CI: 16.1%, 53.8%);  specificity was 95.0% (643 of 682; 95% 
CI: 92.7%, 96.5%), 98.1% (638 of 652; 95% CI: 96.7%, 98.9%), and 95.1% (1030 of 1088; 95% CI: 
93.5%, 96.3%); cancer detection rate was 2.0% (14 of 702), 1.2% (eight of 671), and 1.0% (seven 
of 711) per 100 women-years; and positive predictive value was 25.2% (14 of 54), 33.7% (nine 
of 23), and 9.5% (seven of 68). DCE MR imaging and FFD mammography combined yielded the 
highest sensitivity of 76.3% (16 of 21; 95% CI: 53.8%, 89.9%) and specificity of 93.6% (643 of 691; 
95% CI: 91.3%, 95.3%). AB US did not depict additional cancers. FFD mammography yielded no 
additional cancers in women younger than 43 years, the mean age at diagnosis. In carriers of 
theBRCA2 mutation, sensitivity of FFD mammography with DCE MR imaging surveillance was 
90.9% (10 of 11; 95% CI: 72.7%, 100%) and 60.0% (six of 10; 95% CI: 30.0%, 90.0%) in carriers of 
the BRCA1 mutation because of the high interval cancer rate in carriers of the BRCA1 mutation. 
Conclusion
AB US may not be of added value to yearly FFD mammography and DCE MR imaging surveillance 
of carriers of the BRCA mutation. Study results suggest that carriers of the BRCA mutation 
younger than 40 years may not benefit from FFD mammography surveillance in addition to 
DCE MR imaging.
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Introduction
Intensive breast cancer surveillance is offered to women who are carriers of the breast cancer 
susceptibility gene mutation (BRCA1 and BRCA2) and their first-degree untested relatives. These 
women have a cumulative lifetime risk of developing breast cancer of 45%–87% (192,193). 
Surveillance recommendations are highly heterogeneous. Many surveillance programs start at 
age 25 years and consist of yearly clinical examination and dynamic contrast agent–enhanced 
(DCE) breast magnetic resonance (MR) imaging. From the age of 30–40 years (depending on 
national guidelines), annual full-field digital (FFD) mammography is added to most surveillance 
regimes.
The rationale for adding mammography to breast DCE MR imaging surveillance is to aid the 
detection of mostly in situ carcinoma that may be occult on DCE MR images (194,195). This 
approach is successful for detection of breast cancer at an early stage and has been proven cost-
effective (196–199). Early detection is most desirable because women with BRCA mutations are 
more likely to develop aggressive triple-negative breast cancers (200). Although surveillance 
is intensive, several studies (190) have shown that a large proportion (11%–25%) of cancers 
in these women manifest as interval cancers, mostly in the carriers of the BRCA1 mutation. 
Women who are carriers of the BRCA germline mutation are instructed to perform monthly 
self-examination of the breasts to detect interval cancers at the earliest. Nevertheless, in 
these women prophylactic mastectomy is a valid option to prevent breast cancer. In fact, 
prophylactic mastectomy is preferred over surveillance by 36% of women who are carriers of 
the BRCA mutation between age 25 and 60 years (201). Improved breast cancer detection at an 
earlier and more favourable stage might abate the need for prophylactic mastectomies. Breast 
ultrasonography (US) is a relatively inexpensive, radiation-free, and widely available imaging 
modality. US has been shown (41) to depict additional breast cancers in FFD mammography 
surveillance of women who are at elevated risk. Adding biannual breast US to the yearly routine 
surveillance rounds may lead to earlier detection of cancers in carriers of the BRCA mutation 
(202). 
Nonetheless, in recent studies, annual and biannual US had no additional value to routine 
intensive surveillance with DCE MR imaging and FFD mammography in women with a familial 
or hereditary risk of developing breast cancer (15,55,56,203). 
Three-dimensional automated breast (AB) US is a technique with high potential for supplemental 
breast cancer surveillance (151). AB US is operator independent and reproducible and therefore 
overcomes important limitations of handheld US. Like handheld US, AB US interpretation is 
challenging and might depend on the level of experience of the interpreter. AB US can be 
performed by non-radiologists who acquire large standardized three-dimensional US volumes 
that allow temporal comparison, which makes AB US both usable and affordable for breast 
cancer surveillance (151). AB US has been shown to help detect mammography-negative 
invasive breast cancer in women with dense breasts (151). 
The purpose of this study is to prospectively investigate if early and additional breast cancer 
detection is feasible by adding biannual AB US to a surveillance regimen that includes yearly FFD 
mammography and DCE MR imaging for women carrying a germline BRCA1 or BRCA2 mutation. 
Material and methods
This multicenter prospective trial was approved by the institutional review board. Standard-of-
care imaging was annual surveillance mammography and breast MR imaging. Written informed 
consent was obtained for additional AB US twice yearly, breast imaging and biopsy procedures 
resulting from the AB US examination, and the use of clinical data for research.
Study population
This prospective study was performed at two institutions with enrolment between September 
2010 and November 2012 and follow-up until November 2014. Both institutions, one academic 
and the other a community hospital, offer multidisciplinary breast cancer care with dedicated 
subspecialty-trained breast radiologists. All women between ages 25 and 60 years with a 
known germline BRCA1 or BRCA2 mutation and untested women with a first-degree relative 
with a known BRCA mutation were asked to participate. Women were excluded if a bilateral 
prophylactic mastectomy was performed before enrolment.
Surveillance regimen
An intensified surveillance program was offered that consisted of yearly DCE MR imaging and 
biannual AB US. Yearly FFD mammography was added in all women over age 30 years. The FFD 
mammography, DCE MR imaging, and one of the yearly AB US examinations were performed 
preferably on the same day and no longer than 1 week apart, and the second AB US examination 
was performed approximately 6 months later. The study period for each woman was 2 years, 
thus consisting of five surveillance rounds (i.e., three multimodal [FFD mammography, DCE MR 
imaging, and AB US] rounds and two interval [AB US] rounds), followed by at least 12 months 
of follow-up.
Imaging modalities
FFD Mammography
FFD mammography was performed with a Senographe DS (GE Healthcare, Chicago, Ill), 
Mammomat Inspiration (Siemens, Erlangen, Germany), or a Selenia performance digital 
mammography system (Hologic, Bedford, Mass). Standard mediolateral oblique and craniocaudal 
views were obtained. Images underwent postprocessing on vendor-specific platforms, and they 
were evaluated on dedicated 5-megapixel monitors. 
DCE MR imaging
All DCE MR examinations were performed on a 3-T MR imager with dedicated 16-channel breast 
coils by using a bitemporal breast MR imaging protocol that included multiple conventional 
dynamic T1-weighted acquisitions before and after administration of contrast agent, fast 
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Table E 1 Magnetic resonance imaging and breast MRI protocols.
MRI equipment Magnetom Trio 3T, Skyra 3T, Verio 3T (Siemens)
DCE-MRI protocol 1
Breast coil AI breast coil (Siemens) 16 channel
Contrast agent Dotarem (Guerbet), 2.5 ml/s, 0.1 mmol/kg
Power Injector Medrad, Warrendale, PA
T2 (TSE) T1 (TWIST) T1 (VIBE) DWI (b50/800)
Spatial resolution, mm 1.3 x 1.1 x 2.5 1.0 x 0.9 x 2.5 0.9 x 0.8 x 1.0 1.5 x 1.5 x 4.0
Number of time points 1 20 5 1
Temporal resolution per time point 88 s 4.3 s 80 s 186 s
FOV 340 360 360 340
TE/TR, ms 143/3220 2.02/3.96 1.71/5.50 60/6400
FA 80 20 20 N/A
Parallel imaging factor (GRAPPA) 3 3 3 2
Reordering Standard Standard 3D centric Standard
Central zone N/A 15% N/A N/A
Sampling density outer zone N/A 10% N/A N/A
DCE-MRI protocol 2
Breast coil Invivo sentinelle (vanguard) 16-channel
Contrast agent Dotarem (Guerbet), 2.5 ml/s, 0.1 mmol/kg
Power Injector Optistar elite (Mackinrodt)
T2 (TSE) T1 (TWIST) T1 (VIBE) DWI (b150/800)
Spatial resolution, mm 1.1×1.1×4.0 1.4×1.1×2.6 1.1 × 0.8 × 1.3 2.0× 2.0× 5.0
Number of time points 1 15 6 1
Temporal resolution per time point 254 s 4.3 s 83.5 s 301 s
FOV 360 360 360 380
TE/TR, ms 61/4000 1.93/3.94 1.63/4.52 93/9700
FA 80 20 10 N/A
Parallel imaging factor (GRAPPA) 2 2 3 2
Reordering Standard Standard 3D centric Standard
Central zone N/A 19% N/A N/A
Sampling density outer zone N/A 10% N/A N/A
MRI Magnetic resonance imaging; DWI Diffusion-weighted imaging; FA Flip angle; FOV Field of view; GRAPPA  Generalized 
autocalibrating partially parallel acquisition; N/A Not applicable; TE/TR Echo time/Repetition time; TSE Turbo spin echo; 
TWIST Time-resolved angiography with stochastic trajectories.
dynamic series during contrast agent inflow, diffusion-weighted imaging, and T2-weighted 
acquisitions with or without fat saturation. The protocols are described in detail in Table E1. 
Postprocessing was performed by using a dedicated platform (DynaCAD version 2.1.7; Philips, 
Best, the Netherlands) and included subtraction series and maximum intensity projections for all 
time points. This platform allowed contrast agent wash-in and washout kinetic curve analyses. 
The breast radiologists evaluated contrast enhancement curves of regions suspicious for cancer 
by using the Breast Imaging Reporting and Data System (BI-RADS) MR imaging definition.
US imaging
AB US was performed by trained technologists using a US system (Acuson s2000 Automated 
Breast Volume Scanner Ultrasound System; Siemens). This system acquires three-dimensional 
B-mode US volumes up to 15.8 x 15.4 x 6.0 cm by using a large linear-array transducer (14 
L5 transducer; Siemens). We acquired 318 transverse US images (0.5-mm section thickness) 
per three-dimensional volume acquisition. Two to five acquisitions per breast on predefined 
locations (anterior-posterior, lateral, medial, superior, and inferior) were performed to ensure 
coverage of the entire breast. AB US postprocessing and evaluation were performed on a 
vendor-specific dedicated platform that included multiplanar reformats in coronal and sagittal 
planes by dedicated breast radiologists. In case abnormalities were observed on the AB US scan, 
targeted handheld US with Acuson s2000 systems with a linear-array 18-MHz 18 L6 transducer 
(Siemens) or an AplioXg system with a 12-MHz 12 L5 transducer (Toshiba, Otaware, Japan), 
and if required US guided 14-gauge or 16-gauge biopsy (Magnum; Bard, Tempe, Ariz) was also 
performed by a dedicated breast radiologist. 
Image evaluation
All imaging examinations were evaluated by using the BI-RADS system (156). Cases were 
interpreted by only one of six dedicated breast radiologists (including R.D.M., M.R., M.D.J., and 
R.M.M., with between 2 and 26 years of experience with FFD mammography, US, and DCE MR 
imaging). At the time of first enrollment, all radiologists were relatively inexperienced with whole 
breast screening that used AB US (experience, 1–6 months). The radiologists were instructed 
to evaluate the examinations independently in an unspecified order but were not blinded 
to the results of other modalities. One radiologist interpreted all three examinations that a 
woman underwent in a multimodal surveillance round. BI-RADS scores were given per imaging 
modality and for the combined examination. Women assigned a BI-RADS score of 4 or 5 with 
any of the imaging modalities underwent biopsy. A dedicated breast pathologist examined the 
biopsy specimens. Lesions with a BI-RADS score of 3 were either biopsied, received short-term 
follow-up, or were downgraded to a BI-RADS score of 2 on the basis of a multimodal negative 
assessment. For each modality, all BI-RADS scores of 0 and examinations with BI-RADS scores of 
3–5 were considered to be positive for cancer. Examinations assessed as BI-RADS 1 and 2 were 
considered to be negative for cancer.
A retrospective evaluation of the assessment of previous and current examinations and 
radiologists’ reports of women who were diagnosed with cancer were performed in consensus 
(J.Z. and R.M.M.) to analyse whether cancers were already visible and possibly missed or 
misinterpreted on previous evaluations. The analysis was performed by a radiology trainee 
and Doctor of Philosophy graduate in breast imaging (J.C.M.v.Z., with 3 years of experience in 
breast imaging) and a dedicated breast radiologist with a Doctor of Philosophy degree in breast 
imaging (R.M.M., with 7 years of experience). Breast density and pathologic evaluation was 
retrospectively assessed in cases in which FFD mammography did not lead to cancer detection.
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Follow-up
All women were followed for at least 1 year after the last examination (range, 12–57 months) 
at our institutes except for the women who were lost to follow-up. We cross-checked our study 
database with the Netherlands Cancer Registry database (2003–2014) to confirm the health 
status of all participants, including all women who were lost during follow-up.
Statistical analysis
Surveillance-detected cancer was defined as histologic-confirmed invasive breast cancer 
or ductal carcinoma in situ (DCIS) detected by a radiologist with at least one of the imaging 
modalities during surveillance rounds. Cancer that manifested in the surveillance interval was 
defined as an interval cancer. This includes both true interval cancers that manifested with 
symptoms and incidental cancers detected in prophylactic mastectomy specimens. We analysed 
surveillance performance on the patient level. Sensitivity, specificity, negative predictive value, 
and positive predictive values (positive predictive value for recommendations for anything 
other than routine surveillance and positive predictive value for a performed biopsy) for each 
imaging modality was calculated. True-positive examinations were defined as examinations 
assessed as positive for cancer (BI-RADS score of 0 or 3–5) with a histologic analysis–confirmed 
malignancy. False-positive examinations were defined as imaging findings that were positive for 
cancer with benign histologic findings and/or a 12-month disease-free follow-up. True-negative 
examinations were defined as examinations assessed to be negative for cancer (BI-RADS score of 
1 and 2) with a 12-month disease-free follow-up. False-negative examinations were defined as 
examinations assessed to be negative for cancer with histologic analysis–proven malignancies 
(on the basis of findings from other imaging modalities) or detection of an interval cancer within 
12 months after the round of examinations assessed to be negative for cancer.
Furthermore, we analysed recall rates, biopsy rates, and cancer detection rates per 100 women-
years in surveillance. The performance metric probabilities and 95% confidence intervals were 
statistically corrected for repeated measurements (visits to our institutes) per woman by using 
the generalized estimation equation. Numerators and denominators for percentages are 
reported uncorrected by generalized estimation equation.
We compared the surveillance performance metrics of each modality by using the McNemar and 
chi-square tests. Calculations were performed for all women and separately for the subgroups 
of carriers of germline BRCA1 or BRCA2 mutation. Differences between the subgroups (carriers 
of the BRCA1 versus BRCA2 mutation), remaining cohort versus lost to follow-up, and proven 
carriers of the BRCA mutation versus untested first-degree relatives were evaluated by using 
t-tests and chi-square tests.
P values less than .05 indicated statistically significant differences (R version 3.2.3, R foundation 
for Statistical Computing, Vienna, Austria; and SPSS version 20.0, IBM Statistics, Armonk, NY).
Results 
Study participants
We initially included 330 women (mean age, 41 years ± 9.5 [standard deviation]; range, 25–63 
years) in our study. We excluded 34 women. The reasons for exclusion were strong family history 
of breast cancer but without a proven BRCA germline mutation (n = 24), PTEN (n = 1) or CDH1 (n 
= 1) germline mutations, and noncompliance for the first surveillance visit (n = 8). Consequently, 
296 women with a proven BRCA mutation (BRCA1, 153 women; BRCA2, 128 women) or with a 
first-degree relative with a germline BRCA mutation (BRCA1, five women; BRCA2, 10 women) 
participated in our study. Table 5.1 summarizes patient characteristics. 
Untested first-degree relatives were on average younger (mean age, 30.7 years ± 8.8) than the 
proven carriers of the BRCA mutation (mean age, 41.6 years ± 9.2) (P<.001) and more likely to 
be premenopausal (93% [14 of 15 patients] vs 39.8% [112 of 281 patients]; P<.001).
During the study period, 50 of 296 women (16.9%) who were known carriers of the germline 
mutation opted for prophylactic simple mastectomy over surveillance. In total, 671 FFD 
mammography examinations, 1109 AB US examinations, and 702 DCE MR examinations were 
performed. Twenty-seven women did not return for scheduled surveillance appointments in 
one of the study sites in the subsequent years and were considered to be lost during follow-up. 
More women who were considered lost during follow-up (48% [13 of 27]) attended surveillance 
for the first time at enrolment in our study compared with women who eventually remained 
in the study cohort (27.5% [74 of 269]; P = .02). Figure 5.1 summarizes the patient recruitment 
and surveillance rounds.
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Figure 5. 1 Flowchart shows the number of women, cancers (including DCIS), positive assessments (recalls), 
prophylactic mastectomies, and women lost to follow-up. 
ABUS = AB US, FDR = first-degree relatives, FFDM = FFD mammography.
Assessed for eligibility (n= 330) 
Excluded n= 34 
BRCA mutation negative n = 24 
PTEN mutation n = 1 
CDH1 mutation n = 1 
Non-compliance before the first 
surveillance round n = 8 
 
 
 
Intensified triple-modality surveillance 
BRCA1 germline mutation carriers n=153 
BRCA2 germline mutation carriers n=128 
First degree untested relatives (FDR) n=15 
(BRCA1 n=5, BRCA2 n=10) 
 
First surveillance round 
 
Positive assessment n = 54 (28 
BRCA1, 21 BRCA2, 5 untested FDR) 
Biopsy performed n = 30 (15 BRCA1, 
12 BRCA2, 3 untested FDR) 
Cancer detected n = 6 (2 BRCA1, 4 
BRCA2) 
Interval cancers n = 2 (2 
BRCA1) 
Lost to follow up n = 4 (3 
BRCA1, 1 BRCA2) 
Prophylactic mastectomy n = 8 
(5 BRCA1, 3 BRCA2) 
 
 
Second surveillance round 
 
Positive assessment n = 12 (3 
BRCA1, 8 BRCA2) 
Biopsy performed n = 1 (1 BRCA1) 
Cancer detected n = 0 Interval cancers n = 1 (1 
BRCA1) 
Lost to follow up n = 6 (3 
BRCA1, 3 BRCA2) 
Prophylactic mastectomy n = 13 
(8 BRCA1, 5 BRCA2) 
 
 
Third surveillance round 
 
Positive assessment n = 21 (11 
BRCA1, 9 BRCA2, 1 untested FDR) 
Biopsy performed n = 17 (8 BRCA1, 8 
BRCA2, 1 untested FDR) 
Cancer detected n = 7 (3 BRCA1, 4 
BRCA2) 
Interval cancers n = 0 
Lost to follow up n = 6 (3 
BRCA1, 3 BRCA2) 
Prophylactic mastectomy n = 12 
(7 BRCA1, 5 BRCA2) 
 
Fourth surveillance round 
 
Positive assessment n = 10 (4 
BRCA1, 6 BRCA2) 
Biopsy performed n = 1 (1 BRCA2) 
Cancer detected n = 0 Interval cancers n = 0 
Lost to follow up n = 0 
Prophylactic mastectomy n = 6 (3 
BRCA1, 3 BRCA2) 
 
 
Fifth surveillance round 
 
Positive assessment n = 11 (7 
BRCA1, 4 BRCA2) 
Biopsy performed n = 6 (3 BRCA1, 3 
BRCA2) 
Cancer detected n = 3 (1 BRCA1, 2 
BRCA2) Interval cancers n = 1 (1 BRCA1) 
Lost to follow up n = 13 (4 
BRCA1, 7 BRCA2, 2 untested 
FDR) 
Prophylactic mastectomy n = 12 
(6 BRCA1, 6 BRCA2), (1 
incidental cancer in specimen of 
BRCA2 mutation carrier) 
 
12 months follow up 
 Surveillance-detected cancer after 
study period n= 3 (3 BRCA1) 
MRI, ABUS, FFDM 
 
 
ABUS 
 
 
MRI, ABUS, FFDM 
 
 
MRI, ABUS, FFDM 
 
 
ABUS 
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Cancers
Breast cancer was surveillance detected in 16 women at an average age of 45 years ± 7.3 
(age range, 33–58 years), and 18.7% (three of 16) of breast cancers were detected in women 
who attended surveillance for the first time (Fig 5.2). Table 5.2 summarizes the histologic 
characteristics and detection modes of the breast cancers that were observed. Overall, cancers 
were detected at an early stage, 93.7% (15 of 16) of the screening-detected cancers were T1 
or in situ cancers. Table 5.3 summarizes the characteristics of the cancers not detected with 
surveillance. One 6-mm (invasive) incidental cancer was observed in a prophylactic simple 
mastectomy specimen in a 37-year-old woman who was a BRCA2 mutation carrier. We observed 
four true interval cancers (20.0%; four of 20), three of which were detected by self-examination 
of the breasts in women aged 35, 33, and 28 years. The fourth was detected at an additional 
DCE MR examination performed in a 43-year-old woman who was a BRCA1 mutation carrier and 
who visited one of the centers because of a benign, palpable abnormality in the contralateral 
breast. FFD mammography and US findings were negative for cancer. Three occurred during 
the study period, and one was detected 8 months after the last surveillance round. All were 
triple-negative invasive ductal carcinomas. No true interval cancers were observed in carriers 
of the BRCA2 mutation or in women with a first-degree relative who was a carrier of a BRCA 
mutation (none vs four of 10, respectively; P = .02). Eight of nine invasive cancers that were either 
triple-negative or HER2 type were observed in carriers of the BRCA1 mutation, whereas one of 
seven hormone receptor–positive invasive cancers and one of five pure DCIS cases were BRCA1 
related (eight of nine vs two of 13; P = .001). The mean age of all carriers of the BRCA mutation 
at time of diagnosis was 43 years ± 8. The average age at time of diagnosis was 41 years (range, 
26–53 years) for the carriers of BRCA1 and 45 years (range, 33–58 years) for the carriers of the 
BRCA2 mutation (P= .16).
Figure 5. 2 Images in a 53-year-old woman who is an asymptomatic BRCA1 germline mutation carrier 
at her first round of BRCA surveillance. (a) Surveillance craniocaudal and mediolateral oblique (MLO) 
mammographic images of the right breast. Multiple masses up to 11 mm are visible. (b) MR imaging of 
multiple masses in the subtracted images of the first postcontrast T1-weighted time point. This cancer 
showed a type 3 curve that was suspicious for malignancy. (c) Three-dimensional AB US view of the right 
breast. Multiple masses suspicious for malignancy are seen. The retroareolar hypoechoic mass shown 
here is well circumscribed and shows posterior acoustic enhancement. Pathologic assessment showed a 
multifocal HER-2–enriched high-grade invasive ductal carcinoma with high-grade DCIS in the surrounding 
tissue. Arrowheads = invasive ductal carcinoma.
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Figure 5. 3 An 11-mm invasive hormone-receptor negative HER2-positive ductal carcinoma (arrowhead) 
was detected in the left breast of a 56-year-old BRCA2 mutation carrier with (a) mediolateral oblique (MLO) 
FFD mammography and (b) DCE MR imaging, shown here a T1-weighted subtraction image of the first 
postcontrast time point. (c) AB US scan shows an 11-mm invasive hormone-receptor negative HER2-positive 
ductal carcinoma (arrowhead) that was detected in the left breast of a 56-year-old BRCA2 mutation carrier. 
This cancer showed a type 3 washout curve at MR imaging, suspicious for malignancy. 
A retrospective analysis of the assessments of imaging examinations performed in women 
who were diagnosed with breast cancer showed that in two women, at the location of the 
diagnosed cancer, a lesion was already visible 6 months earlier at the interval AB US examination, 
and it was detected and interpreted by one of the radiologists (Fig 5.3). Both cancers were 
BRCA1 related and high-grade triple-negative; the cancers were described in the report as a 
cyst and consequently classified as BI-RADS 2. No lesions were in retrospect already observed 
but misinterpreted in previous studies of other women in our study that were diagnosed with 
breast cancer. Furthermore, in cases where a cancer was not detected with all three modalities, 
examinations assessed as negative did not show signs of cancer in retrospect. In eight cases, FFD 
mammography did not allow for cancer detection, of these cases, four of eight women showed 
more than 50% breast density and all eight showed dense patches on the mammogram at the 
location of the cancer. Three cases that were negative for cancer at FFD mammography showed 
pure DCIS that was detected only at MR imaging. These three DCIS, as well as five other cancers 
that were negative at FFD mammography, did not manifest with classic microcalcifications that 
would have allowed for detection at FFD mammography. Pathologic evaluation helped to show 
high-grade DCIS in all three pure DCIS cases and, also, four invasive cancers that were negative 
for cancer at FFD mammography were high grade. One cancer showed low grade invasive ductal 
carcinoma and DCIS but without classic low-grade microcalcifications and was only 3 mm.
3b
(d) Six months earlier this cancer was already detected (arrowhead) but classified as a 4-mm BI-RADS score 
2 lesion on the 6-month interval AB US examination.
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Surveillance performance
Table 5.4 summarizes the surveillance performance of all modalities and combinations of 
modalities in the entire cohort. The sensitivity of DCE MR imaging surveillance was 68.1% (14 
of 21; 95% confidence interval: 42.9%, 85.8%), which is considerably higher than the sensitivity 
of both AB US (32.1% [seven of 21]; 95% confidence interval: 16.1%, 53.8%; P = .016) and FFD 
mammography (37.2% [eight of 21]; 95% confidence interval: 19.8%, 58.7%; P = .109). Cancer 
detection rate was 2.0% (14 of 702; 95% confidence interval: 1.1%, 3.3%), 1.2% (eight of 671; 95% 
confidence interval: 0.6%, 2.3%), and 1.0% (seven of 711; 95% confidence interval: 0.5%, 1.9%) 
for DCE MR imaging, FFD mammography, and AB US, respectively. In one woman aged 51 years 
and another aged 58 years, FFD mammography surveillance led to detection of two additional 
intermediate-grade DCIS that were not observed at DCE MR imaging or AB US.
Specificity of DCE MR imaging and AB US was 95.0% (643 of 682; 95% confidence interval: 
92.7%, 96.5%) and 95.1% (1030 of 1088; 95% confidence interval: 93.5%, 96.3%), respectively. 
The specificity of FFD mammography was significantly higher than that of DCE MR imaging at 
98.1% (638 of 652; 95% confidence interval: 96.7%, 98.9%; P = .002). Positive predictive values 
for recommendations for anything other than routine surveillance of DCE MR imaging and FFD 
mammography were 25.2% (14 of 54; 95% confidence interval: 14.4%, 40.3%) and 33.7% (nine of 
23; 95% confidence interval: 17.1%, 55.8%; P = .457), respectively. The positive predictive value 
for recommendations for anything other than routine surveillance of AB US was 9.5% (seven of 
68; 95% confidence interval: 4.7%, 18.4%) and significantly lower than that of DCE MR imaging 
and FFD mammography (P = .010 and .020, respectively). 
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Table 5.5 separately summarizes the performance of surveillance in carriers of the BRCA1 
mutation and BRCA2 cohorts by including first-degree untested relatives. In carriers of the 
BRCA1 mutation, a sensitivity of 60% (six of 10) was obtained by combining DCE MR imaging 
with FFD mammography, though the added yield of the latter was restricted to one DCIS in a 
51-year-old woman.
The combination of DCE MR imaging and FFD mammography in carriers of the BRCA2 mutation 
reached a sensitivity of 90.9% (10 of 11), only missing an incidental cancer in a prophylactic 
simple mastectomy specimen that was negatively assessed in the surveillance round 5 months 
before surgery. In fact, the cancer detection rate of DCE MR imaging in carriers of the BRCA2 
mutation was 2.6% (nine of 325; 95% confidence interval: 1.3%, 5.3%), which was twice the 
cancer detection rate of DCE MR imaging in carriers of the BRCA1 mutation (1.3% [five of 377]; 
95% confidence interval: 0.5%, 3.2%). The positive predictive value for recommendations for 
anything other than routine surveillance of DCE MR imaging in carriers of the BRCA1 mutation 
was 16.3% (five of 30; 95% confidence interval: 6.7%, 35.2%), less than half of that in carriers 
of the BRCA2 mutation (37.7% [nine of 24]; 95% confidence interval: 17.7%, 63.0%). Table E2 
summarizes the surveillance performance of all modalities and combinations of modalities 
for the proven carriers of the BRCA1 and BRCA2 mutation cohorts combined and Table E3 for 
the proven carriers of the BRCA1 and BRCA2 mutation subcohorts separately. The untested 
first-degree relatives (n = 15) are not included in Tables E2 and E3. The screening performance 
results in the proven BRCA germline mutation carrier cohort are comparable to the entire cohort 
including the untested first-degree relatives.
In terms of age, we observed that both FFD mammography and DCE MR imaging helped to 
detect five of seven cancers in women older than the mean age (at the time of cancer diagnosis) 
of 43 years. By combining DCE MR imaging and FFD mammography, all cancers were detected 
in patients older than 43 years. In younger women, nine of 14 cancers were evident at DCE MR 
imaging, while only three of 14 cancers were also detected by using FFD mammography (P = 
.031). AB US did not lead to detection of additional cancers.
Follow-up
In three women, cancer was detected at the first subsequent surveillance round, 1 year after 
the final round of our study. These three women were all carriers of the BRCA1 mutation and all 
three cancers were small T1, lymph node–negative cancers with negative hormonal receptor 
expression (e.g., two triple-negative ductal carcinomas and one HER2-type invasive ductal 
carcinoma). In a fourth woman who was a BRCA1 mutation carrier, a 9-mm grade-III DCIS was 
detected in the 2nd subsequent year of follow-up. All other women remained free of disease 
during a mean follow-up of 23 months ± 10 (range, 12–57 months). 
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Discussion
This multicenter prospective cohort study shows that DCE MR imaging surveillance is most 
essential in the surveillance of women who carry BRCA1 and BRCA2 mutations. Overall DCE 
MR imaging showed a higher sensitivity (68.1% [14 of 21]; 95% confidence interval: 42.9%, 
85.8%) than either AB US (32.1% [seven of 21]; 95% confidence interval: 16.1%, 53.8%) or FFD 
mammography (37.2% [eight of 21]; 95% confidence interval: 19.8%, 58.7%). FFD mammography 
did reveal two additional cases of DCIS in women aged 51 and 58 years that were not detected 
with DCE MR imaging or AB US. AB US did not lead to additional cancer detection beyond that 
available with FFD mammography or DCE MR imaging.
Our results are in line with those of Kuhl et al. (56), Sardanelli et al. (203) and Riedl et al. (15), 
studies, in which biannual or annual handheld US imaging added to DCE MR imaging and FFD 
mammography surveillance of women with high familial or genetic risk has a limited role. The 
results are different from Bosse et al. (202) who showed earlier detection of breast cancers during 
the 6-month interval US imaging surveillance with triple-modality surveillance in carriers of the 
BRCA mutation. In addition, biannual AB US increases the false-positive rate and the biopsy rate, 
which may cause unnecessary anxiety among carriers of the BRCA mutation and may lead to 
additional costs for these women.
The limited value of US imaging might be caused by the appearance at US of typical BRCA-
related cancers because carriers of the BRCA1 mutation are prone to develop triple-negative 
and HER2-positive cancers (190). These cancers tend to mimic benign breast lesions at US, 
especially at an early stage (54,114,116,204). Our study confirms the association between BRCA1 
and hormone receptor–negative breast cancers (P = .001) and also confirms the US phenotype 
of well-circumscribed, round, almost cyst-like lesions because, in our retrospective review, two 
hormone receptor–negative breast cancers were already visible on a previous 6-month AB 
US image. Both were considered benign and classified as lesions with a BI-RADS score of 2. In 
all new imaging modalities, a learning curve might be present, and this may have limited the 
ability of the radiologists in our study to interpret the AB US examinations. DCE MR imaging 
outperformed FFD mammography and AB US in the detection of both invasive cancers and DCIS. 
In 14 of 16 surveillance-detected cancers, FFD mammography or AB US did not add value to DCE 
MR imaging. Nevertheless, two women (both older than 50 years) who presented with a grade 
II DCIS were diagnosed because of microcalcifications at FFD mammography. However, in our 
study, FFD mammography and DCE MR imaging were only complementary for carriers of the 
BRCA mutation older than the mean age of 43 years. In women who were 43 years or younger, 
DCE MR imaging helped to detect significantly more cancers than did FFD mammography (P 
= .031). Moreover, all cancers detected with FFD mammography were also detected by using 
DCE MR imaging. Consequently, according to our results, FFD mammography may have limited 
additional value in women younger than 43 years, especially in those who are carriers of the 
BRCA1 mutation. Our results agree with the meta-analysis of Heijnsdijk et al (190) and Phi et al 
(205) and show that carriers of the BRCA mutation younger than 40 years gain little from FFD 
mammography in multimodality surveillance.
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The age at which FFD mammography surveillance is recommended is still as young as 30 
years (126). This can be questioned because glandular tissue impairs the sensitivity of FFD 
mammography in young women, and calcified DCIS in these women is rare (5). As might be 
expected from recent literature, three (high-grade) DCIS were found in younger women at MR 
imaging only. Moreover, the glandular tissue of younger women is more susceptible to the 
effects of ionizing radiation and, specifically in carriers of the BRCA1 mutation, and therefore, 
more susceptible to oncogenic mutations (206,207). Consequently, we suggest to increase the 
age to start with FFD mammography to at least 40 years. In addition, other emerging imaging 
techniques, such as digital breast tomosynthesis that uses ionizing radiation, might not be 
suitable for surveillance of carriers of the BRCA mutation. Despite the high cancer yield of breast 
DCE MR imaging in our study (20.1 of 1000), particularly in carriers of the BRCA1 mutation, the 
risk of developing interval cancers remains high. In our study, 10 cancers were observed in the 
cohort of carriers of the BRCA1 mutation, of which four cancers (40%) manifested as interval 
cancers. Consequently, the sensitivity of surveillance in carriers of the BRCA1 mutation was lower 
than the overall sensitivity of DCE MR imaging surveillance reported in other studies. Interval 
cancers are more frequently observed in carriers of the BRCA1 mutation according to the meta-
analysis of Heijnsdijk et al (190). In our study, the overall interval cancer rate in carriers of BRCA1 
and BRCA2 combined (20%; four of 20) is comparable to the results from the MRISC trial reported 
by Rijnsburger et al (63), in which the overall interval cancer rate was 21%. Nevertheless, the 
interval cancer rate of 40% observed in our BRCA1 cohort is higher than in their cohort (29%). 
This is likely because of the limited numbers in our study with large confidence intervals.
In our cohort of carriers of the BRCA mutation, 16.9% chose risk-reducing prophylactic 
mastectomy over surveillance. This number is in line with Hoogerbrugge et al (201) and Metcalfe 
et al (208), who reported that prophylactic mastectomies are performed in 11%–18% of carriers 
of the BRCA mutation who initially opted for intense surveillance that includes MR imaging.
Our study had limitations. The radiologists were not blinded to findings from the other modalities 
and the reading order of the modalities was not specified, which could have influenced 
performance for all modalities characteristics either positively or negatively. Our age-suggested 
limit, where supplemental mammography showed no benefit, is based on a posthoc analysis of 
our own population and needs further evaluation from prospective studies. Inexperience with 
whole breast US screening with AB US on the part of our radiologists may have had a negative 
effect on the performance of AB US in our study. 
To conclude, supplemental biannual AB US did not lead to earlier or additional detection of 
breast cancer in carriers of the BRCA mutation, and intensive surveillance of carriers of the BRCA 
mutation with DCE MR imaging protocols also gained little from supplemental mammography in 
women younger than 40 years. Finally, despite high cancer detection rates by DCE MR imaging, 
the high rate of invasive interval cancers in carriers of the BRCA1 mutation underlines the need 
for improvement of breast cancer surveillance for carriers of the BRCA1 mutation. Physicians 
who counsel carriers of the BRCA mutation may take these results into account when discussing 
the benefits and disadvantages of prophylactic simple mastectomy or breast cancer surveillance 
and continue to encourage these women to perform a monthly self-examination of the breasts.
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Abstract 
Objective
To investigate the effect of dedicated Computer Aided Detection (CAD) software for automated 
breast ultrasound (ABUS) on the performance of radiologists screening for breast cancer. 
Methods
90 ABUS views of 90 patients were randomly selected from a multi-institutional archive of cases 
collected between 2010 and 2013. This dataset included normal cases (n = 40) with >1 year of 
follow up, benign (n = 30) lesions that were either biopsied or remained stable, and malignant 
lesions (n = 20). Six readers evaluated all cases with and without CAD in two sessions. CAD-
software included conventional CAD-marks and an intelligent minimum intensity projection 
of the breast tissue. Readers reported using a likelihood-of-malignancy scale from 0 to 100. 
Alternative free-response ROC analysis was used to measure the performance. 
Results
Without CAD, the average area-under-the-curve (AUC) of the readers was 0.77 and significantly 
improved with CAD to 0.84 (p = 0.001). Sensitivity of all readers improved (range 5.2–10.6%) by 
using CAD but specificity decreased in four out of six readers (range 1.4–5.7%). No significant 
difference was observed in the AUC between experienced radiologists and residents both with 
and without CAD. 
Conclusions
Dedicated CAD-software for ABUS has the potential to improve the cancer detection rates of 
radiologists screening for breast cancer.  
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Introduction
Breast cancer is a leading cause of cancer related mortality in women (209). Mammography 
surveillance programs have shown to reduce breast cancer mortality (78,79). However, the 
sensitivity of mammography is suboptimal, and decreases in women with “dense breasts”. 
Consequently, breast ultrasound as an adjunct to mammographic screening is rapidly gaining 
interest worldwide. Handheld ultrasound (HHUS) and Automated 3D breast ultrasound 
systems (ABUS) have been reported to increase the cancer detection rate as a supplement to 
mammographic screening in women with dense breasts (41–44,53,151). 
ABUS is primarily developed for screening. In comparison to HHUS it is less operator dependent 
and acquires full three-dimensional breast ultrasound volumes that are reproducible over time. 
However, for a full coverage of both breasts ABUS consists of two to five acquisitions per breast. 
Each acquisition contains over 300 transverse images and reconstructions in coronal and sagittal 
planes. Consequently, the large size of the ABUS volumes might cause oversight errors in some 
malignancies. 
Accurate CAD-software may help to detect cancers in ABUS datasets and might improve 
efficiency in the workflow of radiologists. However, the optimal method of implementing CAD-
software in the reading process is unknown. False positive (FP) findings should not reduce the 
level of confidence in the software (64,66), an issue that has largely reduced the value of CAD in 
mammography screening (64,210). While recent studies on CAD development for ABUS show 
good results for CAD as a standalone reader (71,76,211), it remains to be determined whether 
CAD-software can aid the radiologist in breast screening with ABUS.
In this study, commercially developed CAD-software is used. It highlights suspicious regions 
that are displayed on an intelligent minimum intensity projection (MinIP) image of the ABUS 
view (Fig 6.1). This MinIP display is integrated in the conventional multiplanar hanging protocol. 
The purpose of this study is to compare the diagnostic accuracy of radiologists screening ABUS 
scans for breast cancer with and without CAD-software support.
Figure 6. 1 Intelligent Minimum Intensity Projection (MinIP) of an ABUS scan of the medial side of the 
left breast. An example is shown of the intelligent MinIP. The crosshair is focused on a breast lesion that is 
marked by the computer aided detection software with a yellow circular marker. The same lesion is also 
enhanced and visualized as a dark spot in the MinIP.
Methods
The need for informed consent for this study was waived by a local ethics committee (IRB). We 
designed a crossover counterbalanced multi-reader-multi-case study (MRMC) where every 
reader read all cases twice in separate reading sessions.
Data acquisition
Cases were obtained with ACUSON S2000 Automated Breast Volume Scanner systems (Siemens, 
Erlangen, Germany) at three institutes. This ABUS system acquires views of 154mm x 168mm x 
60mm with a 14L5BV 5-14MHz automatically driven linear array transducer. Each view consists 
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of 318 contiguous transverse B-mode ultrasound images. It is usually not possible to image an 
entire breast at once, due to the shape of the breast and the limited width of the transducer. 
Therefore, during the examination two to five views at predefined locations of the breast are 
acquired to ensure full coverage. 
Case selection
ABUS scans collected at the clinical sites originated from clinically indicated examinations and 
(high risk) screening. They were labelled as ‘normal’ (n=1064), ‘benign’ (n=260) or ‘malignant’ 
(n=100) based on histological verification or after >1 year of follow up. The malignant cases 
were confirmed by a pathologist after histological evaluation of the biopsy specimen and, 
when available, confirmed by evaluation of the surgical specimen. For this study, we randomly 
selected 40 normal cases, 30 benign cases and 20 malignant cases. None of the dedicated breast 
radiologists or residents who participated as an observer in our study were part of the case 
collection procedure. To avoid bias, the selection was done randomly. For this study, one ABUS 
view per patient was evaluated to save on reading time. The view to be evaluated was randomly 
and objectively selected. This was done based on the presence of lesion annotations, which 
were made as part of the case collection protocol where every case in our scientific archive is 
fully annotated by drawing outlines on the edges of lesions in the ABUS scans using dedicated 
imaging research software. ABUS views of cases with a benign or malignant lesion were only 
included in the random selection procedure if an annotated lesion was present.
Ground truth
All ABUS scans in our imaging archive are annotated by drawing outlines on the boundaries 
of lesions in the ABUS scans using dedicated imaging research software. Annotations were 
stored in a research archive together with a summary of the initial clinical BI-RADS assessment 
and pathohistological report. Lesion size was measured in the ABUS scans by measuring the 
longest axis of the lesion. The lesion annotations served as ground truth to evaluate reader and 
CAD performance.
Computer Aided Detection software
The CAD-software used in this study was provided by Qview Medical Inc. (Los Altos, CA, USA). 
The operating point of this CAD system can be adjusted by defining the number of FP per case. 
However, lowering the FP-rate goes at the cost of a lower sensitivity. For this study we chose 
one FP per view as the operating point. In addition to the CAD marks, the software provides 
a 2D overview image of each ABUS view in which suspicious regions are visible as dark spots. 
This overview image is essentially a minimum intensity projection (MinIP) (figure 1), where the 
region behind the chest wall is automatically removed before the projection is made. However, 
the MinIP does not only show low-intensity (hypoechoic) regions in the ABUS view as dark 
spots, but also enhances suspicious regions detected by the CAD system to make them more 
conspicuous. CAD marks are displayed in the overview by colored circles.  By clicking on a CAD 
mark or any other point on the MinIP, the corresponding region in the ABUS view is instantly 
shown to the reader in the multiplanar panel, allowing efficient review of the 3D image data.
Reading protocol
Reading sessions were performed on a dedicated workstation (Qview Medical Inc., Los Altos, 
CA, USA). This workstation visualizes the transversally obtained B-mode ultrasound images, the 
sagittal and coronal reconstructions in a cross-linked multiplanar hanging protocol. In addition 
to this hanging protocol the intelligent MinIP with CAD marks is displayed during CAD-ABUS 
reading. 
The study set of 90 cases was divided in two subsets of 45 cases. After a training-session half 
of the readers first read 45 cases without CAD-support and then 45 cases with CAD-support 
in one reading session. In a second reading session the reading modes were swapped and the 
order of cases was randomized. Consequently, all cases were read once without CAD-support 
and once with CAD-support. Figure 6.2 shows an example of the CAD-ABUS hanging protocol. 
Between reading sessions, an interval period of at least 5 weeks was observed to minimize any 
memory effect (212).
All readers received the same instructions prior to the reading sessions. In these instructions 
we provided an indication of the prevalence of abnormalities in our dataset. The readers were 
told that approximately half of the cases in the dataset contained one or more abnormalities 
and that 10-30% of the cases contained malignancies. Giving an estimate of the prevalence of 
abnormalities is common practice in reader studies, because radiologists are able to estimate 
the prevalence of abnormalities in the study set during the experiment based on personal 
experience. This may influence their behavior and bias their criteria, which would have a 
negative impact on the results (213). Readers were instructed to mark suspicious lesions in the 
scan when observed and encouraged to report findings in at least half of the cases. Thereafter, 
a BI-RADS score was requested for each finding. A quasi-continuous scale is commonly used in 
reader studies and is preferred over an ordinal scoring system, such as BI-RADS, in ROC analysis 
(157,158). Therefore, we assigned each BI-RADS category to a range on a quasi-continuous 
likelihood-of-malignancy (LOM) scale (0-100). The LOM) as follows:  0-20 for (BI-RADS 1) normal 
findings, 21-40 for (BI-RADS 2) certainly benign findings, 41-60 for (BI-RADS 3) probably benign 
findings, 61-80 for (BI-RADS 4) suspicious findings and 81-100 for (BI-RADS 5) highly suggestive 
of malignancy findings.  
In a normal diagnostic setting, readers spend an average of five minutes for an entire ABUS 
examination of both breasts with three scans per breast. To avoid large deviations from clinical 
practice, in this study we asked the readers to review and report the single ABUS views offered 
in about one minute per case. Readers were blinded to patient information such as family 
history, age, medical history, clinical examination, reports of any other diagnostic imaging test 
and pathology results.
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Figure 6. 2 Screenshot of the CAD aided reading environment. Here a conventional ABUS multiplanar 
hanging protocol (panels A-C) is shown with the addition of the intelligent MinIP image (Panel D) with an 
overlay of CAD marks (green and pink circles). In this case CAD marks an invasive ductal carcinoma. Note 
that the intelligent MinIP also visualizes the cancer as an enhanced dark spot. During the unaided ABUS 
reading session only panels A-C were shown to the reader. The colors of the CAD marks indicate whether 
a lesion is evaluated or not.
Readers
In this study three dedicated breast radiologists participated with 7, 7 and 35 years of experience 
in mammography and breast ultrasound, respectively. All three breast radiologists had at least 
three years of experience with ABUS. Furthermore, three senior radiology residents participated. 
All residents had less than one month of experience with ABUS.
Statistical analysis
Multi-Reader-Multi-Case analysis was performed using the alternative free-response receiver 
operating characteristics (AFROC) method. This method employs jackknifing, ANOVA and 
Wilcoxon rank-sum test to compare the area under the curve (AUC) for both ABUS and CAD-
ABUS reading. Only one rating per case was included as input for the AFROC analysis. For 
non-malignant cases (normal and benign) with FP findings, we used the highest rating. For 
malignant cases we included only the highest rated true positive (TP) findings in the analysis 
(i.e. the marking should be inside the annotated lesion, or within 10 mm from the centre of the 
annotation) so that readers were not rewarded for marking only non-cancer regions in malignant 
cases. We compared the AUC’s with JAFROC statistical package v.4.20. 
We analyzed sensitivity and specificity of ABUS reading and CAD-ABUS reading by using BI-RADS 
3 as the cut-off. Sensitivity and specificity were determined using 2 x 2 contingency tables. 
Operating points representing sensitivity and specificity were added to the AFROC curves for 
all readers. Significant differences were defined at p<0.05.
Results
Patient characteristics
Cases were randomly selected from our database, as a result we included eleven T1 cancers (ten 
node-negative), eight T2 cancers (three node-negative) and one T4 cancer. Because the added 
value of CAD in large cancers, such as T4 stage breast cancer, is limited and this particular cancer 
extended throughout the entire breast and well beyond the boundary of the 3D volume, the T4 
cancer was considered irrelevant for an evaluation of screening performance and was excluded 
from further statistical analysis.  Consequently, 19 invasive cancers were included of which 17 
were invasive ductal carcinomas (IDCs) and 2 invasive lobular carcinomas (ILC). Two IDCs showed 
more than one cancer focus in the selected ABUS view. Mean cancer size was 14.0mm (SD 
6.2). The mean lesion size of benign lesions was 14.1mm (SD 10.0). The median age of patients 
without lesions was 39.5, 49 for patients with benign lesions, and 52 for patients with malignant 
lesions.  The benign lesions were cysts (n=12), benign calcification (n=1), fibroadenomas (n=10), 
sclerosis (n=2), fibrosis (n=4) and one intraductal papilloma. 
Reader performance
Table 6.1 summarizes the performances of the readers. For each individual reader the AUC 
improved when CAD was used. Every reader detected more cancers with CAD support compared 
to reading the ABUS scans without CAD. In four out of six readers a slight specificity decrease was 
observed. One reader showed an increase in specificity after reading with CAD. The average AUC 
improved significantly from 0.77 to 0.84 (p=0.001) (Fig 6.3). Three malignant cases appeared to 
be very challenging to detect.  In one case only one reader once detected the cancer. This was 
in the unaided reading session. The same cancer was missed in the CAD-ABUS reading session. 
Two cancers were missed by all readers in both reading sessions. These three cancers were a 
16mm IDC, an 8mm IDC and one 6mm ILC. These cancers were not marked by the CAD-software 
at the applied FP rate, and were not clearly visible on the MinIP. 
No statistically significant differences were observed between experienced and non-experienced 
readers in the unaided reading session (AUC = 0.77 vs. 0.80), or in the CAD-ABUS (AUC = 0.84 vs. 
0.85) readings (p=0.74 and p=0.90, respectively). 
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Table 6. 1 Performance of individual radiologists and residents reading ABUS with and without CAD support 
measured in sensitivity, specificity and by the area under the AFROC curves (AUC).
Reader AUC ABUS AUC  CAD-ABUS P
a Sensitivity ABUSb
Sensitivity  
CAD-ABUSb
Specificity  
ABUSb
Specificity  
CAD-ABUSb
Radiologist 1 0.849 0.891 0.330 73.7 78.9 92.8 92.8
Radiologist 2 0.676 0.795 0.059 73.7 78.9 48.6 44.3
Radiologist 3 0.782 0.833 0.318 78.9 84.2 77.1 75.7
Resident 1 0.807 0.883 0.238 78.9 89.5 77.1 71.4
Resident 2 0.790 0.831 0.251 73.7 78.9 72.9 84.3
Resident 3 0.723 0.807 0.403 73.7 78.9 78.6 72.3
Average 0.771 0.840 0.001
The performance of all readers individually improves after the addition of CAD support to the evaluation of ABUS. Each 
individual reader detects more cancers with CAD than without. a p value for statistical significance of the difference 
between the AUC of ABUS and CAD-ABUS b Sensitivity and Specificity from a 2 x 2 contingency table at the BI-RADS 3 
cut off point (*LOM=41) on the LOM scale. 
Figure 6. 3 Alternative Free-response Receiver Operating Characteristics (AFROC) curves of the performance 
of radiologists and residents in detecting breast cancers with ABUS. The areas under the AFROC curve 
improve significantly from 0.77 to 0.84 (p = 0.001) after CAD support is added to ABUS evaluation.
Discussion
This study shows that Computer Aided Detection (CAD) can improve radiologists’ performance 
in detecting breast cancer with automated breast ultrasound. During CAD-ABUS reading, 
none of the readers detected less cancers compared to the unaided reading. In fact, all readers 
detected 5.2-10.6% more cancers with CAD supported reading of our dataset, and all readers 
showed improved accuracy as measured by the AUC. The specificity of two readers improved 
when reading with CAD. For four readers a slight decrease of specificity was observed in the 
reading sessions with CAD (range 1.4%-5.7%). The overall accuracy of ABUS reading improved 
significantly with CAD.  To our knowledge this is the first report on the effect of CAD on the 
performance of radiologists screening for breast cancer in ABUS.
Observational studies have shown that adding ABUS to routine mammographic screening 
in asymptomatic women with heterogeneously and extremely dense breasts increases the 
detection rate with 0.19%-0.76% by detecting otherwise unobserved early stage invasive 
cancers (50,53,151). These results for ABUS are comparable to that of studies with supplemental 
handheld ultrasound in screening (range 0.18%–0.42%) (35–37,40,41,44–46). Despite these 
promising results, breast cancer screening with ultrasound remains a challenging and time-
consuming task for radiologists. Introduction of a CAD system for ABUS may make the technology 
more feasible in practice.
In volumetric image data with many slices, such as ABUS, cancers may easily be overlooked. 
Furthermore, interpretation errors may occur when cancers are mistaken for definitively benign 
lesions and therefore not recalled, in particular when carcinomas resemble benign lesions 
(116,214). CAD can help to avoid oversight errors by radiologists, if the CAD-software does 
detect the cancer and the radiologist does not ignore the CAD result (66,215). Moreover, by 
marking lesions as being suspicious the frequency of interpretation errors might be reduced. 
However, too many CAD marks might result in a diminishing confidence of readers in the CAD 
system, and hence a failure of the CAD system to improve reader performance (64). In this study 
we adjusted the average number of marks to one per view. This appeared to be an acceptable 
setting for the readers. 
The optimal implementation of CAD depends on the task and is likely to be different for each 
imaging modality (64,66,77). To maximize the gain from CAD, the system investigated in this 
study uses two different ways of presenting CAD results to the reader: Conventional CAD marks 
and an intelligent MinIP in which “dark spots” may attract attention to relevant lesions.  Most 
dark spots on the MinIP are not real lesions but hypo-echoic artefacts in the ABUS scan due 
to contact artefacts or due to acoustic shadowing caused by Cooper’s ligaments. Real lesions 
that cause dark spots in the MinIP include cysts, ductectasias and fibroadenomas, as well as 
cancers. Because small cancers will show a relatively small dark spot on the MinIP, they may 
easily be ignored by the reader. To avoid that this happens with relevant lesions, CAD prompts 
are projected on the MinIP, thus highlighting the more suspicious abnormalities in the MinIP. 
Results suggest that this dual strategy of CAD display is a good choice for ABUS CAD considering 
the positive effect on the accuracy of the readers. 
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The CAD-software in our study failed to mark three cancers in our dataset. These cancers were 
present in the ABUS images but were very subtle and consequently also missed by the human 
readers in 11 out of 12 reading sessions. In clinical practice these cancers were detected based 
upon clinical information and using a multimodal approach, but clinical information and 
other imaging modalities were withheld from the readers. With knowledge of the location of 
these cancers, they were, however, visible in the images. Improvements to CAD algorithms to 
specifically detect such discrete cancers have been reported (74). Therefore, even small and 
discrete cancers may in the future be detected at low CAD threshold settings, and without 
risking a negative effect of a lower specificity of CAD.
Our study has some limitations. In this observer study we chose to present one view per case 
because of study time constraints. This allowed for an increase of power of the study due to 
the fact that more (malignant and non-malignant) cases could be read in a reasonable time 
span. One may argue that one view does not reflect the true clinical practice of reading ABUS. 
However, many ABUS cases have one view in which a lesion is visible. Therefore, the task of 
interpreting lesions in one view is a realistic clinical task and the performance increase with CAD 
is relevant. Nevertheless, lesions may be visible in more views in practice and the added value 
of CAD may be different in those cases. In particular this may affect the size of the effect of CAD. 
Since lesions visible in two views may be easier to interpret and less likely to be overlooked, 
the effect of CAD may be less. It should be noted however, that also other factors influence the 
effect size, such as the composition of the dataset and independent factors such as a radiologist’s 
motivation or fatigue.  It was the aim of this study to investigate whether there is a benefit 
of adding CAD to ABUS rather than attempting to estimate the size of the effect of CAD to 
be expected in practice. Because all readers evaluated the same set of cases in both reading 
modes, and show a comparable benefit of reading ABUS with CAD, we argue that the relative 
improvement of accuracy due to CAD support observed in our study remains valid also when 
complete exams are read.
In conclusion we demonstrated that radiologists reading ABUS may benefit from the studied 
implementation of CAD-software as it increases cancer detection.
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Abstract
Objectives 
To determine the effect of computer-aided-detection (CAD) software for automated breast 
ultrasound (ABUS) on reading time (RT) and performance in screening for breast cancer. 
Material and methods 
Unilateral ABUS examinations of 120 women with dense breasts were randomly selected from 
a multi-institutional archive of cases including 30 malignant (20/30 mammography-occult), 30 
benign, and 60 normal cases with histopathological verification or ≥ 2 years of negative follow-
up. Eight radiologists read once with (CADABUS) and once without CAD (ABUS) with > 8 weeks 
between reading sessions. Readers provided a BI-RADS score and a level of suspiciousness (0-
100). RT, sensitivity, specificity, PPV and area under the curve (AUC) were compared.
Results 
Average RT was significantly shorter using CAD-ABUS (133.4 s/case, 95% CI 129.2-137.6) 
compared with ABUS (158.3 s/case, 95% CI 153.0-163.3) (p < 0.001). Sensitivity was 0.84 for 
CAD-ABUS (95% CI 0.79-0.89) and ABUS (95% CI 0.78-0.88) (p = 0.90). Three out of eight readers 
showed significantly higher specificity using CAD. Pooled specificity (0.71, 95% CI 0.68-0.75 vs. 
0.67, 95% CI 0.64-0.70, p = 0.08) and PPV (0.50, 95% CI 0.45-0.55 vs. 0.44, 95% CI 0.39-0.49, p = 
0.07) were higher in CAD-ABUS vs. ABUS, respectively, albeit not significantly. Pooled AUC for 
CAD-ABUS was comparable with ABUS (0.82 vs. 0.83, p = 0.53, respectively).
Conclusion 
CAD software for ABUS may decrease the time needed to screen for breast cancer without 
compromising the screening performance of radiologists.
7An efficient artificial intelligence ABUS-tool for radiologistsChapter 7
7
138 139
Introduction
In mammographic screening the sensitivity in women with extremely dense breasts is only 61% 
(6). A four times higher interval cancer rate is reported for these women compared with women 
with fatty breasts (6). Supplemental ultrasound (US) is an effective imaging method to detect 
mammography-negative early stage invasive breast cancer in women with heterogeneously 
and extremely dense breasts (38–40), thus reducing the frequency of symptomatic interval 
carcinomas (139). This is crucial, because detection of breast cancer at an early stage substantially 
improves prognosis, even when using modern therapy regimes (34). This explains the rationale 
and ratification of the breast density inform laws in many states in the USA (216,217) and the 
introduction of supplemental whole breast ultrasound (WBUS) screening in Austria (218).
Performing supplemental WBUS with handheld devices has limitations. It is relatively time 
consuming and difficult to compare to prior examinations. Furthermore, handheld WBUS 
screening is operator dependent and should therefore be performed by trained sonographists, 
which consequently requires substantial resources (32). Automated 3D breast US (ABUS) devices 
have been developed to improve the reproducibility of WBUS and decrease the need for highly 
trained sonographers. An ABUS examination consists of a set of large 3D volumes for each 
breast acquired with a wide automatically driven linear array transducer. The number of volumes 
depends on the size of the breast and in large breasts up to five volumes per breast are acquired. 
There is mounting evidence that, similar to handheld ultrasound, ABUS devices also lead to the 
detection of mammography-negative invasive breast cancers (49–53,92).
A downside of supplemental ultrasound screening is the detection of mammographically occult 
benign lesions that warrant histological verification (41,51,53), thus decreasing the specificity 
of screening. ABUS devices do allow storage of full breast ultrasound volumes, which enables 
the radiologist to compare examinations with relevant priors, which is expected to improve 
specificity in follow-up examinations. Due to the large number of images in the scan, reading a full 
ABUS examination can be lengthy and cancers may easily be overlooked (50). Computer-aided 
detection (CAD) software for ABUS has been developed to aid radiologists in the interpretation 
of ABUS studies (74). CAD software should reduce the reading time of supplemental ABUS and 
may have the potential to improve the screening performance of radiologists. To investigate 
the effectiveness of this approach, we investigated the effect of commercially available CAD 
software for ABUS on the reading time and screening performance of breast radiologists. 
Materials and methods
The need for informed consent for this study was waived by the institutional review board (IRB).
ABUS acquisitions
ABUS examinations were performed with ACUSON S2000 Automated Breast Volume Scanner 
systems (Siemens, Erlangen, Germany). This ABUS system acquires 3D B-mode ultrasound 
volumes over an area of 154 mm × 156 mm using a mechanically driven linear array transducer 
(14L5). Adequate depth and focus can be obtained using predefined settings for different breast 
cup sizes. All ABUS examinations were performed by technicians. To ensure coverage of the 
entire breast two to five overlapping acquisitions were performed at predefined locations. 
The number of acquisitions depends on the size of the breasts and the possibility to compress 
the breasts. Per acquisition 318 slices of 0.5 mm thickness are obtained. A dedicated ABUS 
workstation reconstructs the transverse slices into a 3D volume that can be read in a multiplanar 
hanging, also showing sagittal and coronal reconstructions.
Data and gold standard
Cases were selected from a large multi-institutional imaging archive that consisted of 2158 ABUS 
examinations in 1086 women acquired between August 2010 and February 2015 from screening 
programmes for women at average, intermediate, and high risk and symptomatic women. For 
each woman a full-field digital mammography (FFDM) examination was also available. 
To select only cases with high breast density, breast density was determined using an automated 
volumetric software package (Volpara Density, Matakina Ltd. Wellington, New Zealand) on 1657 
available unprocessed FFDM images. For 501 examinations, where unprocessed FFDM images 
were not available, breast density was visually assessed according to the BIRADS lexicon. 
Examinations of 115 women with a history of breast surgery were excluded; 1187 unilateral 
examinations of breasts in 715 women were scored as Volpara Density Grade 3 and 4 or BIRADS 
density categories C or D. We categorised these dense cases as ‘normal’ (n = 919), ‘benign’ (n = 
140), or ‘malignant’ (n = 128) based on radiology and pathology reports from histopathological 
examinations. ‘Normal’ and non-biopsied ‘benign’ cases were only considered if at least 2 years 
of negative follow-up was available. Subsequently, from these women with dense breasts, we 
included all cases with a mammography-negative malignant lesion (n = 20), ten randomly 
selected malignant cases that were positive on both mammography and ABUS, 30 biopsied 
benign cases and 60 normal cases in the study data set. The study data set thus consisted of 
120 unilateral ABUS evaluations, yielding a total of 375 ABUS volumes. The selected cases were 
anonymised and stripped from information such as age, study date, and imaging institute. All 
lesions were annotated by a breast imaging researcher with > 3 years of experience with ABUS 
based on pathology and radiology reports. These annotations served as the ground truth for 
observer and CAD software detection performance.
CAD software and reading workstation
A prototype workstation was designed and developed specifically for the task of high-
throughput ABUS screening in this observer study (MeVis Medical Solutions, Bremen, Germany). 
In this prototype, each user action was logged with time stamps that were subsequently used 
to estimate the time spent per case. Commercially developed CAD software (QVCAD, Qview 
Medical Inc., Los Altos, CA) was integrated into this workstation. This CAD software is designed to 
detect suspicious region candidates in an ABUS volume and mark them with so-called CAD marks 
(Fig. 7.1). In addition, QVCAD software provides an ‘intelligent’ minimum intensity projection 
(MinIP) of the breast tissue in a 3D ABUS volume that can be used for rapid navigation through 
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ABUS scans and enhances possible suspicious regions. The number of CAD marks displayed 
can be adjusted by setting the average number of false-positive CAD marks per ABUS volume.
In this study, we chose the default setting of one false-positive CAD mark per ABUS volume.
Figure 7. 1 CAD-based minimum intensity projection (MinIP) integrated in a multiplanar hanging protocol 
for ABUS that shows the conventional ABUS planes. The top plane shows the transverse acquisitions, the 
lower left plane the coronal reconstructions, and the lower right plane the sagittal reconstruction. The 
MinIP (bottom row in the middle) is a 2D image where lower intensity regions in the 3D ABUS volume are 
enhanced as dark spots. By clicking on the dark spot, the 3D multiplanar hanging automatically snaps to 
the corresponding 3D location. The CAD marks (coloured square) are displayed on the MinIP
Readers
Seven breast radiologists and one gynaecologist specialised in breast imaging were invited to 
participate in this study. By inviting readers from different institutes and countries we aimed to 
increase the applicability of our results to breast imaging practices in different countries, realising 
that different readers might have slightly varying standards and customs. In some countries, 
also other clinicians are involved in interpreting breast-imaging examinations. Therefore, we also 
invited a non-radiologist (gynaecologist) who specialises in breast imaging with approximately 
10 years of experience in breast ultrasound and mammography and 8 years of experience with 
ABUS. Experience with breast imaging for reader one to reader eight was 7, 10, 4, 8, 8, 20, 4, and 
20 years and specifically with ABUS was 5, 8, 0, 5, 5, 5, 0, and 0 years, respectively.
Study design
All eight readers evaluated all cases twice in two separate reading sessions in an independent 
crossover multi-reader-multi-case (MRMC) study. In each session half of the ABUS cases were read 
conventionally and half of the cases were read using a CAD-based workflow designed for this 
study. We counterbalanced the reading modes and changed the case order by randomisation 
for each reader per reading session. The reading sessions were at least 8 weeks apart (average 
11.0 weeks, range 8.3-13.1) to further minimise any effect of memory bias.
Standard ABUS reading was performed in a multiplanar hanging without CAD software. CAD-
based reading was performed according to specific instructions of a two-step reading protocol. 
The first step was to evaluate all CAD marks and dark spots on the MinIP in a case. Subsequently, 
readers were instructed to scan the coronal reconstruction of each ABUS view in a hanging 
protocol where coronal reconstructions of all ABUS views of a breast are simultaneously shown. 
The readers performed a training session of 20 cases to become familiar with the workstation, 
reading protocol, and CAD software. Readers were given a rough estimate (10-30%) of the 
prevalence of cancer in the study data set because the criteria for a recall may vary between 
radiologists who, as in our study, work at different institutes and in different countries (213) and 
may depend on the prevalence of cancers they expect.
In both CAD-based and conventional reading the readers were instructed to mark and rate 
lesions by placing a finding marker and subsequently determine a BI-RADS assessment score. 
Because a quasi-continuous linear scale is required to perform receiver-operating characteristic 
(ROC) analysis, readers were also asked to provide a level of suspiciousness (LOS) score on a scale 
from 0-100. Note that LOS is not a probability of malignancy as described in the BI-RADS atlas. 
Instead, readers were recommended to use anchor points referring to the BI-RADS scores with 
LOS values of 21, 41, 61, and 81 corresponding to the BI-RADS 1/2, 2/3, 3/4, and 4/5 transitions.
Statistical analysis
We determined the sensitivity, specificity, and positive predictive value (PPV) in both reading 
modes based on BIRADS scores and compared these parameters per reader using paired 
McNemar’s and chi-square tests with bootstrapping (1000 samples) to determine the 95% 
confidence intervals (CI) for individual readers and generalised estimation equation (GEE) for 
pooled data to correct for repeated measurements. An examination was considered positive if 
a BI-RADS 3 score (and its anchor point equivalent of 41 on the LOS scale) or higher was given. 
Furthermore, we determined the area under the curve (AUC) and 95 % CI using an alternative 
free-response receiver-operating characteristics (AFROC) (161,162). For these analyses, when 
multiple findings were present in a case, the finding with the highest rating was used. Ratings 
in malignant cases where the marker was placed outside of the annotated lesion margin were 
not included in the analysis and regarded as a false negative (missed cancer). By doing so, 
readers are not rewarded for a recall based on a false-positive finding accidentally occurring in 
a malignant case. We compared the AUCs for both reading modes for each reader individually 
and also pooled over all readers (random readers, random cases). Reading time was compared 
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for each reader individually by using Student’s t-test with 1000 bootstraps to determine the 95% 
CI and GEE for pooled data. Only the readings recorded within the 95th percentile were included 
in the analysis to correct for inactivity of the reader during the reading sessions.
The ROC analyses were performed using MRMC software (JAFROC, version 4.2.1). The GEE was 
performed using the ‘geese’ function in the ‘geepack’ package in R (v. 3.2.3, R Foundation for 
Statistical Computing, Vienna, Austria). All other analyses were performed with SPSS statistics 
20.0 (IBM Statistics, Armonk, NY).
Results
Patient characteristics
Table 7.1 summarises the patient characteristics in women with breast cancer and Table 7.2 
summarises patient characteristics of women with a ‘normal’ or ‘benign’ ABUS examination.
Table 7. 2 Characteristics of women with an ABUS exam labelled as ‘benign’ and ‘normal’. SD Standard 
Deviation
Mean Age (SD) N symptomatic : screening Mean Size (SD)
Normal cases (n=60) 42.0 (9.5) 4 : 56 N/A
Benign cases (n=30) 44.9 (9.1) 15 : 15 12.4 (5.1)
Fibroadenoma (n=12) 42.9 (5.3) 7 : 5 12.4 (5.7)
Fibrosis/adenosis (n=5) 43.6 (6.3) 1 : 4 10.2 (4.1)
Cystic lesions (n=5) 46.6 (8.8) 3 : 2 14.8 (7.8)
Other benign breast tissue (n=5) 54.6 (13.0) 3 : 2 12.2 (1.9)
Papilloma (n=2) 38.5 (9.2) 1 : 1 14.0 (2.8)
Complex Sclerosing lesion (n=1) 30.0 0 : 1 8.0 (0.0)
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Screening performance
Figure 7.2 and Table 7.3 summarise the screening performance per reader. On average, the 
sensitivity of unaided conventional ABUS reading (84%, 95% CI 78-88) was similar to the 
sensitivity in the CAD-based ABUS reading protocol (84%, 95% CI 79-89) (p = 0.90). Nevertheless, 
half of the readers detected more cancers with CAD, while only two readers detected fewer 
cancers using the CAD-based reading protocol. In the CAD-based readings 6 out of 8 readers 
placed markers on a total of 11 lesions that were actually malignant, but still classified them as 
benign (BI-RADS 2). In the unaided ABUS reading this happened only in four readers and a total 
of five malignant lesions. Hence CAD helped in the detection of additional cancers but could 
not always induce an adequate classification by the readers.
The average specificity for conventional ABUS reading was 67% (95% CI 64-70) and this increased 
to 71% (95% CI 68-75) in the CAD-based reading strategy, although this did not reach statistical 
significance (p = 0.08). The PPV was on average 13.6% higher for the CAD-based ABUS reading 
(50.0%, 95% CI 45-55) compared to the conventional ABUS reading (44.0%, 95% CI 39-49) (also 
not significant, p = 0.07). Overall, seven out of eight readers had higher specificity and PPV with 
CAD than without. Specificity was significantly higher in three out of eight readers (readers 1, 
4, and 6; Table 7.3). Nevertheless, the AUCs did not statistically differ between the conventional 
ABUS reading and the CAD-based workflow (0.82, 95% CI 0.73-0.92 and 0.83, 95% CI 0.75- 0.92, 
respectively) (p = 0.53) (Fig. 7.3) 
Figure 7. 2 Increment in sensitivity and specificity per reader after subtracting the sensitivity and specificity 
of the conventional ABUS reading session from the CAD-based workflow reading session. Ideally all readers 
perform within the upper right quadrant. Ta
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Reading time
Table 7.4 summarises the reading time for each individual reader. On average, reading unilateral 
ABUS examinations using CAD software decreases the overall reading time by 24.9 s/case (SE 
3.43; p < 0.001) (Fig. 7.4), which is a reduction of 15.7%. All readers were faster using CAD software 
(range, 3.1%-26.3%). In six out of eight readers, the CAD-based workflow was significantly faster.
The average reading time for malignant cases decreased by 12.1% (20.5 s/case, SE 6.97, p = 
0.003), for benign cases by 17.3% (28.2 s/case, SE 6.77, p ≤ 0.001), and for normal cases by 16.8% 
(25.3 s/case, SE 4.76) (p ≤ 0.001).
Figure 7. 3 Alternative free-response receiver-operating characteristic curves for conventional ABUS 
reading (striped intervals) and computer-aided detection-based workflow reading (straight line). No 
statistical difference is observed between the areas under the curves.
Table 7. 4 Average Reading time per reader for both conventional ABUS reading and reading the CAD-
based reading workflow. All readers were faster with CAD-software. 6/8 readers were significantly faster. 
ABUS Automated Breast Ultrasound; CAD Computer Aided Detection software
Reader (years 
Experience ABUS)
Average 
Reading time 
ABUS (s)
95% CI (low, 
high)
Average 
Reading time 
CAD-ABUS (s)
95% CI (low, 
high)
Percentage 
decrease
p-value
1 (5) 171.2 156.5 186.5 166.0 150.4 181.0 3.1 0.56
2 (8) 145.4 132.4 159.1 136.1 124.5 149.6 6.5 0.24
3 (0) 146.7 132.6 162.2 123.4 113.0 134.3 15.9 <.001
4 (5) 175.2 158.7 190.8 140.8 130.2 150.1 19.7 0.001
5 (5) 101.2 95.7 108.4 91.2 84.7 97.7 9.9 0.008
6 (5) 138.6 127.1 151.1 110 100.1 119.4 20.6 0.001
7 (0) 217.2 197.9 236.2 160.1 148.0 172.3 26.3 0.001
8 (0) 173.3 173.3 185.2 140.9 132.3 150.0 18.7 0.001
Pooled
Average 158.3 153.0 163.6 133.4 129.2 137.6 15.7 <.001
Normal 151.0 143.6 158.4 125.7 120.0 131.4 16.8 <.001
Benign 163.0 152.6 173.3 134.8 126.4 143.1 17.3 <.001
Malignant 169.3 158.8 180.0 148.8 140.2 157.5 12.1 0.003
Figure 7. 4 Histograms for reading time needed to read all cases in a conventional ABUS protocol (striped 
interval) and for reading in a CAD-based workflow protocol (straight).
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Discussion
Our study shows that CAD software for ABUS can help radiologists to evaluate ABUS examinations 
more efficiently. Radiologists who screen for breast cancer may use CAD software to evaluate 
batches of ABUS examinations 15.7%faster, without decreasing their performance in terms of 
cancer detection. Interestingly, the higher specificity and PPV of the CAD-based reading mode 
suggest that the use of CAD software for ABUS may help radiologists avoid unnecessary recalls 
of healthy women, albeit this did not reach statistical significance. Our results might facilitate 
further implementation of ABUS. Supplemental ABUS in women with mammographically dense 
breasts helps radiologists detect early stage cancers that are occult on mammography (50,51,53). 
Supplemental US screening reduces the interval cancer rate in women with dense breasts 
(39,48), which in general is associated with improved outcome (34). Unfortunately, 31% of 
cancers in supplemental US screening are found to be already visible on a prior screening US 
examination and could still have been detected earlier (219). Reasons for non-detection in WBUS 
screening are usually misinterpretation and oversight errors. In our study, oversight errors in 
malignant cases were more often observed in conventional ABUS reading than in the CAD-based 
reading. In fact, half of the readers detected and correctly classified more cancers in the CAD-
based readings than in conventional ABUS reading. Nevertheless, of the missed cancers several 
were still marked by six readers in the CAD-based reading, but wrongly classified as benign.
Therefore, it appears that the CAD software has the potential to prevent oversight errors in 
ABUS but might require further development to also aid in characterising lesions. Also, the very 
limited experience all readers had with the CAD system might have partly contributed to the 
misclassification of malignant lesions.
Supplemental ABUS has been shown to increase the recall rate in breast cancer screening 
programmes (51,53). The implementation of an intelligent MinIP into the reading environment 
therefore also aims at improvement of specificity. The MinIP uses the greyscale contrast in 
B-mode ultrasound between lesions and healthy tissue to summarise the 3D volume in a 2D 
image; hence normal tissue appears lighter than cancers that show up as dark spots on the 
MinIP. Moreover the CAD software also enhances the more suspicious regions by lowering the 
intensity of the lesion on the MinIP and strengthening the coronal retraction sign, which is highly 
suggestive of breast cancer in ABUS (96). Consequently, the MinIP points out relevant lesions 
and reduces the suspiciousness of irrelevant regions in ABUS volumes. Our study indicates 
that using this CAD software might indeed decrease unnecessary recalls in ABUS by improving 
the specificity and PPV of radiologists. Although the overall results were not significant, a 
positive effect was still seen in seven out of eight readers. Whether ABUS CAD software in 
actual supplemental screening truly helps to decrease the recall rate and improve radiologist’s 
specificity still needs to be investigated prospectively. 
In a previous pilot study, we investigated the effect of CAD software for ABUS on the screening 
performance of readers when screening for breast cancer (220). Our previous study showed that 
concurrent reading CAD software may improve the accuracy of radiologists for evaluation of 
single ABUS volumes. In the current study, the CAD software was implemented into a specific 
CAD-based screening workflow to boost the reading speed during batch reading of whole breast 
ABUS examinations. The purpose of this study was therefore to investigate the effect of CAD 
software on the efficiency rather than on the accuracy. In addition, this study was performed 
using whole-breast examinations only from women with heterogeneously dense or extremely 
dense breasts, thus creating a data set that is representative for supplementary screening with 
ABUS in dense breasts.
The mean reading time of a unilateral ABUS examination with an average of three volumes per 
breast without CAD software in our study was 158.3 s, which is in line with previously reported 
3-9 min for a bilateral WBUS examination (41,51,221). However, our study data set was enriched 
with cancers and suspicious benign cases, which likely increases the reading time per case. Our 
CAD-based reading workflow decreased the average reading time with 15.7% to 133.4 s per 
unilateral ABUS examination. The improvement in reading speed was higher in normal and 
benign cases than in malignant cases. We therefore expect that this gain in efficiency in a true 
screening setting could be higher than in our study.
Navigation of the ABUS examinations using the CAD enhanced MinIP can be performed relatively 
quickly. But in our study the readers were instructed to evaluate all dark spots and CAD marks 
in the MinIP and subsequently also scan the coronal reconstructions of the ABUS volumes. As a 
consequence, our instructions prolonged the reading time in the CAD-based reading sessions. 
Most breast radiologists are familiar with the concept of summarising relevant information of 3D 
breast imaging in a 2D image, as is common practice in tomosynthesis (synthetic mammogram) 
and in dynamic contrast enhanced breast MRI [maximum intensity projections (MIP)]. Kuhl et 
al. reported that looking only at MIPs is a reliable and fast (3-30 s per case) approach to breast 
cancer screening with MRI (222). The CAD enhanced MinIP in our study could theoretically 
be used in a similar way, thus further reducing the reading time required per ABUS volume. 
However, future studies need to elucidate the effect this may have on the sensitivity of ABUS.
Our study has limitations. We did not show corresponding mammograms with the ABUS 
examinations although these modalities are complementary in most screening regimes 
of women with dense breasts and this might positively or negatively affect the screening 
performance. Furthermore, we enriched the data set with benign and malignant lesions from 
both screening and diagnostic examinations to increase the power in this study. By doing so, 
our study data set does not represent clinical practice where the prevalence of benign and 
malignant lesions is lower. Finally, multiple readers had little experience with ABUS and all 
readers were inexperienced with the CAD software package that we implemented in our 
screening environment, which may have negatively affected the screening performance and 
reading time. 
In conclusion, our study shows that the CAD software developed for ABUS has the potential to 
improve the efficiency of reading ABUS by significantly improving the reading speed without 
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decreasing the screening performance. Further research is warranted in a prospective study 
to investigate the effect of CAD on breast cancer detection, screening recalls, and the interval 
cancer rate in screening programmes.
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Abstract 
Purpose
To investigate the effect of using CAD-software to improve the performance of radiologists by 
validating findings reported by radiologists during screening with ABUS.
Material and methods
Unilateral ABUS exams of 120 women with dense breasts that included 60 randomly selected 
normal exams, 30 exams with benign lesions and 30 malignant cases (20 mammography-
negative). Eight radiologists were instructed to detect breast cancer and rate lesions using 
BI-RADS and level-of-suspiciousness scores. CAD-software was used to check the validity 
of radiologists’ findings. Findings found negative by CAD were not included in the readers’ 
performance analysis but the nature of these findings were further analysed. The area under the 
curve (AUC) and the partial AUC for an interval in the range of 80%-100% specificity before and 
after CAD-validation were compared. Sensitivity was computed for all readers at a simulation 
of 90% specificity. 
Results
Partial AUC improved significantly from 0.126 (95%CI 0.098-0.153) to 0.142 (95%CI 0.115-0.169)
(p=0.037) after CAD rejected mostly benign lesions and normal tissue scored BI-RADS 3 or 4. The 
full AUC’s (0.823 vs. 0.833, respectively) were not significantly different (p=0,743)  Four cancers 
detected by readers were completely missed by CAD and four other cancers were detected by 
both readers and CAD but falsely rejected due to technical limitations of our implementation 
of CAD-validation. In this study CAD validation discarded 42.6% of findings that were scored 
BI-RADS ≥3 by the radiologists of which 85.5% were non-malignant findings. 
Conclusion
Validation of radiologists’ findings using CAD-software for ABUS has potential to improve the 
performance of radiologists. CAD-validation might be an efficient tool for double reading 
strategies by limiting the amount of discordant cases needed to be double read.
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Introduction
Population based breast cancer screening with mammography reduces breast cancer mortality 
by 31%-48% (78). Nonetheless, in women with dense breasts sensitivity is as low as 61% 
(compared to 86% in non-dense breasts. Moreover a 5-6-fold increase in interval cancers is seen 
in women with extremely dense breasts (6). While modern therapy regimes for breast cancer 
have improved the life expectancy of breast cancer patients, detecting breast cancer at an early 
stage is still considered vital for patient survival (34). Women with dense breasts may, therefore, 
benefit from supplemental imaging modalities to detect mammographically occult cancer. 
Breast ultrasound with hand-held ultrasound (HHUS) devices has been shown to help detect 
mammography-occult early stage invasive breast cancers in women with dense breasts (38–40). 
However hand-held devices depend highly on the experience of the sonographers and the 
possibility for comparison of screening exams over time is limited (32). Automated 3D breast 
ultrasound (ABUS) devices may overcome the operator dependency of HHUS. The visualization 
of architectural distortion (the so-called retraction phenomenon (223)) in the coronal plane 
improves the characterisation and detection of breast cancer (49). The acquisition protocols are 
standardized so that non-sonographers can acquire large 3D whole breast ultrasound volumes, 
which can be stored in, and retrieved from, medical imaging archive systems, thus enabling 
temporal comparison and double reading strategies. Like supplemental HHUS screening, 
supplemental ABUS also improves the sensitivity of screening, and may likewise lead to an 
increase of unnecessary recalls because of visualisation of benign breast disease that warrants 
histological evaluation (50,53,151,224). The number of ABUS images to read depends on the size 
of a woman’s breast. A bilateral ABUS examination may consist of four to ten 3D ABUS volumes 
to ensure coverage and as a consequence reading ABUS may be a lengthy task and prone to 
interpretation errors. Double reading strategies for ABUS may help to prevent interpretation 
errors (50) but require substantial resources to facilitate.
Computer aided detection (CAD) systems have shown promising results in breast imaging as 
an aid for radiologists reading screening mammograms, but in general may lead to an increase 
in false positive recalls that need to be dismissed by radiologists (65,66). The conventional 
implementation of CAD is by marking regions suspicious for cancer in an image and such 
software has also been developed for ABUS (70,74,76,223). CAD may help to improve sensitivity, 
specificity and/or efficiency of radiologists reading ABUS when implemented as a conventional 
aid (72,220). 
However, there are other ways CAD can be implemented in clinical practice.  In this study we 
propose to use a dedicated ABUS CAD-program to validate findings reported by radiologists 
during screening for breast cancer in ABUS without primary CAD-assistance. Radiologists have 
been shown to have a relatively high false positive recall rate with using ABUS. A large proportion 
of false-positive recalls are caused by benign lesions and ABUS imaging artefacts (99,225). 
The CAD-software used in this study appears to have a good performance in differentiating 
malignancies from benign lesions and artefacts. We hypothesized that most recalls for findings 
that are not recognized as suspicious by the CAD system are based upon artifacts and benign 
lesions. Therefore, the purpose of this study is to evaluate the effect on the performance of 
radiologists after using CAD-software to validate suspicious findings as pointed out by breast 
radiologists screening for breast cancer in ABUS. 
Material and methods
The need for informed consent for using anonymized data in this multi-reader-multi-case 
(MRMC) observer study was waived by the institutional review board.
We used the data from a previously published multi-reader-multi-case study for assessment of 
the added value of a CAD system for validation of findings by radiologists (226). Our previous 
study (23) reported on the effect of CAD on the accuracy of radiologists using ABUS as a 
conventional aid. This study focuses on the effect of CAD on radiologists when implemented 
as a secondary independent interpreter of the radiologists’ findings. As reported elsewhere in 
detail, cases were extracted from a multi-institutional database containing ABUS examinations 
from 715 women. In short, the final dataset consisted of 120 unilateral breast examinations (a 
total of 375 views), with 30 malignant cases, 30 cases containing benign lesions and 60 normal 
cases with 2 years of negative follow-up. All lesions were annotated by a radiologist in training 
with 4 years of experience with ABUS, drawing an outline on the lesion edge using in-house 
built software based on original pathology and radiology reports.
All cases were read twice by 8 independent readers with variable levels of experience with ABUS 
(range 0-8 years), once without the aid of a CAD system in a standard multiplanar hanging, 
and once with the aid of a commercially developed ABUS CAD-software package (QVCAD, 
Qview Medical Inc., Los Altos, CA). This software is designed to detect suspicious regions in an 
ABUS volume and mark them. Furthermore, this CAD-software package provides an ‘intelligent’ 
minimum intensity projection (MinIP) of the breast tissue in a 3D ABUS volume that was 
integrated in the multiplanar hanging protocol. For the current study only the data from the 
unassisted readings were used. All readers annotated suspicious lesions by placing a marker 
in the lesion center, and provided a BI-RADS score per case, as well as a level-of-suspiciousness 
(LOS) score on a linear scale from 0-100 with given anchor points for each BI-RADS assessment 
category (21, 41, 61, 81 for BI-RADS category 2, 3, 4 and 5, respectively).
Validation of findings with Computer Aided Detection software
We used the CAD system, using its default setting of an average of one false positive CAD-region 
per ABUS volume, for retrospective validation of the reader annotations in the unaided reading 
session. For this, we recorded the 3D voxel coordinates of each CAD-region in the study dataset. 
At the used threshold the sensitivity of the CAD system is approximately 82%.
After correlation to CAD findings reader findings were only considered positive when they 
corresponded to the location of a CAD-region (i.e. positive assessment of findings by both reader 
and CAD), all other reader findings were regarded as negative (readers marked the finding as 
Validation of Radiologists’ findings by artificial intelligence softwareChapter 8
158 159
88
positive whereas CAD did not mark the finding). A match was defined as ≤ 10 mm spherical 
distance between CAD region and reader marker. 
Evaluation of CAD-rejected findings
To evaluate the type of findings that were rejected with the CAD system (i.e. the negative reader 
findings after CAD validation), a panel of two experienced readers evaluated in consensus all 
rejected findings that were reported as ≥ BI-RADS 3 by the readers. First, the rejected findings 
were classified as true negatives (TN) or false negative (FN). FNs were defined as a reader’s 
marking pointing out a malignant lesion that was rejected by the CAD system. TN findings 
were findings that were rejected by the system and were not malignant in nature. TNs were 
subsequently classified in consensus as benign, normal breast tissue or artefacts.
Statistical analysis
The area under the alternative free-response operator receiver characteristics (AFROC) curve 
(AUC), was determined for the unassisted ABUS readings and after CAD validation for each 
reader individually and for all readers pooled. Per case only the highest rated lesion was included 
in the analysis. The AFROC analysis included only the LOS scores. False positive findings in 
malignant cases were omitted from the analysis to avoid readers and CAD being rewarded 
while breast cancer was respectively missed or rejected by CAD, which would be the result in a 
normal case-based ROC analysis and therefore we chose AFROC analysis. 
A full AUC represents all trade-offs between sensitivity and specificity of readers independent 
of the set of cases and readers. Nevertheless, in screening a high specificity is required. For that 
reason we also analysed the partial AUC (pAUC) for the false positive fraction (FPF = 1-specificity) 
interval of 0.0-0.2 (based on the range in which the specificity of supplemental ultrasound 
screening has been reported (36,38,39,41,53,81)). Furthermore, sensitivity for all readers was 
determined in a simulated sensitivity analysis at a fixed specificity of 90 percent. PROPROC curve 
fitting was used to approximate the AUC and pAUC, respectively. MRMC AFROC analysis was 
performed using the Obuchowski-Rochette Dorfman-Berbaum-Metz MRMC software (v. 2.50) 
that employs ANOVA and jackkniving (161,162). 
Statistical significance was determined if p < 0.05.
Results
Patient characteristics
The patient characteristics are described in detail in our previous report (226). The average age 
of women in our dataset was 45.1 years (SD 10.4, range 26-77). In the malignant, benign and 
normal subcohorts the average age was 49.8 years (SD 12.1, range 26-77), 44.9 years (SD 9.1, 
range 30-73) and 43.0 years (SD 9.5, range 26-62), respectively. 
The dataset consisted of 84 cases (including 13 malignant and 15 benign cases) that were 
derived from supplemental screening exams and enriched with 36 exams of symptomatic 
women. Median cancer size was 14 mm (SD 8.8, range 7-55) and median biopsied benign 
lesion size was 12.4 mm (SD 5.1, range 6-27).  The subset of cancers consisted of 22 invasive 
ductal carcinomas, 3 invasive lobular carcinomas, 2 invasive intraductal papillary carcinomas, 
two invasive metaplastic carcinomas and one invasive apocrine carcinoma. The benign subset 
consisted of 12 fibroadenomas, 2 papillomas, 3 fibrotic lesions, 2 adenosis, 1 complex sclerosing 
lesion, 5 benign cystic lesions and 5 other benign lesions. 
Reader performance
Table 1 summarizes the results of the readers before and after validation of readers’ findings by 
CAD. The overall difference in AUC was not statistically significant. (0.823 (95% CI 0.730-0.916) 
for unaided reading and 0.833 (95% CI 0.747-0.919) for reading after CAD-validation(p=0.743). 
Validation by CAD improved the partial AUC for the interval within the specificity range of 
80%-100%. The pAUC improved significantly from 0.126 (95% CI 0.098-0.153) to 0.142 (95% CI 
0.115-0.169) (p=0.037) in this specificity interval. Moreover, all readers showed higher pAUC 
after validation with CAD of which two improved their performance statistically significant. Due 
to the large reduction of normal findings all readers showed an improvement in sensitivity in a 
statistical simulation using a fixed specificity of 90% for all radiologists. In fact, pooled sensitivity 
at 90% specificity was 0.654 (95% CI 0.512-0.796) for standard ABUS reading and showed 
improvement to 0.727 (95% CI 0.598 – 0.856) after validation by CAD, although the difference 
was not statistically significant (p=0.061). Figure 1 shows the pooled AFROC curves for both 
standard ABUS reading and after validation by CAD. The AFROC curves cross at approximately 
83% and 50 % specificity likely due to interpolation because of a low number of non-suspicious 
findings reported after CAD validation.
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Figure 8. 1 Alternative Free-response Receiver Operating Characteristics curves for both standard ABUS 
reading and results of ABUS reading after CAD-validation of human-observed findings. In the higher 
specificity ranges (False Positive Fraction = 1 – specificity) results of reading ABUS with CAD-validation 
outperform standard ABUS reading.
Rejected findings after CAD validation
Validation by CAD reduced the number of positive findings, defined as those scored as BI-RADS 
≥3 by the readers, with on average 42.6% (range 31.9%-53.8%) (Examples figure 2 and figure 
3. Based on the consensus reading, on average 49.8% (range 11.6%-73.3%) of CAD-rejected 
cases are related to the presence of a benign lesion, 35.7% (range 13.3%-67.4%) are caused by 
acoustic shadowing artefacts in normal tissue and 14.4% are malignant lesions missed by the 
CAD system (range 7.7%-20.9%). The majority (average 47.5% [range 37.5%–53.3%) of the CAD-
rejected findings were scored by the radiologists as BI-RADS 3, followed by BI-RADS 4 (average 
41.3% (range 26.7-58.3) and BI-RADS 5 (average 10.4% (4.2%-23.2%) (Table 2).
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Figure 8. 2 Example of 
a true negative case. 
A hypoechoic parallel 
oriented well-defined 
mass with posterior 
acoustic enhancement 
and an irregular margin 
was not marked by the CAD 
software. Histopathologic 
evaluation resulted in a 
fibroadenoma without 
atypia.
Figure 8. 3 Example of 
a true negative case. 
A hypoechoic well 
defined parallel oriented 
mass with posterior 
acoustic enhancement, 
calcifications and an 
irregular margin was 
not marked by the CAD 
software. Histopathologic 
evaluation resulted in a 
fibroadenoma without 
atypia.
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Rejected cancers
Four FN cancers were not marked by CAD at the used threshold of one false positive/ABUS 
volume, and therefore always led to a rejection when accurately detected by the readers 
(example figure 4). Two other FN cancers were correctly identified by CAD, but the extent of 
the tumor was larger than 10 mm and as a result the radiologists’ markings were “too far” from 
the CAD marking in the ABUS volume and therefore did not lead to a positive validation of the 
radiologists finding. This lead to incorrect rejection of malignant findings due to the fact that 
the spherical distance between reader finding markers and CAD region markers that was used 
to automatically determine whether CAD-marks and reader findings matched was larger than 
10 mm. Finally, two cancers where visible in multiple ABUS volumes but only marked by CAD 
in one ABUS volume, whereas they were marked by some of the readers in another volume. 
Figure 8. 4 Example of a 
false negative case. A small 
non-parallel oriented 
hypoechoic lesion with 
irregular margins, no 
posterior acoustic effects 
and a strong retraction 
pattern was detected 
and marked correctly by 
multiple readers, but not 
by the CAD software and 
therefore rejected after 
CAD-validation.
Discussion
Our study shows that implementing CAD software for ABUS as a tool to validate radiologists’ 
findings has potential to improve the accuracy of radiologists who use ABUS to detect breast 
cancer in women with dense breasts, albeit at the cost of slightly lowering sensitivity. Especially 
in the highest range of specificities, a significant improvement of the average accuracy 0.126 
(95% CI 0.098-0.153) to 0.142 (95% CI 0.115-0.169) (p=0.037) is observed. We did not observe an 
improvement in the overall pooled AUC. Nevertheless, it is important in screening for (breast) 
cancer to have a method that has high specificity to minimize false-positive screening outcomes 
that may lead to unnecessary anxiety among the screening participants and negatively impacts 
the cost-effectiveness. A post-hoc analysis of significant (≥ BI-RADS 3) but CAD-rejected findings 
shows that CAD validation may discard 42.6% of findings that were scored BI-RADS ≥3 by the 
radiologists and 85.5% of the rejected findings were non-malignant and thus were rejected 
correctly. 
Whole breast ultrasound leads to the detection of mammographically occult breast cancer 
mainly because of visualisation of cancers that are masked by fibroglandular tissue (39,41,46,151). 
Cancers detected by ultrasound tend to be more invasive, node negative and smaller in size 
compared to mammography-detected cancers in screening (80) which may have a positive 
outcome on patient survival (34). A negative effect of supplemental breast ultrasound is an 
increase in recall rates, while up to thirty percent of cancers still could have been detected 
earlier (219). Choi et al. and Vourtsis et al. showed that in asymptomatic women ABUS may 
outperform hand-held devices in terms of recall rate, but also in terms of cancer detection 
(49,52). Recently developed CAD-software for ABUS may improve screening efficiency, aid 
radiologists in detecting subtle cancers and might improve specificity (72,220,226). 
Current CAD systems are designed to be implemented as a tool to assist radiologists during 
evaluation of breast imaging. Such CAD systems may, for example, have a positive effect on the 
outcome of breast cancer patients that underwent mammographic screening (210). However, 
CAD systems in mammographic screening have also been criticised because of an increased 
recall rate induced by CAD (227). Introducing conventional CAD-systems into existing breast 
imaging routines is challenging and depends on several factors such as the intrinsic accuracy of 
the CAD system itself and, on a psychological level, the confidence of radiologists in using CAD 
(64). The latter factor is likely to be of less importance in alternative ways of CAD-implementation 
such as synthetic lesion enhancement, pre-selection of normal cases for reducing workload and, 
according to our study validation of human observed findings by CAD (77).
Albeit the CAD system did not detect some of the cancers detected by the readers, and therefore 
excluded those from further analysis, a fraction of these specific cancers was not rated as very 
suspicious by the readers and consequently would only have been detected at lower specificity 
according to the AFROC analyses in this study. In screening, keeping the recall rate at an 
acceptable level demands a very high specificity. Therefore, we evaluated the average sensitivity 
per reader at a fixed score of 90% specificity (a statistical simulation based on the LOS scores), 
which we deem acceptable in screening practice. At a specificity of 90% the sensitivity for all 
readers is on average 7% higher, thus suggesting that in practice the use of CAD might allow 
a higher cancer detection in screening, based on better selection of recalled cases. In an ideal 
situation radiologists would recall all women with breast abnormalities with a certain degree 
of suspiciousness. But population-based screening should be both accurate and affordable and 
therefore some population-based screening programs have restrictions on the number of recalls 
in order to achieve a positive cost-effectiveness ratio. Our results might imply that using CAD-
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Figure 8. 5 Flow diagram of an example of an ABUS screening workflow that incorporates CAD-validation 
of human-observed findings and reduces the workload of double reading discordant cases.
ABUS, Automated 3D Breast Ultrasound; CAD, Computer Aided Detection; BI-RADS, Breast Imaging Reporting And Data 
System.
validation may allow radiologist to recall more women initially (by lowering their specificity) 
and potentially might improve their sensitivity. 
In an alternative and clinically more acceptable scenario CAD-validation might be used in a 
double reading strategy. This prevents unwanted rejection of malignant cases, while still largely 
reducing the workload for the second reader as only discordant cases need to be reviewed to 
optimize screening performance. Figure 5 shows a schematic workflow of a theoretical double 
reading strategy of ABUS that includes CAD as a validation tool. The effect of combinations of 
CAD and double reading of discordant cases in ABUS requires further investigation.
To our knowledge mammographic screening programs that offer supplemental ultrasound to 
women with dense breasts have not implemented CAD systems. Wilczek et al. used consensus 
arbitration of discordant cases in double reading to reduce false positive recall rates to an 
acceptable level (50). According to our results CAD-validation of radiologists’ findings may 
positively affect the false positive recall rate and thus achieve similar screening sensitivity at 
higher screening specificity.
Our study has limitations. The prevalence of both benign and malignant breast disease was 
artificially enhanced to increase power of this study and does not resemble normal screening 
practice where disease prevalence is lower. ABUS and mammography are usually complementary, 
however we did not show mammography to the readers which may have affected the results 
either positively or negatively. Furthermore, readers in our study were unexperienced with batch 
reading large quantities of ABUS exams which may have affected individual recall strategies.
In conclusion, in this paper we presented results of CAD-validation of radiologist’s findings 
in automated 3D breast ultrasound using commercially developed dedicated CAD software. 
CAD has the potential to help radiologists avoid unnecessary recalls by validating radiologists’ 
reports in screening. CAD-validation may be integrated into double reading strategies and 
consequently might reduce the resources needed for double reading of ABUS by confirming 
cases that were found suspicious and leaving only non-CAD suspicious cases for double reading. 
Whether validation of findings with CAD actually improves the screening performance and 
reduces the costs for double reading needs further prospective investigation.
Chapter 9 
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In this chapter we will discuss our contributions, advances and future perspective of automated 
3D breast ultrasound. 
What benefit is there of ABUS in the breast care clinic? 
Automated whole breast ultrasound systems were already available in the 1980’s but the 
technique was not viable for clinical use at that time. The newest generation of automated 
breast ultrasound systems such as GE Invenia ABUS, Siemens Acuson S2000 ABVS and Hitachi’s 
Sofia are equipped with high-end hardware and software that allows these systems to be easily 
implemented into breast care clinics. Automated breast ultrasound systems allow radiologists to 
evaluate whole breast imaging volumes without the need to perform a lengthy bed-side hand-
held ultrasound examination. By doing so, breast radiologists may create a more efficient clinical 
workflow in their breast care clinic. Furthermore, the ability to acquire, store and retrieve 3D 
imaging volumes enables temporal comparison of relevant exams similar to other 3D imaging 
techniques such as computed tomography and magnetic resonance imaging. An important 
thing to understand about whole breast ultrasound is that the benefits in terms of cancer 
detection as a supplement to x-ray mammography have been well recognized over the past 
twenty years. Breast ultrasound detects breast cancer that is not seen with mammography in 
both screening of asymptomatic women and symptomatic women (150,228). In chapter 2 
we reviewed the published literature after 2008 on prospective trials on supplemental breast 
ultrasound in screening. Our results are comparable to the systematic review by Nothacker et 
al (150) who reviewed the results of studies that were reported until 2008. Both reviews show 
that supplemental ultrasound detects additional early stage invasive breast cancers that are 
occult on mammography, but at the cost of additional false positive recalls. A recent report 
on the results of a population based screening program in Austria confirms the increase of 
cancer detection and false positive recalls following the introduction of supplemental breast 
ultrasound (39). The majority of published prospective studies show the result of a single round 
of screening.  Weigert et al (38,81,82) published their outcomes of screening on the subsequent 
years after the ratification of the breast density notification law in Connecticut and showed 
that the positive predictive value of breast ultrasound and mammography combined improves 
over time indicating the presence of a learning curve that results in a decrease of false-positive 
recalls. A decrease in false-positive recalls over time is also reported by Arleo et al (99) for 
ABUS. Nevertheless, the published studies on supplemental ABUS consist of relatively small 
cohorts. In our opinion, more research on supplemental ABUS with larger cohorts of women 
performed by radiologists and technicians with extensive experience with the technique is 
therefore warranted. Our pictorial essay in chapter 2 describes the technique and its pitfalls 
and reviews the incidence and appearance of the most common findings in breast ultrasound. 
Radiologists and technicians may improve their understanding of ABUS and experience with 
the help of our pictorial essay.
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Is ABUS of added value in diagnosing breast cancer?
A major limitation of ultrasound in screening is the relatively high false positive rate, due to the 
limited capacity to discriminate benign from malignant lesions. ABUS systems however, have 
certain merits in the diagnostic evaluation of breast lesions, that may be useful to prevent false 
positive recalls. In chapter 3 we described the added value of the multiplanar reformats of the 
transverse scanning plane. The results from our observer study show that the MPR’s of ABUS and 
in particular the coronal reconstruction may help breast radiologists in differentiating benign 
from malignant breast disease because of the visualisation of the retraction phenomenon. The 
AUC of all radiologists pooled improved from 0.82 to 0.87 (p=0.01). The retraction phenomenon 
can be described as a stellate pattern that radiates from a breast lesion and is very specific for 
breast cancer and certain high-risk lesions. Our results are in line with other reports that show 
the added value of the visualization of retraction patterns on coronal reconstruction of ABUS 
(93,111). Three-dimensional MPR’s and a comprehensive visualization of retraction patterns 
are not available with standard hand-held ultrasound equipment. According to our results, 
evaluation of the MPR’s might help to avoid a small yet important number of unnecessary 
recalls of benign lesions because in our observer study radiologists downgraded a BI-RADS 3 
assessment to a BI-RADS 2 in 3-18% of the cases. 
The retraction pattern has been reported as a specific imaging biomarker of invasive breast 
cancer, however our study in chapter two revealed that the severity of retraction is variable 
in breast cancer and some cancers might not exhibit a retraction pattern. In chapter 4 we 
hypothesized that the severity of the retraction pattern and other descriptors in the BI-RADS 
lexicon for ultrasound are associated with the molecular subtype classification of invasive ductal 
carcinoma. Modern therapy regimes are increasingly being tailored to the molecular subtype 
of breast cancer because of the varying responses of the different subtypes to treatment (229). 
Imaging biomarkers might help to identify molecular subtypes during the diagnostic process. 
According to our results the descriptors for margin, posterior acoustic features and the ABUS-
specific retraction phenomenon in the coronal plane are associated with molecular subtypes of 
invasive ductal cancer. The strongest descriptor is the retraction pattern severity. Luminal IDC’s 
tend to exhibit a more severe retraction pattern compared to the more aggressive subtypes 
HER2-enriched and triple-negative IDC’s. Interestingly the luminal A subtypes present with a 
more severe retraction pattern compared to luminal B subtypes. These results might imply that 
stromal response is a pivotal factor in the development of a retraction pattern seen in ABUS. 
A large proportion of HER2-enriched and triple-negative IDC’s show a mild to no retraction 
pattern at all and could therefore pose a challenge for a radiologist to detect when it is small 
with a benign-like appearance. Absolute prediction of the molecular subtypes is moderately 
accurate (40.6%) when using the BI-RADS-US lexicon descriptors and the retraction pattern 
severity. Nevertheless, breast imaging is a multimodal approach and the combinations of 
modalities might improve subtype prediction and thus may help to personalise advanced 
therapy strategies.
What is the role of ABUS in today’s breast imaging field?
ABUS systems are designed to overcome limitations of hand-held ultrasound such as operator 
dependency by standardizing the acquisition protocol and to overcome the inability of 
hand-held ultrasound to compare examinations with relevant priors by enabling storage 
and retrieval of large (standardized) 3D imaging volumes. Operators of ABUS need only little 
training compared with hand-held ultrasound which requires highly trained sonographists and 
therefore ABUS might be less costly. In this thesis we have focused on cancer detection and 
differentiation of findings in a screening setting, mainly because ABUS systems are designed 
for mass screening. Nevertheless, other indications have been proposed for ABUS such as a role 
in staging, second-look ultrasound after breast MRI and monitoring treatment response during 
and after neoadjuvant chemotherapy. 
Vendors of these ABUS systems have also been marketing the preoperative capabilities, by 
specifically promoting the coronal reconstruction as the more comprehensive “surgical view” 
because of the supine position of the women during both the scanning process and surgery. It 
is unclear what the effect of 3D ABUS is on the outcome of breast surgery.
The large size of the three-dimensional imaging volumes may allow for a more accurate tumor 
size measurement than conventional hand-held ultrasound and may also result in better 
estimations of the tumor extent than DBT(230,231). In Chapter 2 we describe multiple frequently 
found artefacts that may impair tumor extent measurements using ABUS such as incorrect 
placement of the transducer, air contact artefacts, posterior nipple shadowing, edge shadowing 
and breathing artefacts. As a results of these artefacts the ABUS scans need to be repeated or, 
alternatively, other additional imaging modalities are required. Breast MRI outperforms ABUS, 
hand-held ultrasound and mammography during the staging process in terms of visualizing 
different types of breast cancer (e.g. that includes invasive lobular carcinomas and non-calcifying 
ductal carcinoma in situ which can be very challenging to detect with other modalities such as 
ultrasound), assessing tumor extent and detecting additional disease (230,231). Breast MRI has 
already been established as the most accurate modality for staging and is even more accurate 
than ultrasound, mammography and clinical examination combined (127). Therefore, the role 
of ABUS in a preoperative stage is very limited when breast MRI is available. Furthermore, ABUS 
systems are not able to visualize the axillas, therefore lymfnode assessment as part of the staging 
process is not feasible with ABUS only. Although the evidence of using ABUS during (a part of ) 
the staging process is little, it may be considered when breast MRI is not available. In our opinion 
large studies are needed to investigate the cost-effectiveness of implementing ABUS during 
staging when breast MRI is not available.
Current previously described ABUS systems do not allow real-time evaluation of the images 
during the scanning process and current systems do not allow US-guided biopsies of breast 
lesions. Consequently, breast radiologists will have to resort to hand-held ultrasound guided 
biopsy procedures when an abnormality is seen on ABUS. ABUS does have the advantage of 
re-assessment of already stored images including correlation with breast MRI. Theoretically this 
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might result in a decrease of false-positive recalls and unnecessary anxiety among women when 
used as a second-look modality after breast abnormality detection using breast MRI. Although 
ABUS has been proposed as a non-inferior second look modality after MRI instead of hand-held 
ultrasound (232,233), it is unclear whether the actual cost-effectiveness ratio is positive using 
ABUS instead of hand-held ultrasound as a second-look modality. 
Temporal comparison of 3D imaging volumes is also relevant in monitoring the response of breast 
cancer to neoadjuvant chemotherapy. The current standard practice in response monitoring 
of neoadjuvant chemotherapy is breast MRI. Breast MRI outperforms ABUS, mammography 
and DBT, however early reports have shown that ABUS has good correlation to histological 
evaluation and MRI response monitoring (234–236). Therefore, ABUS might be a practical 
alternative in neoadjuvant response monitoring when breast MRI is not available. As discussed 
earlier, ABUS has potential to help identify imaging biomarkers that may assist in predicting 
(neo)adjuvant chemotherapy outcome (chapter 4).  Nevertheless, in chapter 2 we describe 
sonographically inconspicuous cancers and cancers that are prone to underestimation of tumor 
size using ultrasound (such as invasive lobular carcinoma and ductal carcinoma in situ), which 
should be kept in mind when considering ABUS in neoadjuvant treatment response monitoring. 
Most breast imaging facilities today offer mammography, digital breast tomosynthesis, 
ultrasound and magnetic resonance imaging. For each screening indication, one or more 
modalities are preferred and described in the international guidelines (4,126,237,238). However, 
most current guidelines do not recommend bilateral whole breast ultrasound in asymptomatic 
women. A recent meta-analysis has shown that adding ultrasound to mammography in women 
with dense breasts consistently increases the detection of mammography-occult small but 
invasive breast cancers, but the authors conclude that due to the increase in use of resources 
supplemental breast ultrasound will probably be more feasible in asymptomatic women at 
high risk than those in the average risk population (239). ABUS is considered more efficient 
than screening with hand-held ultrasound because the acquisition is standardized and does not 
require highly trained personnel, however there is currently no evidence that supports the idea 
of a better cost-effectiveness ratio compared with screening with hand-held devices performed 
by highly trained sonographists.
According to the guidelines current standard practice is to offer combined annual breast MR 
imaging and mammography to asymptomatic women at high risk (a lifetime risk (LTR) of more 
than 20%) for the development of breast cancer. Recent publications have shown inconsistent 
results in terms of cancer detection for triple-modality screening protocols that include breast 
MR imaging, mammography and whole breast ultrasound in women at high risk (15,56,202). 
In chapter 5 we prospectively investigated whether the addition of biannual ABUS will lead 
to earlier or additional cancer detection in women who carry the BRCA1 or BRCA2 germline 
mutation. According to guidelines (126,238) screening of these women should consist of annual 
mammography starting from the age of 30 years and annual breast MR imaging starting at the 
age of 25 years. In our study we added ABUS every 6 months and followed 296 women for at 
least three years. According to our results, in BRCA mutation carriers biannual (or annual) ABUS 
does not help to detect additional cancers and does not lead to earlier detection of breast cancer, 
likely because of the overall superiority of breast MR imaging in detection of cancers in an early 
stage. Nevertheless, in two women who carry the BRCA1 mutation (2 out of 10 BRCA1 carriers 
with breast cancer in our study), cancers were detected earlier with the interval ABUS exam, but 
classified as a BI-RADS 2 (benign) lesion. One of these cancers evolved rapidly into a T2 interval 
cancer that could have been treated in an earlier stage if it was recognized as a cancer instead of 
a benign lesion. This underlines the difficulty of detecting breast cancers in BRCA1 carriers with 
ultrasound because in these women a high prevalence of high grade triple-negative invasive 
ductal cancers occurs that may mimic benign breast lesions (63). The positive predictive value of 
ABUS in our study was very low at approximately 10% both in the first round and in subsequent 
screening rounds. Based on our study and the results published by Sardanelli et al (203), Kuhl et 
al (56) and Riedl et al (15) we neither recommend to implement ABUS nor handheld ultrasound 
to a screening protocol that includes breast MR. 
International guidelines recommend to add MR imaging to mammography in women at a LTR 
>20%. But many local guidelines deviate by reserving MR imaging only for the highest risk 
categories due to limited availability of MR equipment and the high costs. Supplemental ABUS 
could help to detect mammography-negative breast cancer in women with dense breasts who 
are at higher risk, but do not participate in a breast MR screening program. Kim et al (240) and 
Cho et al (241) reported higher cancer detection of mammography and ultrasound combined 
compared with mammography alone in women with dense breasts who were treated for breast 
cancer. An unpublished interim analysis of supplemental ABUS in 656 women at high risk with a 
Volpara Density Grade 3 or 4 screened at the Radboud University Medical Center (Nijmegen, NL) 
between July 2014 and September 2015 resulted in an additional cancer detection rate of 3.1 
per 1000 screens (242). All cancers were detected in women who underwent annual follow-up 
after treatment for breast cancer. Therefore, ultrasound (thus also ABUS) remains an alternative 
for women at high risk who do not undergo routine surveillance with MR imaging. 
Rebojl et al (239) state in the conclusion of their meta-analysis that supplemental ultrasound 
might be more feasible in women with the highest breast density because the financial strain 
of organizing supplemental ultrasound screening is likely outweighed by the high prevalence 
of cancers in these women. Modern mammography systems are equipped with digital breast 
tomosynthesis (DBT). DBT also detects mammography negative cancers in women with dense 
breasts (9,11,12). The addition of DBT to routine mammography might negate the need for 
supplemental whole breast ultrasound. However early comparative reports between whole 
breast ultrasound and DBT indicate that detection of breast cancer is better with whole breast 
ultrasound in women with extremely dense breasts (88,89,243).  Larger prospective trials 
should be performed comparing different imaging modalities (including cost-effectiveness) in 
women in different risk categories based on mammographic breast density to further specify 
recommendations for breast imaging. Cost-effectiveness in screening has been thoroughly 
investigated for MRI in the at risk (LTR >20%) population and for mammography in the population 
at average risk, but not for (AB)US or DBT screening. 
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Can artificial intelligence help me as a radiologist with ABUS exams?
In this thesis a commercially developed computer aided detection (CAD) system is used called 
QVCAD (Qview Medical Inc. Los Altos, Ca, USA). QVCAD detects and classifies suspicious regions 
in an ABUS volume. QVCAD creates a two-dimensional  intelligent minimum intensity projection 
(MinIP) of the three-dimensional ABUS volume and projects breast lesions as so called “dark 
spots”. The CAD system behind QVCAD also enhances the visualisation of the most suspicious 
regions in the ABUS volume. The MinIP may be used to quickly navigate through an ABUS 
volume. QVCAD was FDA-approved in 2016 as a concurrent reading tool for ABUS (244). 
In chapter 6 we asked three breast radiologists and three senior radiology residents to read a 
batch of 90 unilateral, single view ABUS exams twice, once with and once without QVCAD. The 
purpose of this study was to investigate the effect of QVCAD on the reading performance of 
ABUS. Secondary, we conducted this study to obtain pilot data for a sample size estimation in 
order to set up a more extensive observer study with QVCAD. The AUC pooled over all readers 
improved from 0.77 to 0.84 (p=0.001) and all readers improved their sensitivity after using QVCAD 
at the cost of a small decrease in specificity in four out of six readers, independent of their level of 
experience with the technique. These results support the fact that cancers can be missed in large 
three-dimensional imaging volumes such as ABUS and a CAD-system can help to prevent non-
detection, especially while reading large batches of exams. However, methodological choices 
such as the choice to present a single view per case may have overestimated the positive effect 
of CAD.
In chapter 7 we adapted the study design of our pilot study by increasing the number of cases 
in our dataset to 120 and show a unilateral whole breast ABUS exam per case (thus including 
all views). The dataset in this study consisted of dense breasts only, and 20 out of 30 cancers 
included were occult on mammography.  Eight dedicated breast radiologists read all cases twice, 
once with QVCAD support and once without. The purpose of this study was to investigate the 
effect of QVCAD on the efficiency of radiologists in batch reading ABUS. Efficiency was defined as 
a trade-off between reading time and reading performance. The radiologists were instructed to 
read each ABUS exam in a CAD-based reading workflow specifically designed for this study and 
integrated into an existing high-end reading environment. The CAD-based reading / screening 
protocol was non-inferior to standard ABUS reading (0.82 vs. 0.83, respectively (p=0.53)). Trends 
were observed in which most readers showed an improvement in both sensitivity and specificity. 
Furthermore, reading time was on average 15.7% faster reading ABUS with the aid of QVCAD. 
These results are in line with recent reports by Jiang et al (245) and Xu et al (246) who both 
reported a slightly improved performance of radiologists reading with QVCAD in respectively 
33% and 9.3% less reading time. All three studies used datasets that were heavily enriched with 
malignant and benign cases and therefore have likely prolonged the reading time artificially.  We 
expect that the time needed to read an ABUS exam while using QVCAD will further decrease in 
a real screening setting where the prevalence of breast disease is very low. Whether the ability 
to help detect breast cancer persists in a real screening setting needs further investigation.
Are there other ways of using artificial intelligence systems for ABUS?
Conventional use of CAD is to prompt CAD-markings in medical images. The concurrent reading 
software such as the system used in chapters 6 and 7 uses machine learning algorithms to 
detect and classify suspicious regions and visualizes them in a CAD-enhanced 2D synthetic 
image. In chapter 8 we investigated an alternative approach to CAD-implementation in ABUS. 
For this study we used the reading data of unassisted ABUS described in the study in chapter 
7. We automatically compared the location of the readers’ findings and the region candidates 
generated by QVCAD. Subsequently we determined which reader findings were accepted by 
CAD (simultaneous CAD finding present) and which were rejected (no CAD finding at the reader 
finding), a process we referred to as CAD-validation. Interestingly this process of CAD-validation 
improved the performance of readers. The partial AUC for the specificity range 80-100% improved 
from 0.126 to 0.142 (p=0.037). Nevertheless, CAD-validation resulted in a small number of false-
negative rejections by CAD. A proportion of the false-negatives were due to initial non-detection 
of CAD at the threshold of 1 false-positive per ABUS volume. But according to our results, the 
sensitivity of radiologists improves with CAD-validation in a statistical simulation with fixed high 
specificity levels. This may imply that radiologists only detect some cancers when they operate 
at low specificity. However, a screening modality such as ABUS requires high specificity for a 
positive cost-effectiveness ratio. Therefore CAD-validation might be a less costly alternative to 
double reading of ABUS in a high specificity screening setting. 
Would a CAD-system work as a standalone reader?
Newer generations of machine learning techniques such as deep learning algorithms and 
hardware with high computational power have great potential to change the field of medical 
imaging. With deep learning algorithms many complex visual tasks can be performed fully 
automated. Many experts question the necessity of a human reader for certain tasks in the 
foreseeable future. In chapters 6-8, a commercially available CAD system for ABUS is investigated 
as an aid to improve the performance of breast radiologists. In figure 9.1 the performance of CAD 
is shown in a free-response receiver operating curve (FROC). A FROC curve shows all trade-offs 
between the number of marked false-positive CAD regions and the fraction of cancers detected 
correctly by the software. At the threshold of 1 false positive CAD-mark per ABUS volume the 
CAD program has a sensitivity of 72% on the study data set in chapter 6 and 82% on the dataset 
in chapter 7. Note that in both studies the cases in the datasets were excluded from the dataset 
used to train the CAD algorithms. 
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In figures 9.2 and 9.3 we compared the location corrected ROC (LROC) curves of CAD as a 
standalone reader with the pooled curves of the readers on the datasets used in chapters 6 and 
7. The data of both readers and CAD are treated similarly in computing the LROC curves and the 
AUC. For each case the highest score is used in the analysis with the exception of malignant cases 
where the cancer is not marked in the ABUS volume (i.e. the mark is given for something else). 
These cases were treated as if they were classified as normal. By doing so, both human readers 
and the CAD system are not rewarded for recall of cases where they actually missed a cancer.
According to these results, the conclusion is that CAD software as a standalone reader is not (yet) 
on par with human readers reading with or without QVCAD assistance (including the promising 
intelligent MinIP image). Compared to highly trained human observers the CAD system needs 
to generate many false positive findings in order to achieve acceptable sensitivity rates in our 
(enriched) study datasets. In chapters 6 and 7 we used the threshold of 1 false positive per 
ABUS volume to limit the number of CAD-marks to a reasonable proportion. Improving the 
sensitivity of the CAD-system would consequently result in much more false-positive cases 
thus diminishing the overall performance of the CAD system as a standalone reader. In an 
unpublished study we presented at the Radiological Society of North America’s annual meeting 
in 2015 we showed that the sensitivity of the CAD system is independent of the biological 
behaviour of breast cancer. Nevertheless, the chance of a cancer being detected by CAD is less 
in cancers smaller than 15 mm (247). Further improvements of the CAD algorithms might also 
help in detecting the smaller cancers at an acceptable number of false positives which might 
eventually tip the scale in favor of using CAD as a standalone reader for ABUS.
Figure 9. 1 Free Response 
Receiver Operating 
Characteristics curve of 
QVCAD as a standalone 
reader on the ABUS 
datasets used in chapters 
6 and 7.
Figure 9. 2 Location 
corrected Receiver 
Operating Characteristics 
showing the performance 
of QVCAD compared to 
the pooled performance 
of the human readers in 
reading ABUS with and 
without QVCAD support 
in chapter 6.
Figure 9. 3 Location 
corrected Receiver 
Operating Characteristics 
showing the performance 
of QVCAD compared to 
the pooled performance 
of the human readers in 
reading ABUS with and 
without QVCAD support 
in chapter 7
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Future directions
The debate on the role of ABUS in today’s breast cancer diagnostic field is not concluded. 
Most breast imaging experts agree that supplemental imaging modalities are wanted and 
that breast magnetic imaging is the most accurate technique for detecting breast cancer that 
is occult on mammography. But breast MR requires substantial resources and currently still 
needs intravenous contrast agent injection. DBT and whole breast ultrasound are less costly 
alternatives, but it is unclear which modality to use for specific risk groups of asymptomatic 
women. Development of personalized multimodal screening strategies using advanced risk 
modelling might help to determine which screening pathway should be offered to women with 
varying risk profiles (248). However, risk models using data from current published literature 
might not be able to accurately estimate the cost-effectiveness ratio of these supplemental 
techniques due to the wide range of false positive recalls generated by DBT or whole breast 
ultrasound reported in literature. It appears that particularly for ultrasound the number of false 
positive recalls declines heavily when used in subsequent screening rounds.  Still, according to 
current literature radiologists who perform whole breast ultrasound with ABUS as a supplement 
to mammography will increase the number of false-positive recalls largely.  In the available 
studies visual assessment of only grayscale B-mode ultrasound is performed. Functional imaging 
such as (shear wave) elastography for ABUS has the potential to help avoid false-positive recalls 
(249–252). Other functional parameters such three-dimensional power Doppler may also have 
additional value in differentiating benign from malignant breast disease in ABUS. Quantitative 
breast ultrasound using multiparametric radiofrequency (RF) data derived from the ABUS 
systems should also be further explored. We also expect that the combination of standard 
B-mode sonography and multiparametric quantitative (functional) analysis will improve the 
differentiation of breast lesions, however such an approach needs validation in diagnostic and 
in screening settings.
ABUS is developed as a supplemental screening modality rather than a primary screening 
modality and therefore will require additional time, personnel and clinical space. Combining 
mammography or DBT with ABUS in one clinical system would be a very efficient development. 
Schaefgen et al (253) and Larson et al (254) have shown preliminary results of prototype systems 
that fuse DBT/mammography and ABUS into one system. The ABUS transducer is mechanically 
driven over the compression paddle of the DBT system while the breast is compressed for the 
CC or MLO acquisitions. This will improve the spatial correlation between the two modalities. 
Nevertheless, Schaefgen et al reported an additional 80 seconds acquisition time for the ABUS 
acquisition on top of the 25 seconds needed for a DBT view acquisition, which might limit its 
practicality. DBT and mammography is mostly experienced by women as very uncomfortable 
and even painful. A woman’s breast is compressed between the compression paddle and the 
detection plate of a mammography/DBT system. Holländer et al (255) recently showed that 
the acquisition time of ABUS may be optimised using plain wave compounding instead of 
spatial compounding without losing vital image quality in a breast phantom study. This may 
create a new window of opportunity for a more successful fused ABUS/DBT system, as using a 
faster acquisition technique would decrease the acquisition time of ABUS to mere seconds and 
consequently would lessen the discomfort of such an examination.
In this thesis we investigated the implementation of CAD and the reading performance of 
radiologists who used a commercially developed CAD software package that is primarily 
designed to be used as a concurrent reading tool. In general, the CAD systems on the market 
are designed to assist radiologists during the tasks of detecting breast lesions and classifying 
lesions as suspicious for cancer or not. The CAD software we used is, according to our results, 
valid to use as an aid in reading ABUS but is not yet up to par with breast radiologists when used 
as a standalone reader. Nevertheless, artificial intelligence and in particular machine learning 
for medical imaging is a rapidly evolving field. Computers with high computational power are 
currently able to use complex algorithms for improved lesion detection and classification. It is 
expected that with newer technology such as advanced graphic cards with heavy computational 
power even more complex machine learning software will be developed to automatically 
perform the more advanced tasks of radiologists. The machine learning algorithms of the 
future may use all information available from an ABUS scanner, including RF data and functional 
imaging and combine it with all the information from other modalities like breast MR and DBT to 
generate a single diagnosis for a woman, maybe even without the interference of a radiologist.
Chapter 10 
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Borstkanker is de meest voorkomende vorm van kanker bij vrouwen in de hele wereld. Door het 
vroegtijdig opsporen van borstkanker met mammografie wordt er een reductie gezien in de 
mortaliteit van borstkanker. Ook aanvullende therapie in de vorm van chemokuren, bestraling, 
oestrogeen- en HER2-neu receptor antagonisten leidt tot het terugdringen van het aantal 
vrouwen dat uiteindelijk komt te overlijden aan de gevolgen van borstkanker. Mammografie 
screening  is echter niet voor iedere vrouw de juiste manier van screenen. Vrouwen met veel 
klierweefsel (zogenaamde dense mammae) hebben een verhoogd risico op het ontwikkelen 
van borstkanker en daarnaast wordt borstkanker vaker niet opgemerkt door de radioloog omdat 
compact klierweefsel in de borst er hetzelfde uit ziet op een mammogram als borstkanker.  In 
dat geval maskeert het klierweefsel de aanwezigheid van borstkanker.   In de meeste  klinieken 
wordt naast mammografie ook tomosynthese, echografie en magnetic resonance imaging 
(MRI)  verricht voor zowel screening als diagnostische of pre-operatieve beeldvorming. 
Geautomatiseerde 3D mamma-echografie (automated breast ultrasound (ABUS)) systemen 
zijn ontwikkeld om  borstkanker op te sporen bij vrouwen  met dense mammae.  In hoofdstuk 
2   hebben we de literatuur vanaf 2008 samengevat waarin prospectief de toegevoegde 
waarde van echografie screening bij vrouwen met dense mammae  werd onderzocht.  Per 
1000 screeningsonderzoeken worden 0.9-7.7 tumoren gevonden bovenop het aantal tumoren 
die worden gevonden met het mammogram. De meeste tumoren die alleen door echografie 
worden gevonden zijn klein maar al wel van het invasieve type waardoor de prognose voor 
deze vrouwen verbetert. In hetzelfde hoofdstuk hebben we de (3D mamma-)echografische 
eigenschappen samengevat van de meest voorkomende kwaadaardige afwijkingen en 
goedaardige afwijkingen die op borstkanker kunnen lijken. Daarnaast trachtten we uit te leggen 
in het hoofdstuk hoe het systeem werkt en welke artefacten vaak worden gezien. 
In hoofdstuk 3 hebben we  onderzocht wat de meerwaarde is van  zogenoemde multiplanar 
reconstructions (MPR) van de axiale ABUS acquisities. De MPRs geven radiologen de mogelijkheid 
om het 3D ABUS volume in 3 orthogonale vlakken te beoordelen te weten, de originele axiale 
opnamen, de sagittale reconstructie en de coronale reconstructie, in hoofdstuk 3 hebben 
we radiologen gevraagd  borstafwijkingen eerst te beoordelen in het axiale vlak en daarna 
te beoordelen op de MPR’s. Hierbij vroegen wij de radiologen om de ernst van het retractie 
patroon, een bepaalde karakteristieke eigenschap van borstkanker die het beste te zien is in 
het coronale vlak,  te beoordelen op een vijf-punts schaal. Dit onderzoek laat zien dat door het 
beoordelen van borstafwijkingen in de MPR’s kwaadaardige en goedaardige afwkijkingen beter 
van elkaar kunnen worden onderscheiden waarbij de Area Under the Curve (AUC) stijgt van 
0.82 naar 0.87 (p=0.01). Dit wordt waarschijnlijk grotendeels bepaald door de visualisatie van 
de retractie patronen veroorzaakt door borstkanker in het coronale vlak.
In hoofdstuk 4 hebben we onderzocht of de ernst van het retractiepatroon (zie hoofdstuk 
3) en andere echografische kenmerken zoals deze beschreven zijn in de BI-RADS-US lexicon 
zijn te correleren aan verschillende moleculaire subtypen van het invasief ductaal carcinoom. 
Er zijn 4 moleculaire subtypen te onderscheiden: het triple-negatieve type, HER2-verrijkte 
type en de luminale typen die zijn onder te verdelen in het luminal A en luminal B subtype 
waarbij het luminal B subtype een aggresiever beloop heeft dan luminal A. Deze subtypen 
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zijn te onderscheiden door een combinatie van de hormoon receptoren, HER2-neu receptoren 
en proliferatie markers. Ieder subtype heeft een  andere prognose en lijkt anders te reageren 
op verschillende therapiën. Vandaar dat het onderscheidend vermogen van beeldvorming 
mogelijk zou kunnen helpen bij het kiezen van een gepersonaliseerde therapeutische strategie. 
Een panel van 2 ervaren mammaradiologen heeft 125 invasief ductaal carcinomen beschreven 
aan de hand van de BI-RADS lexicon en wederom de erst van het retractiepatroon bepaald. 
Met multivariate regressie analyse hebben we laten zien dat tumor randen en de ernst van het 
retractiepatroon karakteristieken zijn die moleculaire subtypen van elkaar onderscheiden op 
ABUS beelden.  Het onderscheid tussen de hormoon-receptor negatieve tumoren en het luminal 
A carcinoom is het beste te maken op ABUS beelden. De ernst van het retractiepatroon lijkt 
geassocieerd met de mate van celproliferatie/aggressie. Hoe aggressiever het invasief ductaal 
carcinoom is, des te milder lijkt het retractiepatroon.  Sommige triple-negatieve tumoren laten 
helemaal geen retractie patroon zien en lopen daarom het risico aangezien te worden voor 
een goedaardige afwijking.
In hoofdstuk 5 hebben we prospectief 296 vrouwen gescreend waarvan 153 de BRCA1 
mutatie dragen en 128 vrouwen  de BRCA2 mutatie. De overige 15 vrouwen hebben een 
eerstegraads familielid die een van de BRCA mutaties draagt. Het risico op het ontwikkelen 
van borstkanker op een jonge leeftijd is zeer groot bij deze vrouwen. Zij krijgen normaliter een 
jaarlijks mammogram aangeboden vanaf hun 30e levensjaar en een jaarlijkse MRI vanaf hun 
25e levensjaar. Desondanks wordt er in deze groep vrouwen toch nog borstkanker ontdekt 
tussen de jaarlijkse screeningsrondes door.  Aan het bestaande screening protocol hebben 
wij gedurende 2 jaar elk half  jaar een ABUS onderzoek toegevoegd.  De toevoeging van 
halfjaarlijkse ABUS heeft niet geleid tot  het eerder opsporen van borstkanker die ontstaat tussen 
de jaarlijkse screeningsrondes in, noch heeft het geleid tot de detectie van tumoren die niet 
zichtbaar waren op het mammogram of MRI. De sensitiviteit en specificiteit voor  mammografie 
was respectievelijk 37.2% en 98.1%, voor MRI 68.1% en 95.0% en voor ABUS 32.1% en 95.1%. 
De positief voorspellende waarde van ABUS is erg laag  (9.5%).  De beste combinatie van 
modaliteiten is een jaarlijkse combinatie van mammografie en MRI alhoewel het mammogram 
niets lijkt bij te dragen bij vrouwen die jonger zijn dan 43 jaar.
In hoofdstuk 6 hebben we 3 ervaren radiologen en 3 ouderejaars radiologen in opleiding 
gevraagd 90 ABUS onderzoeken te screenen op borstkanker. Per casus kregen de lezers 1 view 
van 1 borst te zien. Dit voerden zij eenmaal uit zonder en 1 eenmaal met behulp van een 
geavanceerd Computer Aided Detection systeem wat  speciaal ontwikkeld is voor ABUS.  Alle 
radiologen (al dan niet in opleiding) vonden meer borstkanker met behulp van de CAD software 
al ging dit in 4 van de 6 lezers te koste van een minimale toename in het aantal vals-positieve 
beoordelingen.  De gemiddelde AUC verbeterde van 0.77 naar 0.84 (p=0.001). De resultaten 
van dit experiment en de ervaringen die we hebben opgedaan hebben we gebruikt om een 
nieuwe, grotere studie op te zetten om het effect van CAD software nader  te onderzoeken.
Voor de studie opzet in hoofdstuk 7 hebben we geput uit onze ervaringen met de studie in 
hoofdstuk 6. We hebben een stappenplan bedacht om de ABUS beelden zo structureel mogelijk 
te lezen, waarbij de CAD software centraal staat. De 8 radiologen  kregen de opdracht tweemaal 
een dataset van 120 ABUS onderzoeken van vrouwen met dense mammae te lezen waarin per 
casus alle  views werden getoond (gemiddeld 3 per vrouw). Het CAD-stappenplan bestond uit 
2 stappen. In stap 1 werden de lezers verzocht alle CAD marks en darkspots op CAD beelden te 
beoordelen. Daarna werd hen een scherm getoond waarin de coronale reconstructie van alle 
views van de betreffende borst simultaan naast elkaar konden worden bekeken.  Daarnaast lazen 
de radiologen ook alle casus een keer zonder CAD. De leestijd van de CAD-leesmethode en de 
‘normale’ leesmethode van ABUS verschilde 15.7% in het voordeel van de CAD-leesmethode 
(p<0.001). De AUC van beide leesmethoden (met en zonder CAD) verschilden niet significant 
0.82 vs. 0.83 (p=0.50). De sensitiviteit van beide leesmethoden was 84%. Er werd een trend 
waargenomen dat radiologen minder ABUS onderzoeken als vals-positief beoordeelden in 
de CAD leesmethode, maar deze trend was niet significant. Tevens viel op dat met behulp van 
CAD wel degelijk meer kankers werden gevonden, maar dat die kankers niet altijd juist werden 
geclassificeerd als kanker door de lezers.  
In hoofdstuk 8 hebben we onderzocht of CAD kan worden gebruikt om achteraf te bekijken 
of een verwijzing  van een radioloog wel of niet terecht is. Dit noemen we CAD-validatie. CAD-
validatie simuleerden we op de ‘gewone’ lees resultaten van de 8 radiologen op de dataset uit 
hoofdstuk 7. CAD-validatie houdt in dat CAD per, door radiologen,  gerapporteerde afwijking 
bekijkt of CAD die afwijking ook zou verwijzen. Indien CAD en de radioloog het met elkaar eens 
zijn, werden de scores voor de afwijkingen gebruikt in de analyse. Wanneer de gerapporteerde 
afwijking niet door CAD werd gezien werd deze afwijkingen zogenaamd verworpen door het 
CAD-validatie proces en werd de score die de radioloog had gegeven niet meegenomen in de 
analyse. De partiële AUC (in het specificiteits domein van 80%-100%) van de gemiddelde gewone 
beoordeling van ABUS was 0.126 en verbeterde significant na CAD-validatie  tot 0.142 (p=0.037). 
Dit houdt in dat onder strikte voorwaarden voor verwijzingen, het gebruik van CAD-validatie 
mogelijk ertoe zou kunnen leiden dat meer borstkankers zouden kunnen worden opgespoord 
zonder een toename van vals-positieve  uitslagen. De afwijkingen die het CAD-validatie systeem 
verwierp in deze studie betroffen voor het grootste deel goedaardige afwijkingen of artefacten 
die afwijkingen nabootsten. De radiologen scoorden het merendeel van deze afwijkingen met 
een BI-RADS 3 of 4. Er werden ook afwijkingen verworpen door het CAD-validatie proces die 
terecht door de radiologen als verdacht waren afgegeven als kanker. Eventuele verbeteringen 
aan het CAD-systeem  zouden dergelijke vals-negatieven kunnen voorkomen.
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Iedereen die zich weleens heeft gewaagd aan het schrijven van een dankwoord in zijn of haar 
dissertatie weet wat een verschrikking dit is vanwege het gevaar op het ‘per ongeluk’ vergeten 
om mensen te bedanken. Toch heb ik gepoogd iedereen die een bijdrage heeft geleverd te 
benoemen en te bedanken.
Allereerst wil ik professor Karssemeijer van harte bedanken voor het gestelde vertrouwen in 
mij. Ik herinner me goed onze eerste ontmoeting in de ‘barakken’ van DIAG nadat ik via Roel 
Mus met je in contact was gebracht. Het resulteerde in eerste instantie in een onderzoekje voor 
mijn wetenschappelijke master stage en in een zwik onbetaalde ondersteunende taakjes die we 
later hebben uitbesteed aan studenten maar dan tegen een riante vergoeding.....  De jaren die 
volgden op deze ontmoeting zal ik koesteren als hele mooie jaren waarin ik veel heb geleerd 
en dat heb ik voor het overgrote deel te danken aan jou. Je hebt een overweldigende staat van 
dienst in de mamma-radiologie en ongeveer iedereen die ik de afgelopen jaren heb ontmoet 
in dit werkveld weet wie je bent, ondanks je van nature bescheiden karakter. Ik heb genoten 
van onze samenwerking en ik hoop dat je met Screenpoint grote successen zult gaan oogsten.
Dr. Mann, beste Ritse. Mijn eerste indruk van je was verpletterend omdat je zo ontzettend snel lijkt 
te kunnen schakelen en je schijnbaar onbeperkte en zeer nauwkeurige kennis van borstkanker 
imaging en epidemiologie. Ondanks je jonge leeftijd geldt je al jaren als echte expert op het 
gebied van mamma-radiologie en in het bijzonder de MRI. Met name internationaal ben je een 
wetenschappelijke rockster waar ik enorm van opkeek toen ik voor het eerst meemaakte dat 
mensen met je op de foto wilde tijdens congressen. Tijdens die congressen werd me duidelijk 
wat een geniale netwerker je bent. Van ‘s morgens vroeg tot ‘s avonds laat sta je te knallen met 
presentaties, vergaderingen, diners en de gezelligheid tot in de late uurtjes waarbij jij 19 vd 
20 keer pas uren later terug in je hotel was dan ik. We hebben menig uren aan de bar met bier 
en cocktails de toekomst van onze carrières besproken. Je hebt me enorm geholpen bij het 
opbouwen van mijn carrière in de radiologie waarvoor ik je altijd ontzettend dankbaar zal zijn. 
Het pad wat ik echter nu bewandel is wat anders dan radiologie, maar in die beslissing heb 
je (waarschijnlijk) onbewust een hele belangrijke rol gespeeld. Ritse, je hebt nog een metal 
concert/festival van me tegoed. Laten we dat doen na mijn verdediging, dan hebben we een 
excuus om bij te babbelen. 
Dr. ir. Bram Platel, door je ziekteproces heb je ongeveer halverwege mijn PhD traject moeten 
snijden in je portfolio als PhD-begeleider. Desalniettemin ben je de eerste anderhalf jaar van 
mijn promotie traject nauw betrokken geweest bij mijn onderzoeken en natuurlijk bij de 
ontwikkelingen en afwikkeling van het ASSURE project. Ik heb altijd erg genoten van je nuchtere, 
komische en vaak verfrissende blik op zaken. Ik grinnik nog steeds iedere keer als ik mickey 
mouse oren zie (okee okee ik was er niet bij maar heb wel de fotos gezien). Bram hou je taai en 
het ga je goed op de Fillipijnen.
Mijn paranymfen Tom en Stijn. We hebben elkaar ontmoet in de nazomer van 2005 toen we 
begonnen aan onze studies aan de medische faculteit en aan ons avontuur in het studentenleven. 
Stijn je staat inmiddels op het punt om je vinkje in het specialisten register te zetten achter 
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het vakje traumachirurg, al lijkt het er soms meer op dat je een infectioloog bent gezien je 
kennis over HIV en AIDS. Wees maar gerust, geen toewensingen dit keer. Tom jouw passie voor 
prostaten en piemels de urologie heeft je inmiddels ook al een heel eind gebracht en ik heb 
je inmiddels al een paar keer om advies gevraagd, niet voor mezelf natuurlijk, maar voor mijn 
eigen patiënten. Jullie werken allebei enorm doelgericht en hard aan jullie carrière en daar heb 
ik alle bewondering voor. Jullie zijn ook ontzettend goede vrienden en dat waardeer ik nog veel 
meer. Ondanks dat jullie later aan het wetenschappelijk avontuur zijn begonnen dan ik zijn 
jullie al lang gepromoveerd. Maar ja, echt goed werk heeft gewoon wel wat meer tijd nodig.
Beste Tao, like every researcher I also have been standing on the shoulder of giants, your 
shoulders. Your work in the development of AI for ABUS plays a huge part in this thesis. I enjoyed 
working together with you and I deeply respect your positive attitude.  Tao you have never 
let me down and you were always willing to help me with our experiments. I always liked 
your anecdotes about China. You recently moved back to China, I wish you all the best and 
happiness. Thank you, Tao, I could not have done this without you. Dan Jan Jurre; mooie vent 
ben je toch. Dank voor alle mooie momenten in de DIAG werkkamer die we deelden met de 
dames van de BioMR groep en Andy en Tom. Ik moest altijd even grinneken wanneer je de kamer 
binnen kwam lopen, vrolijk als altijd iedereen gezamelijk gedag zei en Isabell nog eventjes apart. 
Ik mis onze wekelijkse kapsalon bij de fest en onze ritten naar huis. Ik zie je bij de komende 
aandeelhoudersvergadering van Better than Screenpoint, Better than Matakina, Better than 
Qview en Better than Thirona (met vagina logo), dan drinken we een kop whisky. Colin; jij bent 
letterlijk en figuurlijk een mooie vent. Ik heb altijd graag met je samengewerkt binnen DIAG maar 
dat geldt voor iedereen. Ik zou het leuk vinden als je een keer op de koffie komt. Wel vantevoren 
ff bellen dan haal ik eerst je portretten van de muur in de woonkamer want ik zou het vervelend 
vinden als je daar ongemakkelijk van wordt. Steven Schalekamp dank dat ik je paranymf mocht 
zijn. Vreemann, mooi mens, ik heb ontzettend genoten van onze samenwerking. Ik zag in jou de 
perfecte persoon om de frustraties van het werk op te kunnen botvieren en dat was wederzijds 
volgens mij. De congressen waren altijd heel gezellig en kapsalons met JJ waren erg vet. Helaas 
was het niet meer beschikbaar toen jij je glorieuze promotie binnen hengelde, maar je hebt nog 
een schilderij van een harige vrouw van me tegoed. Albert met jou heb ik mooie momenten in 
Nijmegen, Chicago, Girona, Tarragona en Salou beleefd, dank voor alle gezelligheid en voor de 
ondersteuning bij de ASSURE projecten waar je bij betrokken werd nadat Mandana ons verliet. 
Heel veel succes in je carrière ik weet zeker dat die mooie dingen gaat brengen voor jou en je 
mooie gezin. 
Rickert en Mark kan ik natuurlijk niet onvermeld laten. Bedankt voor de gezellige koffiemomenten. 
Verder bedank ik ook nog in onwillekeurige volgorde Katharina, Paul, Sjoerd (SST-dragons), Henk 
Roozen, Rieneke van Bert, Babak, Mohsen, Freerk, Sven, Thijs Cage, Mehmet, Kaman, graag 
gedaan! Alejandro, you’re welcome! Wulphert, Clarissa, HenkJan, Eva, Rashindra, Geert, Ajay, 
Sil, Midas, Sarah, Marcel Oei, Jakob, Michiel, en Henk Roozen nog een keer.
I would also like to thank the ASSURE collaboratives Daniel, Thorsten, Hans-Jörg and Jan at MeVis 
Medical Solution, André and Thomas Grivègnée at Institute Jules Bordet, Julia at Mediri (thank 
you for your patience) and Hanneke and Carla at UMCU. Also thanks to all co-authors and special 
thanks to Angels and Francisca in Tarragona (ES) and Mathijn and Matthieu in ‘s-Hertogenbosch. 
Without your input and data, this thesis would not have existed.
During my PhD track I met a group of inspiring young breast radiologists who somehow put 
their trust in me and accepted me in their circle. Together we formed the EUSOBI Young club. 
Thank you my dearest Paola, Maria-Adele and Betty, for all of your hard work and also for the 
cool moments we share. 
Mijn broers Wip en Peer en mijn zus Helleke. Ik heb niet heel veel aan jullie gehad in de 
totstandkoming van dit boekje, maar ook geen last van jullie gehad dus dan toch maar dank! 
En het beste hè! Nee hoor, ik hou van jullie allemaal. Dat dat ook maar eens gezegd mag worden. 
Peter, ik hou van je. Wilbert, ik hou van je. Helmi, ik hou van je. Dank voor alle wijze lessen die 
jullie als oudere broers en zus me hebben gegund.
Lieve mama, het was even schrikken in het voorjaar van 2014 toen pa ons vertelde dat je een 
vervelende uitslag had gekregen vanuit het bevolkingsonderzoek voor borstkanker. Gelukkig 
kreeg je in het Jeroen Bosch Ziekenhuis, geheel tegen de richtlijnen, ter aanvulling van de gewone 
borstfoto een tomosynthese en een ABUS scan waarop een tweede tumor werd gevonden in 
je andere gezonde borst die niet was gezien bij het bevolkingsonderzoek. Inmiddels zijn we 
ruim 5 jaar verder en gaat het harstikke goed met je. Helaas hebben we in 2014 vlak na je eerste 
behandeling onze pa plots verloren. Ik had de afronding van mijn promotie graag samen met 
hem willen vieren en hij zal komende tijd weer eens vaker door mijn gedachten flitsen. Ik denk 
dat hij trots is en dat haalt de scherpe randjes van het gemis af. Het is een cliché maar ik heb 
alles te danken aan de springplank die jij en pa mij hebben gegeven. Mama, dank voor alles.
Dan de allerliefste kinderen van de hele wereld. Lieve Madelief en lieve Guus. Jullie zijn nu nog 
te klein om dit te kunnen lezen en ik vraag me af of je het ooit gaat doen, maar weet dat jullie 
mijn drijvende kracht zijn achter alles wat ik doe en de keuzes die ik maak in het leven. Met 
name tijdens het schrijven van dit boekje heb ik, tegen mijn zin in, op meerdere momenten meer 
aandacht gehad voor mijn computer scherm dan voor jullie. Dat ga ik tweehonderd procent 
inhalen zodra ik klaar ben. Dat beloof ik, beloven jullie dan dat jullie altijd zo lief en klein zullen 
blijven? Ik hou verschrikkelijk veel van jullie allebei.
Liefste Willemieke. Als er iemand anders is die misschien nog wel meer lucht gaat krijgen dan 
ik zodra dit boekje klaar is dan ben jij het. Je hebt avonden lang allenig moeten doorbrengen 
als ik weer eens een deadline had, papers moest schrijven, presentaties moest voorbereiden 
of dit boekje af wilde krijgen. Achteraf besef ik me dat ik hier weleens te ver in ging (misschien 
wel vaker dan eens) wanneer ik bijvoorbeeld op vakantie nog een paper aan het schrijven was 
of stukken aan het nakijken was in de verloskamers van het JBZ. Je hebt mij de ruimte gegeven 
om zoveel mogelijk uit mijn carrière te halen terwijl jij ook aan je eigen carrière werkte en de 
dagelijkse logistieke operatie rondom de kindjes op je nam. Lieve Willemieke, je bent de liefde 
van mijn leven. Samen komen we de dingetjes in het leven wel door, ook wanneer het druk 
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is. Over een maand (uitgaande van de datum van mijn verdediging) stappen we samen in het 
huwelijksbootje en daar kijk ik erg naar uit. Dank lieve schat, voor alles.
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